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ABSTEACT 
In the field of medicinal chemistry, steroids have been one of the most attractive areas 
for investigation due to their biological activities. Bioorganic chemists have reporied a 
number of modifications in natural steroids resulting in the promotion of heir 
activities. Even a small change in steroid moiety can elicit an extensive biological 
response. All these facts have attracted researcher to explore these after modifying 
them suitably to induce various pharmacological properties. This is still to jc a 
fascinating field worldwide. Our laboratory is concerned mainly with the synthesis of 
steroidal compounds and their identification by chemical and spectral studits. a 
number of reports dealing with the preparation of modified steroids have appeared 
from our laboratory. The work embodied in this thesis describes the synthes s of 
modified steroids and their biological behavior. The identification of newly 
synthesized compounds has been ascertained by IR, 'H N M R , '^C N M R , MS and 
elemental analysis. The whole work is divided into five chapters namely, 
Chapter-1: Steroidal pyrazolines 
Chapter-2: Steroidal pyranones 
Chapter-3: Steroidal pyrazolones 
Chapter-4: Steroidal thiazolidinones 
Chapter-5: Biological evaluafion of newly synthesized compounds 
The results are summarized below. 
CflAFIER-1 
Stenaidai fujnwfoUHeA 
Pyrazoline derivatives are important electron rich nitrogen heterocycles which pia;/ an 
important role in the diverse biological activities. These nitrogen heterocycles widely 
occur in nature in the form of alkaloids, vitamins, pigments and as constituents of 
plant and animal cells. Substituted pyrazolines have significant importance due to 'heir 
wide spread pharmacological properties such as anticarcinogenic, antidiabetic, inti-
inflammatory, DP-TV inhibitors, antitumor and antiparkinsonian. The above 
pharmaceutical interest prompted us to synthesize new substituted steroidal pyrazolines 
(IV-IX). The substrates selected for initial studies include cholest-5-en-7-one (I), 3/6-
acetoxycholest-5-en-7-one (II) and 3/9-chlorocholest-5-en-7-one (III). To the best of 
our knowledge, this is the first report about the synthesis of steroidal pyrazolines 
using nano metal oxide as a heterogeneous catalyst. The products obtained have lieen 
characterized on the basis of their spectral (IR, 'H N M R , '^C NMR, MS) studies and 
elemental analysis. 
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Biological synthesis ofZnO nanoparticles using C. albicans and studying their 
catalytic performance in the synthesis of steroidal pyrazolines. Shamsuzzaman. 
Ashraf Mashrai, H. Khaiiam and R. N. Aljawfi 
Arabian J. Client. 2013 (in press); http://dx.doi.Org/10.1016/j.arabjc.2013.05.004 
CflAFreR-2 
StenoicUU fi^noHOHea-
It is known that many pyranone derivatives demonstrate a wide spectrum of 
pharmacological and biological activities. Various natural products also contain 
pyranone nucleus. Due to their biological significance there is a need to deveiop a 
new protocol for the synthesis of these compounds. Furthennore the development 
of new methods with greater efficacy, convenient procedures and better yield is of 
interest. This prompted us to synthesize new steroidal pyranone derivatives (X-XV) 
using readily available cholest-5-en-7-one and its analogs (I-ITI) in the presence of 
chitosan as heterogeneous, basic and green catalyst. With the best of our know ledge 
there are no literature data available regarding the synthesis of steroidal pyranone 
derivatives using chitosan as a catalyst. 
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Green synthesis and biological evaluation of steroidal 2H-pyrans as anticancer and 
antioxidant agents. Shamsuzzaman, Ashraf Mashrai, H. Khanam, M. Asif A. A\\, 
A. Sherwani and M. Owais. 
Journal of King Saud University-Science, 2013 (in press); 
http://dx.doi.Org/10.1016/j.jksus2013.10.001 
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Stenoidai fufia^otoHeA 
In the recent past, the synthesis of pyrazolone derivatives have attracted attention of 
organic chemists because of the interesting physiological activity and profmnd 
endocrinological interest associated with them. With this realization, some papers appeared 
dealing with the synthesis of pyrazolones. This prompted us to undertake the work ir this 
area. We subjected some easily available steroidal ketones (XVI-XVIII) to the reac:tion 
with cyanoacetohydrazide (CNCH2CONHNH2) and obtained 6-(5'-Amino-3'-oxo-
dihydro-4//-pyrazol-4'-ylidine)-5a-cholestane (XIX), 3/?-acetoxy-6-(5'-amino-3'-oxo-
dihydro-4//-pyrazol-4'-ylidine)-5a-cholestane (XX) and 3y(?-chloro-6-(5'-amino-3'-3xo-
dihydro-4^-pyrazol-4'-ylidine)-5a-cholestane (XXI) respectively. The products 
obtained have been characterized on the basis of their spectral (IR, ' H N M R , ' ' C N M R 
and MS) studies and elemental analysis. 
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Synthesis, evaluation and docking studies on steroidal pyrazolones as anticancer 
andantimicrobial agents. Shamsuzzaman, Ashraf Mashrai, A. Ahmad, A. M. Dar, H. 
Khanam, M. Danishuddin and A. U. Khan 
Med. Chem. Res. 2013 (in press); DOI 10.1007/s00044-013-0636-y 
IV 
CaAFIER-4 
Stenoielai tkaiy)lUU»toHeA 
In recent years, thiazolidinones are the most extensively investigated class of 
compounds. Such type of compounds have many interesting activity profiles namely 
COX-1 inhibitors, inhibitors of the bacterial enzyme MurB, non-nucleoside inhibitors 
of HIV-RT and antihistaminic agents. Consequently, many different protocols have 
been developed that allow the synthesis of thiazolidinone skeleton. These meihods 
employ a one-pot three-component condensation or a two-step synthesis. Motivated 
by these facts a successful attempt is made to synthesize steroidal thiazolidinones 
(XXII-XXIV) by a convenient one-pot method. For this purpose 5a-cholestan-6-one 
(XVI), 3/?-acetoxy-5a-choiestan-6-one (XVII) and 3/?-chloro-5a-cholestan-<)-one 
(XIII) were allowed to react with mercaptoacetic acid and hydrazine hydrate m the 
presence of DCC. The structure of the products have been characterized on the basis of 
their spectral (IR, ' H N M R , '^C N M R and MS) studies and elemental analysis. 
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CHAFIER-S 
The global production of new drugs has increased in the last decades, and altht>ug!i 
many of the products have been beneficial for mankind, many of them are also toxic 
and can accumulate within organisms. In the global drug market, steroid drugs ank 
second only after antibiotics. Search of novel drugs is field of current and gro^v•lng 
interest and many compounds have been synthesized to this aim. One possibility to 
achieve this goal is the combination of a steroid molecule with structural eieirents 
possessing appropriate biological activities. The advantage of employing hydrophobic 
steroid units is their ability to interact with cell membranes and thus pave the wav for 
biological activity of such hybrid molecules. To gain insight on how modificatior s on 
ring-B in steroids nucleus can affect the biological activity, different steroidal 
derivatives with a variety of functionalities attached to steroidal skeleton have oeen 
synthesized and evaluated in silico and in vitro for their biological activity. In the /;; 
slico studies, we studied the physicochemical parameters "Rule of Fi\e" ol the 
synthesized compounds and we calculated the bioactivity score for six criteria, GPCR 
ligand activity, ion channel modulation, kinase inliibition activity, protease inhibitor, 
enzyme inhibitor and nuclear receptor ligand activity. The cytotoxic potential of the 
synthesized compounds were studied against panel of selective human cancer celis by 
MTT assay. The panel of cancer cells encompassed HepG2 (hepatocellular 
carcinoma), A549 (lung adenocarcinoma epithelium), SW480 (colon 
adenocarcinoma), HeLa (cervical carcinoma) and HL-60 from (promyeloc\lic 
leukaemia). Doxorubicin and Cytarabine were used as cytotoxic drugs of reference. 
The compounds were also tested against one normal cell line PBMC (Blood 
peripheral mononuclear cell isolation). The newly synthesized compounds were 
screened against a variety of bacterial strains (Streptococcus pyogenes, 
Staphylococcus aureus, Pseudomonas aeruginosa, Escherichia coli and Klebsiella 
pneumoniae) by disk diffusion method. The susceptibility of the bactena to the test 
compounds was determined by the formation of an inhibitory zone after 18 h of 
incubation at 36 °C. The minimum inhibitory concentration (MIC) of all the 
compounds was determined. Ciprofloxacin was used as positive control, whereas 
DMSO poured disk was used as negative control and then minimun] inhibitorv 
VI 
concentration (MIC) was evaluated by the macro-dilution test. The in vitro antifungal 
activities were carried out using (Candida albicans, Aspergillus fitmi^atits. 
Trichophyton mentagrophytes and Penicillium marneffei) by agar diffusion method. 
The minimum inhibitoiy concentration (MIC) and Inhibition zones were detemnned 
as in antibacterial activity. The activity of the synthesized compounds was compared 
with Fluconazole as positive control and DMSO as negative control. The synthesized 
compounds were also tested for antioxidant activities by I,ldiphenylpicrylhydrazyl 
(DPPH) method. GOLD (Genetic Optimization for Ligand Docking) 5.0 was used for 
docking of compounds (XIX- XXIV) against S12 and CYP 51 proteins. 
vii 
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In the field of medicinal chemistry, steroids have been one of the most 
attractive areas for investigation due to their biological activities. Bioorganic chemists 
have reported a number of modifications in natural steroids resulting in the promotion 
of their activities. Even a small change in steroid moiety can elicit an extensive 
biological response. All these facts have attracted researcher to explore these after 
modifying them suitably to induce various pharmacological properties. This is still to 
be a fascinating field worldwide. Our laboratory is concerned mainly with the 
synthesis of steroidal compounds and their identification by chemical and spectral 
studies, a number of reports dealing with the preparation of modified steroids have 
appeared from our laboratory. The work embodied in this thesis describes the 
synthesis of modified steroids and their biological behavior. The identification of 
newly synthesized compounds has been ascertained by IR, ' H N M R , '^C N M R , MS 
and elemental analysis. The whole work is divided into five chapters namely, 
Chapter-1: Steroidal pyrazolines 
Chapter-2: Steroidal pyranones 
Chapter-3: Steroidal pyrazolones 
Chapter-4: Steroidal thiazolidinones 
Chapter-5: Biological evaluation of newly synthesized compounds 
The results are summarized below. 
CHAPTCR-l 
Pyrazoline derivatives are important electron rich nitrogen heterocycles which 
play an important role in the diverse biological activities. These nitrogen heterocycles 
widely occur in nature in the form of alkaloids, vitamins, pigments and as 
constituents of plant and animal cells. Substituted pyrazolines have significant importance 
due to their wide spread pharmacological properties such as anticarcinogenic, 
antidiabetic, anti-inflammatory, DP-fV inhibitors, antitumor and antiparkinsonian. The 
above pharmaceutical interest prompted us to synthesize new substituted steroidal 
pyrazolines (IV-IX). The substrates selected for initial studies include cholest-5-en-7-one 
(I), 3^-acetoxycholest-5-en-7-one (II) and 3y?-chlorocholest-5-en-7-one (III). To the 
best of our knowledge, this is the first report about the synthesis of steroidal 
pyrazolines using nano metal oxide as a heterogeneous catalyst. The products obtained 
have been characterized on the basis of their spectral (IR, ' H N M R , '^C N M R , MS) studies 
and elemental analysis. 
RNHNHVZnO 
C2H5OH, reflux 
(I-III) 
X 
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CI 
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(IV-IX) 
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Biological synthesis ofZnO nanoparticles using C. albicans and studying their 
catalytic performance in the synthesis of steroidal pyrazolines. Shamsuzzaman, 
Ashraf Mashrai, H. Khanam and R. N. Aljawfi 
Arabian J. Chem. 2013 (in press); http://dx.doi.Org/10.1016/j.arabjc.2013.05.004 
CflAPTER-2 
SienoccCcd pcfMtuMCd. 
It is known that many pyranone derivatives demonstrate a wide spectrum of 
pharmacological and biological activities. Various natural products also contain 
pyranone nucleus. Due to their biological significance there is a need to develop a 
new protocol for the synthesis of these compounds. Furthermore the development 
of new methods with greater efficacy, convenient procedures and better yield is of 
interest. This prompted us to synthesize new steroidal pyranone derivatives (X-XV) 
using readily available cholest-5-en-7-one and its analogs (I-III) in the presence of 
chitosan as heterogeneous, basic and green catalyst. With the best of our knowledge 
there are no literature data available regarding the synthesis of steroidal pyranone 
derivatives using chitosan as a catalyst. 
RCHiCOOEt/ Chitosan 
»-
CH3OH, reflux 
(I-III) (X-XV) 
X 
H (I) 
OAc (II) 
CI (III) 
X R R 
H CI (X) CH3CO (XIII) 
OAc CI (XI) CH3CO (XIV) 
CI CI (XII) CH3CO (XV) 
Green synthesis a?id biological evaluation of steroidal 2H-pyrans as anticancer and 
antioxidant agents. Shamsuzzaman, Ashraf Mashrai, H. Khanam, M. Asif, A. Ali, 
A. Shenvani and M. Owais. 
Journal of King Saud University-Science 2013 (in press); 
http://dx.doi.0rg/lO.IOl6/j.jksus.2Oi3.lO.OOl 
ni 
CHAFreR-3 
StenoicCai fitfMi^d(Me^ 
In the recent past, the synthesis of pyrazolone derivatives have attracted attention 
of organic chemists because of the interesting physiological activity and profound 
endocrinological interest associated with them. With this realization, some papers appeared 
dealing with the synthesis of pyrazolones. This prompted us to undertake the work in this 
area. We subjected some easily available steroidal ketones (XVl-XVIIl) to the reaction 
with cyanoacetohydrazide {CNCH2CONHNH2) and obtained 6-(5'-Amino-3'-oxo-
dihydro-4^-pyrazol-4'-ylidine)-5a-cholestane (XIX), 3/?-acetoxy-6-(5'-amino-3'-oxo-
dihydro-4//-pyrazol-4'-ylidine)-5a-cholestane (XX) and 3y?-chloro-6-(5'-amino-3'-oxo-
dihydro-4//-pyrazol-4'-ylidine)-5a-cholestane (XXI) respectively. The products 
obtained have been characterized on the basis of their spectral (IR, ' H N M R , '^C N M R 
and MS) studies and elemental analysis. 
(XVI-XVIII) 
X 
H (XVI) 
OAc (XVII) 
CI (XVIII) 
N-NH 
(XIX-XXI) 
X 
H (XIX) 
OAc (XX) 
CI (XXI) 
Synthesis, evaluation and docking studies on steroidal pyrazolones as anticancer and 
antimicrobial agents. Shamsuzzaman, Ashraf Mashrai , A. Ahmad, A. M. Dar, H. 
Khanam, M. Danishuddin and A. U. Khan 
Med. Chem. Res. 23 (2014) 348-362 
IV 
CHAPTER-A 
In recent years, thiazolidinones are the most extensively investigated class of 
compounds. Such type of compounds have many interesting activity profiles namely 
COX-1 inhibitors, inhibitors of the bacterial enzyme MurB, non-nucleoside inhibitors 
of HIV-RT and antihistaminic agents. Consequently, many different protocols have 
been developed that allow the synthesis of thiazolidinone skeleton. These methods 
employ a one-pot three-component condensation or a two-step synthesis. Motivated 
by these facts a successful attempt is made to synthesize steroidal thiazolidinones 
(XXII-XXIV) by a convenient one-pot method. For this purpose 5a-cholestan-6-one 
(XVI), 3;?-acetoxy-5a-cholestan-6-one (XVII) and 3y9-chloro-5fx-cholestan-6-one 
(XIII) were allowed to react with mercaptoacetic acid and hydrazine hydrate in the 
presence of DCC. The structure of the products have been characterized on the basis of 
their spectral (IR, 'H N M R , '^C N M R and MS) studies and elemental analysis. 
\ 
NH2NH2/ HSCH2COOH 
DCC, C6H6, reflux 
(XVI-XVIII) 
X 
H (XVI) 
OAc (XVII) 
CI (XVIII) 
(XXII-XXIV) 
X 
H (XXII) 
OAc (XXIII) 
CI (XXIV) 
CHAFTER-S 
The global production of new drags has increased in the last decades, and 
although many of the products have been beneficial for mankind, many of them are 
also toxic and can accumulate within organisms. In the global drug market, steroid 
drags rank second only after antibiotics. Search of novel drags is field of current and 
growing interest and many compounds have been synthesized to this aim. One 
possibility to achieve this goal is the combination of a steroid molecule with stractural 
elements possessing appropriate biological activities. The advantage of employing 
hydrophobic steroid units is their ability to interact with cell membranes and thus 
pave the way for biological activity of such hybrid molecules. To gain insight on how 
modifications on ring-B in steroids nucleus can affect the biological activity, different 
steroidal derivatives with a variety of functionalities attached to steroidal skeleton 
have been synthesized and evaluated in silico and in vitro for their biological activity. 
In the in slico studies, we studied the physicochemical parameters "'Rule of Five'" of 
the synthesized compounds and we calculated the bioactivity score for six criteria, 
GPCR ligand activity, ion channel modulation, kinase inhibition activity, protease 
inhibitor, enzyme inhibitor and nuclear receptor ligand activity. The cytotoxic 
potential of the synthesized compounds were studied against panel of selective human 
cancer cells by MTT assay. The panel of cancer cells encompassed HepG2 
(hepatocellular carcinoma), A549 (lung adenocarcinoma epithelium), SW480 (colon 
adenocarcinoma), HeLa (cervical carcinoma) and HL-60 from (promyelocytic 
leukaemia). Doxorabicin and Cytarabine were used as cytotoxic drugs of reference. 
The compounds were also tested against one normal cell line PBMC (Blood 
peripheral mononuclear cell isolation). The newly synthesized compounds were 
screened against a variety of bacterial strains {Streptococcus pyogenes. 
Staphylococcus aureus, Pseudomonas aeruginosa, Escherichia coli and Klebsiella 
pneumoniae) by disk diffusion method. The susceptibility of the bacteria to the test 
compounds was determined by the formation of an inhibitory zone after 18 h of 
incubation at 36 °C. The minimum inhibitory concentration (MIC) of all the 
compounds was determined. Ciprofloxacin was used as positive control, whereas 
DMSO poured disk was used as negative control and then minimum inhibitory 
VI 
concentration (MIC) was evaluated by the macro-dilution test. The //; vitro antifungal 
activities were carried out using {Canclic/a a/bicans, Aspergillus Ju/nigcitiis. 
Trichophyton mentagrophytes and Penicillhim marneffei) by agar diffusion method 
The minimum inhibitory concentration (MIC) and Inhibition zones were determined 
as in antibacterial activity. The activity of the synthesized compounds was compared 
with Fluconazole as positive control and DMSO as negative control. The synthesized 
compounds were also tested for antioxidant activities by l,ldiphenylpicrylhydrazyl 
(DPPH) method. GOLD (Genetic Optimization for Ligand Docking) 5.0 was used for 
docking of compounds (XIX- XXIV) against S12 and CYP 51 proteins. 
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Steroids have been a prime focus of research due to their fascinating structural 
framework and their excellent ability to penetrate cell membranes and oind to the 
nuclear and membrane receptors. Even a small change in steroid moiety cm elicit an 
extensive biological response. Steroids represent constituents of biomembranes and 
hormones, fulfil protective functions, stimulate plant growth, etc. Many 
representatives of this group are widely used in medicine as essentials of anti-
inflammatory, anabolic and contraceptive drugs. All these facts havf attracted 
medicinal chemists and biochemists to explore these after modifying them suitably to 
induce various pharmacological properties. It is therefore not surprising that steroids 
considerably interest not only chemists, but also pharmacologists and physicians. 
Steroids research in the mid-to late 20"' century progressed to biomimetic 
chemistry and tracer work medicinal and pharmacological chemistry as well. Dunng 
the early and middle years of steroid chemistry, synthetic efforts focused primarily 
upon the ring system and some of the more simple fijnctional side chains. These 
studies were directed primarily towards the development of synthetic methods for the 
construction and modification of the cyclic skeleton and were due, of couise, to the 
demand for potent pharmaceutical agents. In addition, progress in synthetic methods 
and separation and identification techniques prompted more detailed studies of these 
derivatives. Within the last decade intensive research on modified steroids has yielded 
many imaginative syntheses of general interest and has contributed much to the 
development of novel biologically potent compounds. 
Our laboratory is mainly concerned with the synthesis of steroid denvatives 
and their identification by spectral and analj^ical studies. The aim of the present work 
then is to survey the synthesis of modified steroids as well as some relevant chemistry 
involving transformations of the ring A and B for the preparation of compounds of 
biological importance. It also attempts to provide steroid chemists pursuing new 
syntheses of steroids or compounds with similar structures. This doctoral thesis 
comprises the design and synthesis of modified steroids and their biological 
screening. 
CHAPTEE-1 

The pyrazoline ring (1) system consists of a monounsaturated five membered 
ring containing two adjacent nitrogen atoms. 
,—NH 
(1) 
Over the years, the synthesis of pyrazoHnes has received ccnsiderable 
attention because of their noteworthy applications. Certain compounds containing the 
pyrazoline moiety were synthesized to have an important therapeutic potent al, mainly 
as anti-inflammatory, antidepressant, antipyretic, antibacterial, antifungal and 
antitumor agents. That's why preparation of pyrazolines itself shows remarkable 
interest and is thus highly attractive area of synthetic organic chemistry. 
Assad' synthesized pyrazolines and pyrazoles from /»-hydroxyacetophenone 
using NH2NH2 in acetic acid and evaluated their antimicrobial properties. 
Chincholkar and Jamode^ synthesized 4-aroyl-subsituted pyrazolines (3) and 
pyrazoles (4) [R ' = H, Me, R^ = H, MeO, R^  = H, MeO, 3,4-methylenedioxyl] by 
cyclocondensation of 3-aroylflavanones (3) with PhNHNH2. 
(2) (3) (4; 
Green et al.^ synthesized steroidal [16a,17 a-crj-2'-pyrazolines (6) and [16.17-
d] pyrazoles (7). 3^-Acetoxyandrostadienes (5) [R = MeCO] with PhCCl: NNHPh/ 
EtsN gave steroidal pyrazolines (6) and similar cycloaddition reactions of compound 
5 [R = AcO] provided androstenopyrazoles (7) [R = Ph, R ' = Ph, 4-CIC6H4]. 
o 
II H , C - C - 0 
MeOC N—N N - N 
(5) (6) (7) 
2'-Hydroxy-4'-acetamidochalcones on reaction with NH2OH in ethanol provided 
isoxazoline (8) [X=0] while with NH2NH2 and PhNHNH2, respective pyrazolines (8) 
[X = NH and NPh] were obtained.'* 
NHAc 
(8) 
Doyl et al. carried out the dipolar addition of diazocarbonyl compounds to 
a,y9-unsaturated esters and nitriles in the presence of pyridine, which resulted in the 
formation of 2-pyrazolines. Halo and hydroxyl aryl pyrazolines were synthesized by 
Latif e/ al!' Cycloaddition of CH2N2 to RC6H4SO2 CH: CH [R = H, 4-Br, 4-Cl, 2-Me, 
4-Me] in the presence of EtsN gave 3-aryl sulphonyl-2-pyrazoline.' The dichalcones 
(9) [R = H, F, CI, Br, MeO] were cyclized with R ' N H N H S [R' = H, Me, Ph] to give 
the dipyrazolines (10).^ 
4-RC6H4COCH=CH—<A^ />—CH=CHCOC6H4R -4 
(9) 
4-RC6H4 
(10) 
C6H4R -4 
Cyclization of ketones (11) with NH2NH2, PhNHNHs and NH.OH produced 
pyrazolines and isoxazolines (12)'' [R=Ph, 4-MeOC6H4, 4-CIC6H4, 4-02NC„H4. 
PhCH:CH, X = NAc, NPh, O] respectively. Some 3-aroyl-4-aryl-2-pyrazol nes'" were 
prepared by condensation of a,^-unsaturated ketones with diazomethane in Et3N. 
,N 
C=0 
1 
CH 
II 
CH 
I 
R 
(11) 
(12) 
Kumar and Hussain" prepared N-[4-(acetyl/phenyl-5-aryl pyrazoline-3-yl) 
phenyl] aryl sulphonamides (14) [R = H, Me, R ' = H, CI, OMe, Me, NO2, R.' = Ac, 
Ph] by cyclization of compound (13) with NH2NH2 and PhNHNH2. 
/ ^ R—(f >^—SO,NH—<;\ />—COCH=CH—(\ > - R ' 
(13) 
R- r^ SO-,NH- W /~A\ N-N v\ /-^' 
R2 
(14) 
Some l,3,5-triphenyl-3-pyrazoline derivatives (15) [R = H, OMe, Clj were 
synthesized by heating 3- and 4-hydroxy chalcone derivatives with PhNHNH; using 
acetic acid as catalyst. The synthesized compounds were found to possess antifungal 
activity. Mishriky et al}^ reported the synthesis of l-acetyl-3,5-diaryl-A~-pyrazolines 
(16) [R ' = Ph, anisyl, HO(MeO)C6H3, R^  = ClaCftHj, FC6H4] by reacting chalcones 
with NH2NH2 in AcOH. The formation of aflatoxin by Aspergillus flavus was 
inhibited by compound 16. 
OH 
NPh 
(15) (16) 
Maib and Jerzmanowaska''' carried out the reaction of chromones (17) [R = 
R ' = H, Me] with H2NNHCSNH2 to give pyrazolines (18) [R^ = H, Me] and pyrazoles 
(19) [R^ = H, CSNH2, R''=R^ = H, Me]. 
(17) 
NHNHC(S)NH2 
•^^NC(S)NH2 
Shingare and Siddiqui reported the formation of arylsulfonyl pyrazolines and 
isoxazolines (20) [X = NH, NPh, O, R = H, Me, R ' = H, Me, CI, R^ = substituted Ph, 
heteroaryl] by the cyclocondensation of chalcones with NH2NH2, PhNHNH2 or 
NH2OH. 
Roda et al}^ prepared 5-aryl-l-phenyl-3-(3-isopropyl-4-iydroxy-6-
methylphenyl)-2-pyrazolines (21) [R = H, 2-, 3-, 4-OH, 2- and 4-Cl, 3- anc 4-NO:. 4-
OMe, 4-NMe2, etc.] by cyclocondensation of the chalcones with PhNHNH^ Kleefeld 
and Dutzmann'^ synthesized l,3,5-triphenyl-2-pyrazohne (22) by reacting 1-phenyl-
3-(4-hydroxy phenyl)-2-propen-l-one and PhNHNH2 in AcOH. They were used for 
the control of Erysiphe graminis. 
(21) (22) 
Upadhyay et al.'^ cycUzed 4-PhS02NHC6H4COCH: CHAr [Ar = Ph, 2-
O2NC6H4, 3-CIC6H4, 2-hydroxy-l-naphthyl, etc.] with NH2NH2/ AcOH or PhNHNHj 
to give pyrazoHnes (23) [R = Ac, Ph]. Singh' reported the condensation reaction of 
substituted thiazoHdinones with PhCHO or/7-anisaldehyde in the presence of NaOAc 
in AcOH to give phenyliminobenzyhdene thiazolidinones (24) [R = Ph, R ' = H, Ph, R 
= 4-MeOC6H4, R ' = Ph], which on cycHzation with hydrazines ga\e 
thiazoHdinopyrazolines (25) [R = Ph, R' = H, Ph, R = Ph, R ' = Ph, R' = H, Ph, R = 4-
MeOC6H4, R ' = Ph, R^  = H]. 
O 
H-
(23) 
•N 
PhN S 
(24) 
PhN 
CHR 
(2:5) 
;20 Sonare and Doshi carried out the condensation of 2'-hydroxy-4'-niethoxy 
chalcones (26) [R* - OMe, R^ = H, R ' = R^  = H, R '=R^ = OCH2O] with NH^NH, in 
ethanol to give l//-3-(2'-hydroxy-4'-methoxy)-5-substituted phenyl-2-pyrazolines 
(27). 
MeO OH 
MeO 
(26) 
-R-
1-Aryl-4,6-dimethyl pyrimidin-2 (l/f)-ones (28) [R = H, Me, OMe] with 
NH2OH and ACNHNH2 led to isoxazolines and pyrazolines (29)."' [same R, X = O, 
NAc] respectively. Compounds 30 and 31 were prepared by the reaction" of 
araldehyde hydrazones and araldoximes with biftinctional olefins in the presence of 
chloramine-T. 
Me. 
R 
o 
(28) 
R-
Me, 
\\ / -NHCONH 
(29) 
Me 
X' N 
N^N'Ph 
SOj-Ph S02-Ph 
(30) (31) 
Bratenko et al^^ synthesized 1-aryl (heteryl)-3-[3-aryl (heteryl)-4 pyrazolyl] 
propenones (34) [ R ' = Ph, R^ = Ph, 4-FC6H4, 4-CIC6H4, 4-BrC6H4, 4-MeOC6H4] by 
condensation of 4-aryl (heteryl)-4-formylpyrazoles (32) [R* = Ph, 2-thienyl, 5-methyl-
2-ftiryl, 3-pyridyI] with methyl aryl (heteryl) ketones (33) [R^ = Ph, 4-FC6H4, 4-
CIC6H4, 4-BrC6H4, 4-EtC6H4, 4-MeOC6H4]. The compound 34 on reaction with 
phenylhydrazine yielded I-phenyl-3-aryl (heteryl)-5-(4-pyrazolyl)-2-pyrazolines (35) 
[ R ' = Ph, R^ = Ph, 4-FC6H4, 4-CIC6H4, 4-BrC6H4,4-EtC6H4, 4-MeOC6H4]. 
CHO 
N-N 
Ph 
O 
H^C'^R^ 
(32) (33) (34) (35) 
Pimenov et al}'^ carried out the reaction of ketones (36) [n =0, 1, 0 R = H, H. 
NO2] with 99% hydrazine hydrate under acidic conditions (acetic acid, su furic acid) 
which gave cycHc product 5-(l-adamantyl)-3-phenylpyrazoHne (37). 
(CH2)„COCH=CH—(\ />—R 
(36) (37) 
— R 
Condensation of 3^-hydroxy-16-[(4-chlorophenyl) iTiethylene]-androst-5-en-17-one 
(38) with hydrazine hydrate in acetic acid afforded 1'-acetyl-r-//-5'-(4-chlorophenyr) 
androst-5-en-[17,16- c]-pyrazoline-3y9-ol (39). r-//-5'-(4-chlorophenyl)-androst-5-en-
[17,16- c]-pyrazoline-3y5-ol (40)^^ was also prepared by refluxing the compound 38 
and hydrazine hydrate in dioxane for 5 h. 
N-NH 
Bonacorso et al.^^ reported the regiospecific synthesis of a novel series of 4-
phenyl- and 3-alkyl(aryl)-5-hydroxy-5-trifluoromethyl-4,5-dihydro-l//-l -
tosylpyrazoles (pyrazolinyl jD-tolyl sulfones) (43). The l-/)-tosyl-2-pyrazolines were 
obtained from the cyclocondensation reaction of 3-phenyl- and 4-alkyl(aryl)-1,1,1-
trifluoro-4-alkoxy-3-alken-2-ones (41), [where alkyl are H, Me and aryl are -('6H5, 4-
CH3C6H4, 4-OCH3C6H4, 4-FC6H4, 4-CIC6H4, 4-BrC6H4] with /?-tosylhydrazine in a 
yield of 58 to 92% when toluene was employed as solvent. Their antimicrobial 
activities were also studied. 
O OR 
F,C R' 
R^ 
(41) 
O, 
Me 
NHNH2 
(42) 
R 
R' 
R^ 
Et 
H 
H 
Me 
Me 
H 
Me Me Me Me Me Me Me 
Ph 4-MePh 4-MeOPh 4-BrPh 4-ClPh 4-FPh H 
H H H H H H Ph 
A series of N'-nicotinoyl-3-(4'-hydroxy-3'-methyl phenyl)-5-(substituted 
phenyl)-2-pyrazolines (44)^^ were synthesized by the reaction between isoniazid 
(INH) and chalcones in the presence of acetic acid. [R - 4-methoxy phenyl, 4-chloro 
phenyl, 4-dimethyIamino phenyl. Phenyl, 3,4-dimethoxy phenyl, 2,3,4-trimethoxy 
phenyl, furyl, 4-fluoro phenyl, 2-chloro phenyl, 2,6-dichloro phenyl, 3-nitro phenyl]. 
(44) 
Amir et al.^^ synthesized a series of 3-(4-biphenyl)-5-substituted phenyl-2-
pyrazolines (49) [R = H, 2-Cl, 4-Cl, 4-N(CH3)2, 4-CH3, 4-OCH3, 3,4-(OCH3)2, 2,4,6-
(OCH3)3] and l-benzoyl-3-(4-biphenyl)-5-substituted phenyl-2-pyrazolines (48) [R, 
same as above] by condensation of chalcones with hydrazine hydrate. 3-Aryl-l-(4-
biphenyl) propen-1-ones (47) [R, same as above] were synthesized by treating 4-
acetyl biphenyl with aromatic aldehydes in the presence of methanol-dioxane and 
potassium hydroxide solution. These upon treatment with hydrazine hydrate and few 
drops of concentrated HCl, gave 3-(4-biphenyl)-5-substituted phenyl-2-pyrazolines 
(48). Reaction of compounds 48 with benzoyl chloride in presence of pyrimidine gave 
1 -benzoyl-3 -(4-biphenyl)-5-substituted phenyl-2-pyrazolines (49). 
^ ^ R 
(yo^. 
R 
(45) (46) (47) 
^ R 
(48) (49 > 
Rathish et al^'^ carried out the reaction of chalcones (52) with 4-hydrazinon 
benzenesulfonamide hydrochloride and obtained 1,3,5-trisubstituted pyrazoHnes 
bearing benzene sulfonamides (53). The intennediate chalcones (52) were prepared 
by base catalyzed Claisen-Schmidt condensation of the aromatic ketones (51) with 
different aromatic aldehydes. 
V Clh 
o 
(50) 
+ 
OHC 
(51) (52) 
SO2NF; 
(53) 
R-
R = 
R' 
50a, 52a-g, 53a-g; R ' = OH, R^ = OCH3, 50d, 52r, 52s, 53r, 53s 
50b, 52h-o, 53h-o; R ' = R^  = OCH3 
50c, 52p, 52q, 53p, 53q; R ' = OH, R^ H 
A series of l-acetyl/propyl-3-aryI-5-(5-chloro-3-methyl-l-phenyl-l//-pyrazoI-
4-yl)-2-pyrazolines (57) [R' = H, 4-CH3, 4-OCH3, 3-NO2, 4-Cl, 4-Br, 4-NO:, R^  = 
CH3, CH3CH2] were synthesized by Girisha et al. in one step by condensing suitably 
substituted propenones, NH2NH2.H2O and acetic/propionic acid. The 3-(5-chloro-3-
methyl-l-phenyl-l//-pyrazol-4-yl)-l-(aryl)-2-propen-l-one (56) [R' same as above] 
was prepared by the reaction of aldehyde (54) with appropriately subsituted 
10 
acetophenones (55) [R same as above]. These compounds were also screened for 
analgesic and anti-inflammatory activity. 
H3C CHO It N CI + 
HiC 
H,C 
(54) (55) (56) (57) 
Banday et al. synthesized 17-pyrazolinyl derivatives of pregnenolone (60) [R 
= C6H5, 3-FC6H5, 4-FC6H5, 4-CH3C6H5, 2-CH3C6H5, 3-CH3C6H5, C4H3O, 4-
OMeCeHs, 2-OMeC6H5, 2-CIC6H5] from the chalcone (59) in the presence of 
NH2NH2.H2O and AcOH. Compound 59 was prepared by condensation of 
pregnenolone (58) with various aromatic aldehydes. 
HO 
(58) (59) (60) 
Pant et al?^ carried out the synthesis of 3,5-diaryl-N-substituted pyrazolines 
(64) from a^-unsaturated ketones (63) and hydrazine hydrate with acetic/formic acid 
in ethanol/DMSO. Compounds (63) were prepared by condensation reaction of 
various aromatic aldehydes and ketones. [63a, 63b: R = R = R = H, R= CH3; 63h, 
63i: R = R'= R^- H, R^= R^ = Br; 62a, 63b: R = R'= R^ = R =^ R^  = H; 62i, 63j: R= 
R^- R^ = H, R ' = CI, R'' = Br; 62b, 63c: R = R'= R^ = R^ = H, R^  = NO2; 62j, 63k: R -
R'= R^= H, R^- Br, R^  = NO2; 62c, 63d: R = R'= R^=R^ = H, R^ = CI; 62k, 631: R -
R'= R^- H, R^= CI, R^  - NO2; 62d, 63e: R = R '= R^= R^ - H, R^ = NO2; 621, 63m: R 
11 
= R = R = H, R^= NO2, R = Br; 62e, 63f: R = R ' - R^ = H, R'= R = NO2; 62m. 63n; 
R = R ' = R-= R^= H, R^ = CI; 62f, 63g: R = R ' = R^=R^= H, R ' - Br; 62n. 63o; R = 
R ' = R- = R^ = H, R^  = OH; 62g, 63h: R = R ' = R^=R^ = H, R^= Br; 62o, 63p R - R-= 
'^ ^^Vrs-^ -i^ '^ ' X \ 
(63) 
I 
R 
(64) 
I 
/ 
Singh et al. reported the synthesis of pyrazoline derivatives (66) [R = R 
R^= H, R ' = R ^ = H, R^ = N 0 2 , R^ = R ^ = H, R ' = CI, R ' = R - = H, R^ = CI, R ' - R - = H, 
R^= Br] from dibenzalacetones (65) [R ' , R^, R^ same as above], formic acid and 
hydrazine hydrate in ethanol. They also studied photophysical properties of these 
compounds. 
O 
c=c-c-c=c 
H H H H 
R 
(65) (66) 
12 
Ql)i6euMo^ 
Pyrazoline is an important nitrogenous five-membered heterocyclic compcnent ol tiie 
drugs. Literature survey revealed that numerous pyrazoline derivatives have tound their 
clinical application. Several analogies of pyrazolidin-3,5-diones, pyrazolin-3-ones and 
pyrazolin-5-ones are also available as drugs; examples are felcobuzone, metobutazone. 
morazone, famprofazone and ramifenazone . Besides these, many pyrazoline derivatives 
have been found to possess a broad spectrum of biological activities such as antitumor, 
-if '1-1 T O 
anti-inflammatory, MAO-B inhibitors, agonist of cannabinoid receptors and 
antioxidant.''^ Out of these biological activities of pyrazolines and their derivati\es, 
antimicrobial and anticancer activities are of particular interest. Many pyrazoline oerivatives 
are also reported in the literature as having potent antifungal activity,"*" which were assayed 
against Cephalosporium acremonium, Helminthosporiiim oiyzae and Acheya orion and were 
found extensively active. In view of these reports and in continuation of our previous work'*' 
in steroidal chemistry, we have synthesized some new steroids containing pyrazoline ring 
fused with steroidal ring-B by using biosynthesized ZnO nanoparticles as a catalyst. The 
substrates selected for initial studies include cholest-5-en-7-one (67), 3y?-acetoxycho est-5-en-
7-one (68) and 3y^-chlorocholest-5-en-7-one (69)'* .^ The attractive features of this prcitocol are 
simple reaction procedure, short reaction time and easy products. The structures of newiy 
synthesized compounds have been assigned on the basis of elemental analysis and spectral 
(IR, 'H N M R , '^C N M R , MS) studies. To the best of our knowledge, this is the fust report 
about the synthesis of steroidal pyrazolines using nano metal oxide as a catalyst. 
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RNHNH-, /ZnO 
C2H5OH, reflux 
(67-69) 
X 
H (67) 
OAc (68) 
CI (69) 
(70-75) 
X R R 
H H (70) Ph (73) 
OAc H (71) Ph (74) 
CI H (72) Ph (75) 
Biological synthesis of ZnO nanoparticles using C. albicans and studying their Catalytic 
performance in the synthesis of steroidal pyrazo lines. Shamsuzzaman, Ashraf Mashrai, 
Hena Khanam, Rezq N. Aljawfi 
Arabian J. Chem. 2013 (in press):http://dx.doi.org/10.1016/i.arabic.2013.05.004 
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Reaction of cholest-5-en-7-one (67) with hydrazine hydrate: Sa-Cholestano-fS. 7- c dj-
pyrazoUne (70): 
Steroidal a,y9-unsaturated ketone 67 in ethanol was allowed to react with hydrazine 
hydrate under reflux condition in the presence of ZnO nanoparticles for 3 h, after usual v\ ork 
up and recrystallization a single product 70, m.p. 134-136 °C, was obtained. 
NH7NH, H,0 
C2H5OH, ZnO nano 
reflux, 3 h 
(67) (70) 
Characterization of compound 70 as 5a-cholestano-[5, 7- c d]-pyrazoline: 
The elemental analysis of compound 70 corresponded to the molecular formula 
C27H46N2.The IR data provided evidence for the formation of the expected compound. The 
compound showed intense band in the region of 3267 cm' due to N-H stretching vibration. In 
addition, other important absorption band at 1657 cm"' was attributed to C=N stretching. 
Further evidence for the formation of compound 70 was well supported by its ' H hMR and 
'"'C NMR spectra. The ' H N M R spectrum of the compound exhibited one-proton singlet at ^ 
5.2 for NH (exchangeable with D2O). Angular and side-chain methyl protons were observed 
at d 1.19 (CIO-CH3), 0.75 (CI3-CH3), 0.91 and 0.85 for other methyl protons. '^ C NMR 
spectrum of the compound also supported the proposed structure and displayed characteristic 
signals aXd 155 for C=N and 45 for C-N, in addition to the signals of cholestane series. The 
mass spectrum was also in good agreement with its molecular formula which exhibited strong 
molecular ion peak at m/z 398. 
On account of the above descriptive discussion, the compound 70 can be suitably 
characterized as 5a-cholestano-[5, 7- c dj-pyrazoline. 
15 
cholestano-[5, 7- c dj-pyrazoline (71): 
Steroidal ^.^-unsaturated ketone 68 in ethanol was allowed to react with hydrazine 
hydrate under reflux condition in the presence of ZnO nanoparticles for 3 h, after usual work 
up and recrystallization a single product 71, m.p. 137-139 °C, was obtained. 
H,C 
NH^NH, HoO 
C2H5OH, ZnO nano 
reflux, 3h 
O 
H N — N 
(68) (71) 
Characterization of compound 71 as 3p-acetoxy-5a-cholestano-[5, 7- c dj-pyrazoline: 
The elemental analysis of compound 71 corresponded to the molecular formula 
C29H4gN202. The IR data provided evidence for the formation of the expected structure. The 
compound showed intense band in the region of 3270 cm'' due to N-H stretching vibration. In 
addition, other important absorption bands at 1736 and 1655 cm'' were attributed to C=0 and 
C=N, respectively. Further evidence for the formation of compound 71 was well supported 
by its ' H N M R and '^ C NMR spectra. The ' H N M R spectrum of the compound exhibited 
one-proton singlet at S 5.3 for NH (exchangeable with D2O). A one-proton broad multiplet 
centered at S 4.7 was assigned to C3-aH (axial, W V2 = 15 Hz) and a sharp singlet for three 
acetoxy group protons appeared at 2.03. Angular and side-chain methyl protons were 
observed at t> 1.18 (CIO-CH3), 0.70 (CI3-CH3), 0.92 and 0.85 for other methyl protons. '^ C 
NMR spectrum of the compound also supported the proposed structure and displayed 
characteristic signals at S 156 for C-N and 47 for C-N, in addition to the signals of 
cholestane series. The mass spectrum was also in good agreement with its molecular formula 
which exhibited strong molecular ion peak at m/z 456. 
On account of the above evidences, the compound 71 can be suitably characterized as 
3P-acetoxy-5a-cholestano-[5, 7- a dj-pyrazoline. 
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Reaction of 3p-chlorocholest-5-en-7-one (69) with NH2NH2.H2O: 3p-Chloro-5a-
cholestano-[5, 7- c d]-pyrazoline {72): 
Steroidal a,y5-unsaturated ketone 69 in ethanol was allowed to react wit? hydrazine 
hydrate under reflux condition in the presence of ZnO nanoparticles for 3.5 h, after usual 
work up and recrystallization a single product 72, m.p. 140-142 °C, was obtained. 
NH2NH2H2O 
C2H5OH, ZnO nano 
reflux, 3.5 h 
(69) 
Characterization of compound 72 as 3p-chloro-5a-cholestano-[5, 7- c dj-pyrazoline: 
The elemental analysis of compound 72 corresponded to the molecular fonnula 
C27H45CIN2 (Beilstein positive). The IR data provided evidence for the formation of the 
expected structure. The compound showed intense band in the region of 3265 cm" due to N-
H stretching vibration. In addition, other important absorption bands at 1650 and '^ 76 cm' 
were attributed to C=N and C-Cl stretchings, respectively. Further evidence for the formation 
of compound 72 was well supported by its ' H N M R and '^C NMR spectra. The 'H N M R 
spectrum of the compound exhibited one-proton singlet at 3 5.4 for NH (exchangeaole with 
D2O). A one-proton broad multiplet centered at S 3.9 was assigned to C3-aH (axial, PV V? =' 
15 Hz). Angular and side-chain methyl protons were observed at S 1.19 (CIO-CH3), 0.75 
(CI3-CH3), 0.92 and 0.86 for other methyl protons. '^ C NMR spectrum of the compound also 
supported the proposed structure and displayed characteristic signals at 157 for C=N and 48 
for C-N, in addition to the signals of cholestane series. The mass spectrum was also in good 
agreement with its molecular formula which exhibited a strong molecular ion peak at m/z 
432/434. 
On account of the above descriptive discussion, the compound 72 can be suitably 
characterized as 3P-chloro-5a-cholestano-[5, 7- c dj-pyrazoline. 
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c dj-pyrazoline (73): 
Steroidal ^./^-unsaturated ketone 67 in ethanol was allowed to react with phenyl 
hydrazine under reflux condition in the presence of ZnO nanoparticles for 3 h. After usual 
work up and recrystallization from methanol a solid compound 73 was obtained, m.p. 185-
187 °C. 
PhNHNH, 
C2H5OH, ZnO nano 
reflux, 3 h 
(67) (73) 
Characterization of compound 73 as 2'-phenyl-5a-cholestano-[5, 7- c dj-pyrazoline: 
The elemental analysis of compound 73 corresponded to the molecular formula 
C33H50N2. The selected diagnostic bands in IR spectrum of synthesized compound 73 
provided useful information for determining its structure. The absorption bands at 3095, 1590 
and 1406 cm'' confirmed the presence of aromatic ring. In addition, other important 
absorption bands at 1640 and 1233 cm'' were attributed to C=N and C-N, respectively. 
Further evidence for the formation of compound 73 was well supported by its ' H N M R and 
'^C NMR spectra. The ' H NMR spectrum of the compound exhibited signals at S 7.34-7.32 
(m, 2H), 7.2-7.1 (m, 2H), 6.8 (m, IH) attributed to aromatic protons. Angular and side-chain 
methyl protons were observed at (51.12 (CIO-CH3), 0.71 (CI3-CH3), 0.92 and 0.85 for other 
methyl protons. '^C NMR spectrum of the compound also supported the proposed structure 
and displayed characteristic signals at ^ 156 for C=N and 48 for C-N, in addition of the 
signals of cholestane series. The mass spectrum was also in good agreement with its 
molecular formula which exhibited strong molecular ion peak at m/z 474. 
On account of the above evidences, the compound 73 can be suitably characterized as 
2'-phenyl-5a-cholestano-[5, 7- c dj-pyrazoline. 
Reaction of 3P-acetoxycholest-5-en-7-one (68) with phenyl hydrazine: 3P-Acetoxy-2'-
phenyl-5a-cholestano-[5, 7- c dj-pyrazoline (74): 
Steroidal a,;5-unsaturated ketone 68 in ethanol was allowed to react with phenyl 
hydrazine under reflux condition in the presence of ZnO nanoparticles for 3 h. At^er usual 
work up and recrystallization from methanol a solid compound 74 was obtained, m.p. 180-
182 °C. 
H C^ 
PhNHNH-, 
O 
CyH^OH, ZnO nano /^^. 
reflux, 3 h "3<-
r 
(68) (74) 
Characterization of compound 74 as 3p-acetoxy-2'-phenyl-5a-cholestano-[5, 7- c dj-
pyrazoline: 
The elemental analysis of compound 74 corresponded to the molecular formula 
C35H52N2O2. The selected diagnostic bands in IR spectrum of the synthesized compound 
provided useful information for determining its structure. The absorption bands at 3130, 1564 
and 1394 cm"' confirmed the presence of aromatic ring. In addition, other important 
absorption bands at 1734 and 1630 cm'' were attributed to C=0 (ester) and C=N, 
respectively. Further evidence for the formation of compound 74 was well supported by its 
' H N M R and '•'C NMR spectra. The ' H N M R spectrum of the compound exhibited signals at 
d 7.30-7.34 (m, 2H), 7.1-7.2 (m, 2H) and 6.9 (m, IH) assigned to aromatic protons. P'. one -
proton broad multiplet centered at 8 4.6 was assigned to C3-aH (axial, W V2 = 15 Hz) and a 
sharp singlet for three acetoxy group protons appeared at 2.01. Angular and side-chain 
methyl protons were observed at d 1.19 (CIO-CH3), 0.75 (CI3-CH3), 0.92 and 0.85 for other 
methyl protons. '^C NMR spectrum of the compound also supported the proposed structure 
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signals of cholestane series. The mass spectrum was also in good agreement with its 
molecular formula which exhibited strong molecular ion peak at m/z 532. 
On account of the above evidences, the compound 74 can be suitably characterized as 
3P-acetoxy-2'-phenyl-5a-cholestano-[5, 7- c d]-pyrazoline. 
Reaction of 3P-chlorocholest-5-en-7-one (69) wit/t phenyl hydrazine: 3fi-Chloro-2'-phenyl-
5a-cholestano-[5, 7- c d]-pyrazoline (75): 
Steroidal a,y9-unsaturated ketone 69 in ethanol was allowed to react with phenyl hydrazine 
under reflux condition in the presence of ZnO nanoparticles for 3 h. After usual work up and 
recrystallization from methanol a solid compound 75 was obtained, m.p. 170-172 °C. 
PhNHNH, 
C2H5OH, ZnO nano 
reflux, 3 h 
(69) (75) 
Characterization of compound 75 as 3P-chloro-2'-phenyl-5a-cholestano-[5, 7- c d]-
pyrazoline: 
The elemental analysis of compound 75 corresponded to the molecular formula 
C33H49CIN2 (Beilstein positive). The selected diagnostic bands of IR spectrum of the product 
provided useful information for determining its structure. The absorption bands at 3129, 1590 
and 1407 cm"' confirmed the presence of aromatic ring. In addition, other important 
absorption bands at 1635 and 743 cm"' were attributed to C=N and C-Cl, respectively. 
Further evidence for the formation of compound 75 was well supported by its H NMR and 
'^C NMR spectra. The ' H NMR spectrum of the compound exhibited signals at 5 7.31-7.32 
(m, 2H), 7.1-7.2 (m, 2H), 6.8 (m, IH), assigned to aromatic protons. A one-proton broad 
multiplet centered at d 3.9 was assigned to C3-«H (axial, W'A = 17 Hz). Angular and side-
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chain methyl protons were observed at d" 1.19 (CIO-CH3), 0.75 (C13-CH?), 0,92 and 0,85 for 
other methyl protons. "C NMR spectrum of the compound also supported the proposed 
structure and displayed characteristic signals at 5 157 for C=N and 49 for C-N, in addition of 
the signals of cholestne series. The mass spectrum was also in good agreement vvith its 
molecular formula which exhibited prominent molecular ion peak at mz 508/510. 
On account of the above evidences, the compound 75 can be suitably characterized as 
3P-chlorO'2'-phenyl-5a-cholestano-[5, 7- c dj-pyrazoline. 
Synthesis of catalyst 
ZnO nanoparticles were biosynthesized under green conditions by using C. albicans 
as a green, reusable, nontoxic and inexpensive heterogeneous catalyst, 
Characterization of catalyst 
JJV spectrophotometry study 
The UV-vis absorption spectra findings demonstrate a novel technique for the 
preparation of ZnO nanoparticles (Figure 1), by dispersing ZnO nanoparticles in distilled 
water and using distilled water as the reference. An absorption peak focused at 381 nm (3.26 
eV) was found. 
3 
id 
c 
Q» 
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Figure 1. UV-visible spectrum of ZnO nanoparticles 
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XRD analysis 
X-ray diffraction was taken in order to further confirm ZnO phase of the 
nanoparticles. The XRD patterns of the obtained ZnO nanoparticles are shown in Figure 2. 
Powder XRD of the product was carried out with Cu Ka radiation (X = 0.1540 nm), 
employing a scanning rate of 0.02° s~' and 29 ranges from 20" to 80° for ZnO. All the peaks 
of XRD are very well matched with the hexagonal phase (wurtzite structure) by comparison 
with the data from JCPDS card No. 89-7102 and no indication of a secondary phase. The 
strong and narrow diffraction peaks indicate that the product has well crystalline structure. 
The crystallite size of the nanoparticles was calculated using Debye Scherrer formula 
D = K Xyp Cos e. 
Where, K is constant, X is the wavelength of employed X-rays (1.54056 A), p is corrected full 
width at half maximum and 0 is Bragg's angle. The 20 value from the equation comes out to 
be at 35.815 and therefore the calculated crystallite size of the powder particles is as about 25 
nm. 
TO 
A-<JLA. 
60 
2© (degrees) 
Figure 2. XRD image of the ZnO nanoparticles 
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SEM and TEM analysis 
The conformation of the nanostructure morphology of ZnO particles comes irom the 
analysis of SEM and TEM micrographs. SEM micrograph (Figure 3) showed the average 
size of nanoparticles between 15-25 nm. 
Figure 3, SEM image of the ZnO nanoparticles 
The size and morphology of ZnO particles analyzed by TEM is represented in Figure 4. This 
image reveals that most of the ZnO nanoparticles are quasi-spherical and their diameter is 
about ~20 nm. This result is in accordance with the value calculated from the X-ray 
diffraction. 
Figure 4. TEM image of the ZnO nanoparticles 
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Photoluminescence analysis 
The PL spectrum of ZnO nanoparticles consists of two emission peaks (Figure 5). A 
weak deep-level emission at 2.3 eV in the visible range caused by a structural defect. The 
other peak in the UV range at 3.04 eV which can be explained by the direct combination of 
excitons through an exciton-exciton collision process and the lower energy peak in the 
asymmetric UV emission is associated with band-to-acceptor transitions due to the large 
binding energy of ZnO. 
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Figure 5. The PL spectrum of ZnO nanoparticles 
Thermal stability 
The differential thermal analysis and themio gravimetric analysis (DTA/TGA) has been 
performed for the biosynthesis ZnO nanoparticles. TGA curve (Figure. 6) indicates that the 
weight loss starts at -200 °C because of the evaporation of water, the major weight loss occurs 
between 340 to 550 °C, which is around 40 % of the original weight due to the removal and 
decomposition of organic groups present in the sample during the biosynthesis. No 
decomposition or reaction occurs at temperatures above 700 °C. The exothermic peak observed 
in the DTA plot as shown in Figure 6 between 370-520 °C illustrates the maxima at -435 °C 
which exemplifies the bum-out of organic composition. Apart from this, no other exothermic or 
endothermic peak is present in DTA curve. 
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Figure 6. TGA and DTA curves of ZnO nanoparticles 
The catalytic performance of ZnO in the synthesis of steroidal pyrazolines 
As expected, the catalytic system is influenced by various reaction parameters, such 
as amount of the catalyst employed, effect of catalyst and solvent system. 3yff-Acetoxycholest-
5-en-7-one and hydrazine hydrate in ethanol were selected as model substrates for carrying 
out the optimization studies for synthesis of steroidal pyrazolines. 
Catalytic Loading 
The effect of catalyst loading on the synthesis of model reaction was mvestigated by 
varying the catalyst amount from 0 to 10 mol % (Table 1). 
Table 1. Effect of catalyst loading on the model reaction. 
Entry 
1 
2 
3 
4 
Catalysts (mol %) 
2.5 
5 
7.5 
10 
Time (h) 
4 
3 
3 
3 
Yield (%)" 
30 
80 
80 
80 
Yields are related to isolated pure products 
It was found that 5 mol % of the catalyst was sufficient to get optimum yields in less reaction 
time while less than 5 mol % of the catalyst increased the reaction time. Use of more than 5 
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mol % of the catalyst did not show any profound effect on the reaction rate as well as the 
yield this may be attributed to the coagulation of ZnO nanoparticles which decreased the 
effective surface area of the catalyst/^ 
Effect of solvent 
We then tried to screen the reaction in various organic solvents in order to optimize 
the reaction conditions using ZnO nanoparticles as catalyst (Table 2). 
Table 2. Solvent screening for the model reaction. 
Entry 
1 
2 
3 
4 
5 
Solvent 
Acetonitrile 
Methanol 
DMSO 
Toluene 
Ethanol 
Yield (%)' 
40 
75 
60 
30 
80 
"Yields are related to isolated pure products 
The solvent screening experiments revealed that the reaction yield is dependent on the 
polarity and the coordinating ability of the solvents. The polar solvents afforded better yield 
than the nonpolar ones and the best result was obtained in ethanol in which ZnO 
nanoparticles catalyst worked most efficiently by phasing out of the desired product. 
Recyclability of Catalyst 
After completion of the model reaction in specified time, the catalyst was recovered by 
filtration, washed with dichloromethane and methanol and dried at 150 °C for 4 h and used 
for the subsequent cycle.'*'' The results revealed that the catalyst exhibited good catalytic 
activity up to five cycles (Table 3). 
Table 3. Recycling study of catalyst for the model reaction. 
Entry 
1 
2 
3 
4 
5 
6 
Time (h) 
3 
3 
3 
3 
3 
6 
Yield (%)' 
80 
80 
80 
80 
80 
50 
'Yields are related to isolated pure products 
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Studying the superiority ofZnO nanoparticles over some other metal oxide nanoparticles 
Various catalysts were employed to evaluate the capability and etiiciency of the 
catalyst (Table 4). Initially, the model reaction was performed in the absence of any catalyst 
and the reaction proceeded very slow and the expected product was in a very small quantity 
(entry 1) and when the model reaction was examined with MgO, CaO, Fe20-, and AhO^ 
nanoparticles using 5 mol% of each catalyst separately the reaction took longer time period 
for completion with lower yield of the product (entry 2-5). With ZnO nanoparticles the 
reaction was accelerated and yield of the desired product was maximum (Table 4, entry 6). 
Table 4. The superiority of ZnO nanoparticles over some other metal oxide nanoparticles. 
Entry Catalysts Time (h) Yield (%)" 
24 20 
MgO 12 28 
CaO 10 30 
Fe203 32 
AI2O3 53 
ZnO 80 
Yields are related to isolated pure products 
These observations may be explained by HSAB (hard and soft acid base) concept 
Unlike Zn^ ^ which is a borderline Lewis acid, all the rest of nanoparticles are classified as 
hard Lewis acids and the first step of the reaction is formation of intermediate by the 
interaction of Lewis acid catalyst with rather soft Lewis base unsaturated carbonyl group was 
assumed to be efficient for ZnO nanoparticles than the other."*^  
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With these excellent results in our hand, the mechanism of the reaction can be 
proposed which involves Michael addition and then intramolecular cyclization catalyzed by 
ZnO nanoparticles as presented in Scheme 1. In first step, ZnO nanoparticles increase the 
electrophilicity of carbonyl group which in turn accelerate the Michael addition step. At the 
time of cyclization, the particular catalyst plays the key role where ZnO acts as a mild acid 
and activates the ketone group by polarization (through coordination) and hence facilitates 
the intramolecular nucleophilic attack by the NH2 group leading to the ring closure which 
ultimately forms the final product and again the catalyst enters into the catalytic cycle. 
^ 
^ 
. / ^^9 NNH, „ / 
Scheme 1. Proposed mechanism of formation of 5a-cholestano-[5, 7- c c/]-pyrazoline 
derivatives catalyzed by ZnO nanoparticles. 
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Stereochemistry 
The stereochemical assignation of C5-N bond has been estabhshed on the basis of 
mechanism as well as on 'H and '^C NMR spectral analysis of the compounds. During the 
course of reaction, the nucleophilic attack of N of the reagent at C-5 does occur preferably 
from less hindered (a) side because of the steric encumbrance imposed by axial (ji) methyl 
group at C-10, resulting axial (a) position of C5-N bond and trans to ClO-axial methyl group 
(A/B ring junction trans). The determination of ring fusion stereochemistry in angularly 
methylated six-membered ring compounds is not an easy task by either chemical or physical 
methods, NMR spectroscopy may, however, greatly aid in the solution of this problem. ' C 
NMR values of C-19 and C-9 are strongly dependent on the ring fiision stereochemistry. The 
cis and trans steroids differ most significantly at C-19 and these signals will surely be of 
prime value to characterize the nature of the ring junction.''^ In d\\-trans steroids, the C-19 
resonance is well separated from the majority of those of the other carbons. In the compounds 
70-75, C-19 chemical shift values were observed in the range of 16-18 ppm, which is 
consistent with values obtained for trans steroids"*^ (A/B ring junction trans). Furthennore the 
half band width {WIQ) values of C3-axial proton in the 'H NMR spectrum of the synthesized 
compounds clearly suggest that A/B ring junction is trans.^^ 
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General 
Melting points were determined on a Kotler apparatus. The IR spectra weni recorded 
on KBr pellets with Interspec 2020 FT-IR Spectrometer spectro Lab and values are given in 
cm"'. 'H and '-^ C NMR spectra were run in CDCI3 on a Bruker Avance II 500 NMR 
Spectrometer at 500 MHz and 125 MHz, respectively. Chemical shifts (S) are n;ported in 
ppm relative to the TMS ( ' H NMR) and to the solvent signal ('^ C NMR spectra). Mass 
Spectra were recorded on a JEOL D-300 Mass Spectrometer. Thin layer chromatography 
(TLC) plates were coated with silica gel G and exposed to iodine vapors to check the 
homogeneity as well as the progress of reaction. Sodium sulfate (anhydrous) was used as a 
drying agent. The optical absorbance spectra were taken by using UV-vis double beam 
Perkin-Elmer LAMDA 35 spectrophotometer at room temperature in the wavelength range of 
300-600 nm. X-ray diffraction (XRD) patterns of the nanoparticles were obtainec at room 
temperature, with a step of 0.02°, using Bniker D8 ADVANCE X-ray diffractometer with Cu 
Ka radiation (?.= 1.54178 A) in the range of 0° <20<1OO° at 40 kV. SEM images were 
obtained using a field emission scanning electron microscope (JSM-7600F, JEOl., Tokyo 
Japan) at an accelerating voltage of 15 kV and TEM images were obtained with ultra-high 
resolution FETEM (JEOL, JEM-2100F) at an accelerating voltage of 200 kV. 
Photoluminescence (PL) spectra were measured using a Cary Eclipse EL06063917 
fluorescence spectrophotometer with a xenon arc lamp as the light source. The thermal 
studies were carried out using TGA/DTA- 60H instrument (SHIMADZU) at a heating rate of 
20°Cmin"'. 
3fi-Chlorocholest-5-ene: 
Freshly distilled thionyl chloride (20 mL) was added gradually to cholesterol 25 g) at 
r.t. A vigorous reaction ensured with evolution of gaseous products. When the reaction 
slackened, the mixture was gently heated at temperature 50-60 °C on water bath for 1 h and 
then poured into water with constant stirring. The yellow solid thus obtained was filtered 
under suction and washed several times with ice-cold water and air dried. Recrystailization 
from acetone gave 3y5-chlorocholest-5-ene (20 g), m.p. 95-96 °C (reported, m.p. 96-97 "C)."*^  
Cholest-5-ene: 
3y9-ChIorocholest-5-ene (10 g) was dissolved in warm amyl alcohol (230 niL) and 
sodium metal (20 g) was added in small portion to the solution with continuous stirring over a 
period of 8 h. The reaction mixture was warmed occasionally. When all the sodium metal 
was dissolved, methanol was added and the reaction mixture was poured into water, acidified 
with dilute HCl and then allowed to stand overnight. A white crystalline solid thus obtained 
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was filtered under suction and washed thoroughly with water and air dried. The crude 
material was recrystallized from acetone to provide cholest-5-ene as cubes (8.3 g), m.p. 88-89 
°C (reported m.p. 89-91 °C). ^^' 
Cholest-5-en-7-one (67): 
A solution of butyl chromate [t-butyl alcohol (60 mL), CrOs (20 g), acetic acid (84 
ml) and acetic anhydride (10 mL)]''^ was added at 0 °C to a solution of cholest-5-ene (8 g) in 
CCI4 (150 mL), acetic acid (30 mL) and acetic anhydride (10 mL). The contents were 
refluxed for 3 h and then diluted with water. The organic layer was washed with sodium 
bicarbonate solution (5%) and water and then dried over anhydrous sodium sulfate. 
Evaporation of the solvents under reduced pressure furnished cholest-5-en-7-one (67) which 
was recrystallized from methanol (3.1 g), m.p. 128 °C (reported, m.p. 125-129 °C).'* "^ 
3P-Acetoxycholest-5-ene: 
A mixture of cholesterol (100 g), pyridine (150 mL, freshly distilled over KOH) and 
freshly distilled acetic anhydride (100 mL) was heated on a water bath for 2 h. The reaction 
mixture was poured into ice cold water and solid mass thus obtained was filtered under 
suction, washed thoroughly with water until free from pyridine and then air-dried. 
Recrystallization of the crude product from acetone gave 3/?-acetoxycholest-5-ene (95 g), 
m.p. 114 °C (reported, m.p. 115-116 °C).^ ^ 
3p-Acetoxycholest-5-en-7-one (68): 
A solution of butyl chromate [t-butyl alcohol (60 mL), CrOi (20 g), acetic acid (84 
mL) and acetic anhydride (10 ml)]''^ was added at 0 °C to a solution of 3y9-acetoxycholest-5-
ene (8 g) in CCI4 (150 mL), acetic acid (30 mL) and acetic anhydride (10 mL). The contents 
were refluxed for 3 h and then diluted with water. The organic layer was washed with sodium 
bicarbonate solution (5 %) and water and then dried over anhydrous sodium sulfate. 
Evaporation of the solvents under reduced pressure furnished 3^-acetoxycholest-5-en-7-one 
(67) which was recrystallized from methanol (3.2 g), m.p. 161-163 °C (reported, m.p. 164 
3P-Chlorocholest-5-en- 7-one (69): 
A solution of butyl chromate [t-butyl alcohol (60 mL), CrOs (20 g), acetic acid (84 
mL) and acetic anhydride (10 mL)]''^ was added at 0 °C to a solution of 3y9-chlorocholest-5-
ene (8 g) in CCI4 (150 mL), acetic acid (30 mL) and acetic anhydride (10 mL). The contents 
were refluxed for 3 h and then diluted with water. The organic layer was washed with sodium 
bicarbonate solution (5 %) and water and then dried over anhydrous sodium sulfate. 
Evaporation of the solvents under reduced pressure furnished 3^-chlorocholest-5-en-7-one 
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(69) which was recrystalHzed from methanol (3.4 g), m.p. 144 °C (reported, m.p. 144-145 
General procedure for the synthesis of steroidal pyrazoline derivatives (70-75): 
A mixture of a,y?-unsaturated steroidal ketones (67-69) (1 mmol), hydrazine hydrate/ 
phenyl hydrazine (1 mmol) and ZnO nanoparticles catalyst (5 mol%), in ethanol (5 mL) was 
refluxed for 3-3.5 h. The progress of the reaction was followed by TLC. After completion of 
the reaction, the mixture was filtered to remove the catalyst and the filtrate was taken in 
diethyl ether, washed with water and dried over anhydrous sodium sulfate. Removal of 
solvent gave the crude product which was recrystalHzed from methanol to obtain the pure 
compounds (70-75). 
5a-Cholestano-[5, 7- c d]-pyrazoline (70) 
Yield (82%); m.p. 134-136 °C; Anal. Calcd for C27H46N2: C, 81.34, H, 11.63, N, 7.03; found; 
C, 81.37, H, 11.66, N, 7.05; IR (KBr) v cm"' 3267 (NH), 1657 (C=N), 1268 (C-N); 'H N M R 
(CDCI3, 500 MHz) 6 5.2 (s, IH, NH), 2.32 (s, 2H, C6-H), 1.19 (s, 3H, CIO-CH3), 0.75 (s, 3H, 
CI3-CH3), 0.91 and 0.85 (other methyl protons); '^C NMR (CDCI3, 125 MHz) d 15:i, 65, 47, 
46, 45, 43, 42, 41, 40, 39, 36, 35, 32, 31, 30, 29, 28, 27, 26, 25, 24, 23, 22, 22, 21, IS, 16; MS 
(EI): {m/z) 398 [M^ ]. 
3p-Acetoxy-5a-cholestano-[5, 7- c d]-pyrazoline (71) 
Yield (80%); m.p: 137-139 °C; Anal. Calcd for C29H48N2O2: C, 76.27, H, 10.59, N, 6.13; 
found; C, 76.24, H, 10.55, N, 6.9; IR (KBr) v cm'' 3270 (NH), 1736 {OCOCU^), 1655 
(C=N), 1265 (C-N), 1235 (C-O); 'H NMR (CDCls, 500 MHz) 8 5.3 (s, IH, NH), 4.7 (m, IH, 
C3a-H, WY2^\5 Hz, A/B trans), 2.5 (s, 2H, C6-H), 2.03 (s, 3H, OCOCH3), 1.1^ (s, 3H, 
CIO-CH3), 0.70 (s, 3H, CI3-CH3), 0.92 and 0.85 (other methyl protons); '^ C NMR (CDCI3, 
125 MHz) 5 172 , 156, 74, 66, 47, 46, 45, 43, 42, 41, 40, 39, 36, 35, 32, 31, 30, 29, 28, 27, 26, 
25, 24, 23, 22, 21, 20, 19, 16. MS (EI): {m/z) 456 [M^]. 
3p-Chloro-5a-cholestano-[5, 7- c dj-pyrazoline (72) 
Yield (82%); m.p. 140-142 °C; (Beilstein positive); Anal. Calcd for C27H45CIN2: C, 74.87, H, 
10.47, N, 6.47; found; C, 74.85, H, 10.48, N, 6.44; IR (KBr) v cm"' 3265 (NH), 1650 (C=N). 
1254 (C-N) , 776 (C-Cl); ' H NMR (CDCI3, 500 MHz) S 5.4 (s, IH, NH), 3.9 (m, IH, C3a-H. 
WV2=\7 Hz, A/B trans), 2.65 (s, 2H, C6-H), 1.19 (s, 3H, CIO-CH3), 0.75 (s, 3H, Cl.^-CHj). 
0.92 and 0.86 (other methyl protons); '^C NMR (CDCI3, 125 MHz) S 159, 64, 60.2, 48, 47. 
46, 43, 42, 41, 40, 39, 36, 35, 32, 31, 30, 29, 28, 27, 26, 25, 24, 23, 22, 21, 19, 16; MS (EI): 
(m/z) 432/434 [M^]. 
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2'-Phenyl-5a-cholestano-[5, 7- c dj-pyiazoline (73) 
Yield (70%); m.p. 185-187 °C; Anal. Calcd for C33H50N2: C, 83.84, H, 10.62, N, 5.90; found; 
C, 83.87, H, 10.66, N, 5.92; IR (KBr) v cm"'1640 (C=N), 3095, 1590, 1406 (aromatic ring), 
1233 (C-N); 'H N M R (CDCI3, 500 MHz) S 7.34-7.32 (m, 2H), 7.2-7.1 (m, 2H), 6.8 (m, IH), 
2.32 (s, 2H, C6-H), 1.12 (s, 3H, CIO-CH3), 0.71 (s, 3H, CI3-CH3), 0.92 and 0.85 (other 
methyl protons); '^C NMR (CDCI3, 125 MHz) S 156, 147, 131, 130, 122, 115, 113, 65, 48, 
47, 46, 43, 42, 41, 40, 39, 36, 35, 32, 31, 30, 29, 28, 27, 26, 25, 24, 23, 22, 21, 20, 19, 16; MS 
(EI): (m/z) 474 [M^ ]. 
3P-Acetoxy-2'-pltenyl-5a-cholestano-[5, 7- c dj-pyrazoline (74) 
Yield (80%); m.p. 180-182 °C; Anal. Calc. for C35H52N2O2: C, 78.90, H, 9.84, N, 5.62; 
found; C, 78.88, H, 9.82, N, 5.58; IR (KBr) v cm"' 3130, 1564, 1394 (aromatic ring), 1734 
(OCOCH3), 1630 (C=N), 1242 (C-N), 1239 (C-0); ' H NMR (CDCI3, 500 MHz) S 7.30-7.34 
(m, 2H), 7.1-7.2 (m, 2H), 6.9 (m, IH), 4.6 (m, IH, C3a-H, W'A^IS Hz, A/B trans), 2.32 (s, 
2H, C6-H), 1.19 (s, 3H, CIO-CH3), 0.75 (s, 3H, CI3-CH3), 0.92 and 0.85 (other methyl 
protons); '^C NMR (CDCI3, 125 MHz) S 172, 156, 145, 130, 129, 120, 116, 114, 74, 66, 48, 
47,46, 43, 42,41, 40, 39, 36, 35, 32, 31, 30, 29, 28, 27, 26, 25, 24, 23, 22, 21, 20, 19, 16; MS 
(EI): (m/z) 532 [M^]. 
3P-Chloro-2'-phenyl-5a-cholestano-[5, 7- c d]-pyrazoline (75) 
Yield (76%); m.p. 170-172 °C; (Beilstein positive); Anal. Calc. for C33H49CIN2: C, 77.84, H, 
9.70, N, 5.50; found; C, 77.88, H, 9.72, N, 5.54; IR (KBr) v cm"' 3129, 1590, 1407 (aromatic 
ring), 1635 (C=N), 1235 (C-N), 743 (C-Cl); 'H NMR (CDCI3, 500 MHz) 6 7.31-7.32 (m, 
2H), 7.1-7.2 (m, 2H), 6.8 (m, IH), 3.9 (m, IH, C3a-H, W V2 = 17 Hz, A/B trans), 2.32 (s, 2H, 
C6-H), 1.19 (s, 3H, CIO-CH3), 0.75 (s, 3H, CI3-CH3), 0.92 and 0.85 (other methyl protons); 
'^ C NMR (CDCI3, 125 MHz) 6 157, 146, 128, 126, 119, 115, 114, 64, 60, 49, 47, 46, 43, 42, 
41, 40, 39, 36, 35, 32, 31,.30, 29, 28, 27, 26, 25, 24, 23, 22, 21, 19, 16; MS (EI): {m/z) 
508/510 [M'']. 
Biological synthesis ofZnO nanoparticles 
The ZnO nanoparticles were prepared by biological methods. C. albicans cells were 
allowed to grow as a suspension culture in sterile distilled water containing nutrient broth 
media for 24 h and treated with 1.0% NaCl. 25 ml of culture was taken and diluted four times 
by adding 75 mL of sterile distilled water containing nutrients. This diluted culture solution 
was again allowed to grow for another 24 h. 20 mL aqueous solution of 1 mM zinc oxide 
(ZnO) was added to the culture solution and it was kept at 30 °C for 24 h until white 
deposition starts to appear at the bottom of the flask, indicating the initiation of 
33 
transfonnation. The culture solution was cooled and allowed to incubate at room temperature 
in the laboratory ambience. After 15 h, the culture solution was observed to have distinctly 
makeable coalescent white clusters deposited at the bottom of the flask. The reaction mixture 
was subjected to centrifugation for 15 min. The resulting pellet was stored at dark until 
further used. 
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CHAPTEE^ 

The pyranone ring system (1) consists of unsaturated six membeed ring 
containing ethereal oxygen and ketonic group. Steroidal derivatives having pyranone 
ring ilised with steroidal nucleus are tenned as steroidal pyranones. 
O 
(1) 
Pyranones and corresponding derivatives have been the subject oi" much 
research due to their importance in the field of synthetic and medicinal chemist y such 
as antiviral,' stimulant,^ anticonvulsant,^ miticidal activities.'* Inspite of being building 
blocks in the field of synthetic and medicinal chemistry, pyranone rings are highly 
susceptible to nucleophillic attack at the electrophillic centres (C-2, C-4 and C-6) and 
a variety of synthetic approaches for the preparation of arenes and heteroarenes.^ 
Furthermore the development of new methods with great efficiency, convenient 
procedures and better yields is of interest. The theoretical part of this chapter includes 
the recent reports of synthesis of pyranones by different workers. 
Christ et al.^ reported that dihydro-l,4-pyran (2) are cyclic ethers of aldehydes 
or ketones, and these substances might be expected to behave as vinyl ether. 
Ar O y 
0 
(2) 
Livingstone and his coworkers ^ isolated and characterized Lapachenole a 
substance present in the wood of "Brazilian white peroba". Its structure has been 
elucidated as 4'-methoxy-6,6-dimethylnaphtho (r,2'-2,3) pyran (3) and confirmed by 
the total synthesis of its dihydroderevative. 
OMe 
(3) 
Later they synthesized 6-methoxy-2,2-dimethyl-7,8-benzochroman-4-one (5) from the 
esterificafion of 4-methoxy-l-naphthol with 3,3dimethylacryloyl chloride by the Fries 
38 
rearrangement of 4-methoxy-l-naphthyl-3,3-climethylacrylate (4) in absence of solvent 
followed by acidic isomerization and ring closures. 
OMe 
O-C-CH^CHMei 
O 
, (4) (5) 
Anjaneyulu et al^ reported the synthesis of 7,8-benzo 2,2-dimethyl 
chromanones (6, 7) [R = R' = CH3] and 5,6-benzo-3,4-dihydro-4-phenyl coumanns 
(8-11) [R = C6H5] by the reaction of 1-naphthol and 2-naphthol with SbCb, 
polyphosphoric acid, H2SO4 and ZnCl2. 
R ^ R 
R' 
(6) (7) (8) 
(9) (10) (11) 
Gupta et al? reported the direct synthesis of dihydro lapachenole (13) from 
hydroxy-4-methoxy-2-(3-hydroxy-3-methylbutyl) naphthalene (12). 
OCH, 
MeO 
super dry benzene 
OH 
(12) (13) 
Hlubucek et al}^ reported the synthesis of evodionol methyl ether (14) and 
lapachenole (15) from 2,6-dimethoxy-4-hydroxyacetophenone and 4-methoxy-l-
naphthol, respectively. 
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MeO 
MeO 
OMe 
OMe 
(14) (15) 
Khanna and co-workers" synthesized 2,2-dimethyl-naphtho [1,2- b] pyran (16) 
by the treatment of I-naphthol with 2-chIoro-2-methylbut-3-yne followed by the 
cyclization with N, N-dimethylanilme. Catalytic reduction of 2,2-dimethylnaphtho 
[1,2- b] pyran (16) gave 3,4-dihydro-2,2-dimethylnaphtho [1,2- b] pyran (17) 
Similarly the corresponding isomers 2, 2-dimethylnaphtho [2,3- b] pyran (19) and 3,4-
dihydro-2,2-dimethylnaphtho [2,3- b] pyran (18) have been synthesized starting from 
2-naphthol. 
OMe OMe 
(16) (17) (18) (19) 
Georgiadis et al}''' synthesized 2-methyl-2-[p-benzenesulphonyl) phenyl]-6-
hydroxy-2//-pyran-3(6//)-one (23) from/'-(benzenesulphonyl) acetophenone (20). 
/ = \ O O Li / : = ^ OH 
R 
CH3 1) Et20 
2)H20 
\\ / 
(20) 
CH3 
(21) 
^o> 
CH2C12 R. 
ci5 ISOMER (20%) + // ^ 
Q 
MCPB \i:^ 'x L-H 
trans ISOMER (80%) 
(22) (23) 
Ahluwalia and co-workers'^ synthesized 2,2-dimethyl-2//-naphtho[l,2- 6] 
pyran (25) by the reduction of 3,4-dihydro-2,2-dimethyl-2//-naphtho [1,2- b\ pjran 
(24) with DDQ or NBS. They also reported the synthesis of 1,2-dihydro-3,3-dimethyl-
40 
3//-naphtho [2,1- b] pyran (27) and 3,3-dimethyl-3//-naphtho [2,1- b] pyran (26) from 
2-naphthol. 
(24) (25) (26) (27) 
Kabbe and Widdig'"* reported the synthesis of 4-chromanones (30) by the 
condensation of o-hydroxy acetophenones (28) with aliphatic carbonyl compounds 
(29) in presence of pyrrolidine. 
aCOCHj + R ' - C 0 - R 2 K OH 
(28) (29) 
Suwanborirux et al}^ isolated some new chromones (31) and (32) from 10% 
aq MeOH extract of twigs and leaves of Spathelia sorbifolia. 
H OH H OAc 
Tanden et al}^ reported the synthesis of 2,3-dihydro-2,2-dimethyl-4//-naphtho 
[1,2- 6]-pyran-4-one (34) by the one-step cyclization of l-(3-m_ethyl-2-butenoyloxy)-
naphthalene (33) with ZnCIa-
O CH3 
O' ^ ^ "CH3 
ZnCl2 
(33) (34) 
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Kidwai and co-workers'^ synthesized 3-(4'-methylquinolino-2'-yl()xo)-2//-
benzopyran-2-ones (37) [R ' = CH3, OCH3, H, R^  = CH3, OCH3, H, R ' = OCH,, CH3, 
H] by the reaction of (4'-methylquinoHno-2'-yloxo) acetic acid hydrazide (35) with 2-
hydroxy-4-substituted benzaldehyde followed by cyclization in presence of PI'A. 
N O C-NHNH2 
HO R' 
OHC-O-R^ 
R^ 
HO 
N O C - N H N = C H - , 
II \\ 
O \\ 
R 
R-
(35) (36) 
PPA 
(37) 
Speranza et al. isolated fiiroaloesone a new 2-acetonyl-5-methyl-4//-furo 
[2,3- 6][l]benzopyran-4-one (38). 
CH3 
O 
(38) 
Nelson et al}'^ reported that y^keto ester (39) undergoes reduction with >»aBH4 
followed by the reaction with TsOH to give 2-pyranone unit (40). 
Me () 
OBu 
Me Me 
i) NaBH4, EtOH 
ii) TsOH, Toluene 
(39) (40) 
Mali et al?^ reported that the dihydroxy phthalide (41) was monoprcip-2-
ynylated using 3-chloro-3-methylbut-l-yne in DMF solution in the presence of 
42 
K2CO3, KI and Cul to give the prop-2-ynyl ether (42), which on heating in N,N-
dimethylanUne solution provided salfredin Bn (43), which had pyran ring. 
OH r> OMe Q OH Q 
HO' ^^ ^ O'^^ ^'^^' 
(41) (42) (43) 
i) 3-Chloro-3-methyIbut-l -yne, K2CO3, KI, Cul, DMF, 60 °C, 4h. 
ii) PhNMej, 210 °C, 6h or MWI, 3min. 
Paradkar et al?^ synthesized naturally occurring angular naphthopyrans (45) 
starting from 2-acetyI-l-naphthol derivatives (44) [R = OMe, H] and linear 
naphthopyran (47) from 3-acetyl-2-naphthol (46). 
OH O 
acetone 
pyrrolidine 
acetone 
pyrrolidine 
(46) (47) 
Feng et al?^ reported the synthesis of chiral (/?)-2-phenyl-2,3-dihydro-4//-
pyran-4-one (50) from aldehyde (49) [R = Ph, 4-MeOC6H4, 4-MeC6H4, etc.] and 
Danishefsky's diene (48) using chiral Hs-BINOL-Ti. 
OMe O 
O 
_, ;i „ 20% catalyst 
OTMS TEA 
(48) (49) (50) 
Hepworth et alP synthesized 2//-l-benzopyran (52) from electrocyclization 
of aryl propagaryl ethers (51) which were readily prepared from phenols and alkynols. 
43 
(51) (52) 
Tanaka and Hua"'' prepared 2//-pyranone (55) by the palladium catalyzed 
reaction of internal alkynes (54) with (Z)-3-chloro-2-heptenaoate (53) in presence of 
Et3N. 
COOMe + 
(53) (54) (55) 
Elmaati and his co-worker^^ synthesized pyranone derivative (58) by the 
reaction of 3-dimethylamino-2-(l,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-l//-
pyTazole-4-carbonyl) acrylonitrile (57) with ethyl cyanoacetate dimer. 
An 
H.C 
H.C-K 
CN 
DMF-DMA HjC 
xylene 
O Et02C CN 
Et02C NH, 
NMe, EtOjC 
(56) 
HjC 
An= HjC 'N 
N 
Ph 
(57) (58) 
O 
r26 Banciu et al. reported the preparation of 2,3,7-triphenylcyclopenta [c] pyran 
(61) from 1,2-diphenylethanedione (benzyl) (59) and cyclopentadiene (60). 
// /V—Ph 
2 < ? = ? - - . „ „ NaOMe 
0 = C - P h 
(59) (60) (61) 
Yadav et al.^^ synthesized 2,4-dialkoxy-2-aryl-3,4-dihydro-2//-]-benzop}Tans 
(67) by the reaction of salicyldehydes (65) with acetophenones (66) in presence of tri 
methyl ortho form ate and scandium triflat (catalytic amount) at ambient temperature 
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OMe 
TMOF 
Sc(0TF)3* R^^  
CH, 
(65) (66) 
R = H, 3-OMe, 5-Cl 
Ar = C6H5, 2-Naphthyl, 4-BrC6H4 
Clarke and Martin'^ ^ obtained single diastereomer of highly substituted 
tetrahydropyran-4-one (69) [R = hexyl, i-Pr, Ph, R ' = Ph, Pr, hexyl] from /?-ketoester 
(68). 
o 
0 O 
MeO 
„ . OH BF3.0Et2 
- ^ ^ ^ ^ ^ R R'CHO 
MeOjC/,. 
R R'' ^ O ' 
(68) (69) 
Autino and co-workers ^^  synthesized chromanones (71) by the cyclization of 
3-aryl propiononitriles (70) by using AICI3 in the molar ratio of 1:1 in absence of 
solvent. [R = H, 6-CH3, 6-OCH3] 
"^^  i- anhyd.AlClj 
ii-H+ R 
O 
(70) (71) 
Rizzacasa et al?^ synthesized salicylihalamide a novel metabolite isolated 
from western Australian Marine sponge a pyranone unit (73) from Apicularen A (72). 
R 
O-
NC 
^C, ,H,5N0 
acid or base 
C,,H,5N0 
0 O 
(72) (73) 
Peuli et al.^^ prepared 3',4'-dihydro-6'-nitrol5p/ro [cycloheptane-r,2(2'-//)[l] 
benzopyran]-4'-one (76) by the nitration of 2-hydroxyacetophenone (74) and 
subsequent treatment with appropriate carbocyclic ketone in presence of pyrrolidine. 
45 
.NO. 
-*HO 
(74) 
N(3. 
i) Cone. HNO3, AcOH 
ii) Carbocyclic Ketone, pyrrolidine, toluene, reflux. 
Kang et al.^'^ isolated various strains from the roots of Mimosa pudica and one 
strain was identified as 2-hydroxymethyl-chroman-4-one (77). 
H 
-O. 
Toste et alP reported the formation of benzopyrans (79) by the propargylation 
of phenols (78) catalyzed by a cationic ruthenium complex or protic acid. 
OH ArOH 
5% (dppm) 
Ph 5% KPFg 
5% MeN02 
Re(0)Ci3 
(78) (79) 
Islam et al?* prepared 8-hydroxy-5-phenyl-furo [2,3- /i]benzo(Z»)pyran-7-one 
(81) by reaction of (ir)-l-(4,6-dihydroxybenzofuran-5-yl)-3-phenylprop-2-en 1-one 
(80) with DDQ. The products were tested for anti bacterial effects. 
OH O 
(80) 
46 
Yachevskii et al?^ described the preparation of 2,6-bis-polyfluroalkyl-4//-
pyran-4-ones (83) [R' = CHF2, CF3, C2H4H, C4H9, R ' = CHF,, CF3, C2F4H] by 
dehydration of bis-polyfluoroalkyl containing 1,3,5-triketones (82). 
O 
0 0 0 X 
R R R i ' ^ 0 ^ R2 
(82) (83) 
X = H2SO4, PPA, HCl/MeOH, (Me3SiO)3 PO, (EtP02)„/CHCl3. 
Yakura and co-workers^^ reported the stereoselective synthesis of 2,3-
disubstituted-3-pyranone (85) as a major product (82 %) and (86) by copper catalyzed 
oxonium ylide formation-[2,3] shift of (55, 7i?)-5-allyloxy-l-diazo-8-(/3-methoxy-
benzyloxy)-7-methyl-2-octanone(84). 
OPMB PPMB OPMB 
(84) (85) (86) 
Trauner and co-worker^^ reported the syntehsis of mollugin a chromene (88) 
from 67t - electrocyclization of vinyl o-quinonemethide (87). 
OH OH 
(87) (88) 
Markopoulou et al?^ reported the preparation of 2-amino-4-oxo-47/-
chromene-3-carbonitrile (92) through a typical reaction of flinctionalized acetyl 
salicylic acid (89) with N-hydroxybenzotriazole (90) and malononitrile (91) [ R ' = H, 
CI, CH3, OCH3, R^ - H, OCH3, R^ = H, OCH3]. 
47 
Lopez et al?'^ obtained steroidal pyranone derivatives 94, 96 and 98 from 93, 
95 and 97, respectively. 
AcO CH2CI2 AcO' 
(93) (94) 
AcO' CH2CI2 /\cO 
(95) (96) 
AcO CH2CI2 AcQ 
48 
2',2'-dimethyl-cholesta-4,6-dien[7,6- 6]-pyran-4'-one (101) was prepared by 
the cyclization of 2-acetylcholesta-2,4-dien-3-ol (99) with pyrrohdine, dry benzene 
and dry acetone using Dean Stark separator through conventional heating.'*'^  
H,C 
(99) (100) 
(101) 
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m ^l6eaM(m/ 
The importance of heterocyclic compounds has long been recognized in the 
field of synthetic organic chemistry and uses of pyranones are well established. 
Especially after the discovery that some pyranones are associated with a variety of 
physiological properties.'*' They are also used in perfumes, cosmetics and 
pharmaceutical industry. Pyranone moiety as also present in number of ratural 
products including flavanoids, that interact with various enzymes and receptor system 
of pharmacological significance."" Many pyranone derivatives have been found to 
possess a broad spectrum of biological activities such as 
antitumor,'*^antiHIV/^antimicrobial,'''*antifungal,'*^ and antioxidant."*^ hispire of being 
important in medicinal chemistry, synthesis and reactions of pyranones have been 
widely investigated and ulilized for the preparation of multitude of heterocyclic 
compounds and may also be used as intermediates in the manufacture of compounds 
of physiological importance. In view of these reports and in continuation of our 
previous work in steroidal chemistry, we have developed a new, highly efficient 
method for the synthesis of substituted steroidal pyranones (105-110) using chitosan 
as heterogeneous, basic and green catalyst. The substrates selected for initial studies 
include cholest-5-en-7-one (102), 3y5-acetoxycholest-5-en-7-one (103) and ofi-
chlorochoIest-5-en-7-one (104). The structures of newly synthesized compounds 
have been assigned on the basis of elemental analysis and spectral (IR, 'H N M R , '^C 
NMR, MS) studies. With the best of our knowledge there are no literature data 
available regarding the synthesis of steroidal pyranone derivatives using chitosan as a 
catalyst. 
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(102-104) 
X 
H (102) 
OAc (103) 
CI (104) 
X 
H 
OAc 
CI 
R 
CI 
CI 
CI 
(105) 
(106) 
(107) 
R 
CH3CO 
CH3CO 
CH3CO 
(108) 
(109) 
(110) 
Green synthesis and biological evaluation of steroidal 2H-pyrans as anticancer and 
antioxidant agents. Shamsuzzaman, Ashraf Mashrai, H. Khanam, M. Asif, A. AH, 
A. Sherwani and M. Owais. 
Journal of King Saud University-Science 2013 (in press); 
http://dx.doi.0rg/lO.lOl6/j.jksus.2Oi3.lO.OOl 
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Reaction of cholest-5-en-7-one (102) with ethyl chloroacetate: 3'-Chloro-3',6'-
dihydro-Sa- cholest-6-eno-[5, 7- d e]-2H-pyran-2-one (105): 
Steroidal a,y5-unsaturated ketone 102 in methanol was allowed to reflux with 
ethyl chloroacetate in the presence of chitosan (20 mol%) for 11 h, after usua' work 
up it provided a single product 105, m.p. 124-126 °C. 
ClCH,COOEt 
CH3OH, chitosan 
reflux, 11 h 
(102) 
Characterization of compound 105 as 3'-chloro-3',6'-dihydro-5a-cholest-6-eno-[5, 
7- d e]-2H'pyran-2-one: 
The elemental analysis of the compound 105 corresponded to the molt;cular 
formula C29H45CIO2 (Beilstein positive). The IR data provided evidence for the 
formation of the expected product. The compound showed intense band in the region 
of 1730 cm'' due to OCOCHCl stretching vibrations. In addition, other important 
absorption bands at 1614, 1145 and 751cm'' were attributed to C=C, C-O and C-Cl 
stretchings, respectively. Further evidence for the formation of compound 105 was 
well supported by its ' H N M R and '^C NMR spectra. The ' H N M R spectrum of the 
compound exhibited a one-proton singlet at (5 5.1 for Ce-H and another one pioton 
singlet at 4.3 for Cs'-H. Angular and side-chain methyl protons were observed at S 
1.19 (CIO-CH3), 0.75 (CI3-CH3), 0.91 and 0.85 for other methyl protons. '^C NMR 
spectrum of the compound also supported the proposed structure and displayed 
characteristic signals at <5 162 for C=0, 150 for Ce, 122 for C? and 66 for C,', in 
addition to the signals of cholestane series. The mass spectrum was also in good 
agreement with its molecular formula which exhibited strong molecular ion peak at 
m/z 460/462. 
On account of the above descriptive discussion, the compound 105 can be 
suitably characterized as 3'-chloro-3',6'-dihydro-5o.-cholest-6-eno-[5, 7- d e]-2H-
pyran-2-one. 
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3',6'-dihydro-3P-acetoxy-5a-cholest-6-eno-[5, 7- d eJ-2H-pyran-2 one (106): 
Steroidal «,y9-unsaturated ketone 103 in MeOH was allowed to reflux with 
ethyl chloroacetate in the presence of chitosan (20 mol%) for 10 h, after usual work 
up, a single product (106), m.p. 123-125 °C, was obtained. 
ClCHiCOOEt 
CH3OH, chitosan 
reflux, 10 h ^ 
H3C-C-O 
(103) 
Characterization of compound 106 as 3'-chloro-3',6'-dihydro-3P-acetoxy-5a-
cholest-6-eno-[5, 7- d e]-2H-pyran-2-one: 
The elemental analysis of the compound 106 corresponded to the molecular 
formula C31H47CIO4 (Beilstein positive). The IR data suggested the formation of the 
expected product. The compound showed intense band in the region of 1735 cm'' due 
to OCOCHCl stretching vibration. In addition, other important absorption bands at 
1615, 1142 and 754 cm"' were attributed to C=C, C-0 and C-Cl, respectively. Further 
evidence for the formation of compound 106 was well supported by its ' H N M R and 
'^C NMR spectra. The 'H NMR spectrum of the compound exhibited a one proton 
singlet at d 5.3 for Ce-H and one proton singlet at 4.4 for Ca'-H. A broad multiplet 
integrating for one proton at 6 4.6 was assigned to C3-aH (axial, W'/2= \2 Hz) and a 
sharp singlet for three acetoxy group protons appeared at 2.03. Angular and side-chain 
methyl protons were observed at ^ 1.18 (CIO-CH3), 0.70 (CI3-CH3), 0.92 and 0.85 
for other methyl protons. '^C NMR spectrum of the compound also supported the 
proposed structure and displayed characteristic signals at ^ 170 for C3, 161 for C=0, 
150 for Ce, 120 for C7 and 68 for C3', in addition to the signals of cholestane series. 
The mass spectrum was also in agreement with its molecular formula which exhibited 
a prominent molecular ion peak at m/z 518/520. 
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On account of the above evidences, the compound 106 can be suitably 
characterized as 3'-chloro-3',6'-dihydro-3P-acetoxy-5a-cholest-6-eno-[5, 7- d e]-2H-
pyran-2 one. 
Reaction of 3P-chlorocholest-5-en-7-one {104) with ethyl chloroacetate: 3ji,3'-
Dichloro-3',6'-dihydro-5a cholest-6-eno-[5, 7- d e]-2H-pyran-2-one (107) 
Steroidal a,^-unsaturated ketone 104 in MeOH was allowed to reflu< with 
ethyl chloroacetate in the presence of chitosan (20 mol%) for 10 h, after usua work 
up and recrystallization provided a single product 107, m.p. 122-124 °C, was 
obtained. 
ClCH,COOEt 
CH3OH. chitosan 
reflux, 10 h 
(104) 
Characterization of compound 107 as 3/i,3'-dichloro-3',6'-dihydro-5a-choli'st-6-
eno-[5, 7- d eJ-2H-pyran-2-one: 
The compound 107 was correctly analyzed for C29H44CI2O2 (Beiistein 
positive). The IR data provided evidence for the formation of the expected product. 
The compound showed intense band in the region of 1732 cm'' due to OCOC'HCl 
moiety. In addition, other important absorption bands at 1612, 1140 and 752 cm"' 
were attributed to C=C, C-0 and C-Cl stretchings, respectively. Further evidence for 
the formation of compound 107 was well supported by its ' H N M R and '^C NMR 
spectra. The ' H NMR spectrum of the compound exhibited a one proton singlet at S 
5.1 for Ce-H and another one proton singlet at 4.2 for C3'-H. A one-proton b-oad 
multiplet centered at d 3.8 was assigned to C3-aH (axial, W'/2 = \2 Hz). Angular and 
side-chain methyl protons were observed at <5 1.19 (CIO-CH3), 0.75 (CI3-CH3), 0.92 
and 0.86 for other methyl protons. '^C NMR spectrum of the compound ilso 
supported the proposed structure and displayed characteristic signals at S 162 for 
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C=0, 150 for Cf,, 122 for C7, 67 for C3' and 59 for C3, in addition to the signals of 
cholestane series. The mass spectrum was also in agreement with its molecular 
formula which exhibited a strong molecular ion peak at m/z 494/496. 
On account of the above descriptive discussion, the compound 107 can be 
suitably characterized as 3P,3'-dichloro-3',6'-dihydro-5a-cholest-6-eno-[5, 7- d e]-
2H-pyran-2-one. 
Reaction of cholest-5-en-7-one (102) with ethyl acetoacetate: 3'-Acetyl-3',6'-
dihydro-cholest-6-eno-[5, 7- d eJ-2H-pyran-2-one (108): 
Steroidal a,y9-unsaturated ketone 102 in methanol was refluxed with ethyl 
acetoacetate in the presence of chitosan (20 mol%) for 12 h, after usual work up and 
recrystallization a single product 108, m.p. 170-172 °C, was obtained. 
CHjCOCHjCOOEt 
CH3OH, chitosan 
reflux, 12 h 
HaC-c'Y' 
o o 
(102) (108) 
Characterization of compound 108 as 3'-acetyl-3',6'-dihydro-cholest-6-eno-[5, 7- d 
e]-2H-pyran-2-one: 
The elemental analysis of the compound 108 corresponded to the molecular 
formula C31H48O3. The IR data provided evidence for the formation of the expected 
product. The compound showed intense band in the region of 1720 due to CHCOCH3, 
while 1677 due to OCOCH, stretching vibrations. In addition, other important 
absorption bands at 1621 and 1246 cm' were attributed to C=C and C-0 respectively. 
Further evidence for the formation of compound 108 was well supported by its ' H 
NMR and '^ C NMR spectra. The ' H N M R spectrum of the compound exhibited a 
one-proton singlet at 5 5.31 for Ce-H and another singlet for one proton at 3.31 for 
C3'-H. Angular and side-chain methyl protons were observed at <5 1.18 (CIO-CH3), 
0.70 (CI3-CH3), 0.92 and 0.85 for other methyl protons. '^C NMR spectrum of the 
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compound also supported the proposed structure and displayed characteristic signals 
at S 165 for CHCOCH3, 160 for OCOCH, 158 for C7, 116 for €5, and 65 for CS,m 
addition to the signals of cholestane series. The mass spectrum was also in good 
agreement with its molecular formula which exhibited strong molecular ion peak at 
m/z 468. 
On account of the above evidences, the compound 108 can be suitably 
characterized as 2'-acetyl-S',6'-dihydro-cholest-6-eno-[5, 7- d e]-2H-pyran-2-onp. 
Reaction of 3fi-acetoxycholest-5-en-7-one (103) with ethyl acetoacetate• 3fi-
Acetoxy-3'-acetyl-3',6'dihydro-cholest-6-eno-l5, 7- d e]-2H-pyran-2-one (109): 
Steroidal a.yff-unsaturated ketone 103 in methanol was allowed to reflux with 
ethyl acetoacetate in the presence of chitosan (20 mol%) for 13 h. Usual work un and 
recrystallization provided a single product 109, m.p. 176-178 °C. 
CHjCOCH^COOEt ^ 
CH3OH, chitosan 
reflux, 13 h O 
H3C-C-O 
H 3 C - C ^ 
(103) 
o o 
(109) 
Characterization of compound {109) as 3p-acetoxy-3'-acetyl-3',6'-dihydro-cholest-6-
eno-[5, 7- d e]-2H-pyran-2-one: 
The elemental analysis of the compound 109 corresponded to the molecular 
formula C33H50O5. The IR data provided evidence for the formation of the expected 
product. The compound showed intense band in the region of 1715 due to CHCOCH:,, 
while 1673 due to OCOCH stretching vibrations. In addition, other important 
absorption bands at 1622 andl245 cm"' were attributed to C=C and C-O, respectively. 
Further evidence for the formation of compound 109 was well supported by its 'H 
NMR and '^C NMR spectra. The 'H N M R spectrum of the compound exhibited a 
one- proton singlet at J 5.21 for Ce-H and another one-proton broad multiplet centered 
at 8 4.7 was assigned to C3-aH (axial, W 'A = ]6 Hz). A singlet for one proton at -) 
3.21 was assigned to Cs'-H and a sharp singlet for three acetoxy group protons 
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appeared at 2.03. Angular and side-chain methyl protons were observed at r)' 1.18 
(CIO-CH3), 0.70 (CI3-CH3), 0.92 and 0.85 for other methyl protons. '^ C NMR 
spectrum of the compound also supported the proposed structure and displayed 
characteristic signals at S 168 for CHCOCH3, 163 for OCCCH, 152 for C7, 112 for 
C6, 72 for C3 and 64 for C'3, in addition to the signals of cholestane series. The mass 
spectrum was also in good agreement with its molecular formula which exhibited 
prominent molecular ion peak at m/z 526. 
On account of the above evidences, the compound 109 can be suitably 
characterized as 3P-acetoxy-3'-acetyl-3',6'-dihydro-cholest-6-eno-[5, 7- d e]-2H-
pyran-2-one 
Reaction of 3fi-chlorocholest-5-en-7-one {104) ethyl acetoacetate: 3P-Cliloro-3'-
acetyl-3',6'-dUiydro-cholest-6-eno-l5, 7- d e]-2H-pyran-2-one (110): 
Steroidal ketone 104 in methanol was allowed to reflux with ethyl acetoacetate 
in the presence of chitosan (20 mol%) for 16 h, after usual work up and 
recrystallization a single product 110, m.p. 165-167 °C, was obtained. 
CH3COCH2COOEt 
CH3OH, chitosan 
reflux, 16 h 
H 3 C - C ^ 
(104) 
o o 
(110) 
Characterization of compound 110 as 3p-chloro-3'-acetyl-3',6'-dihydro-cholest-6-
eno-[5, 7- d e]-2H-pyran-2-one: 
The elemental analysis of the compound corresponded to the molecular 
formula C31H47CIO3 (Beilstein positive). The IR data provided evidence for the 
formation of the expected product. The compound showed intense band in the region 
of 1718 due to CHCOCH3, while 1675 due to OCOCH stretching vibrations. In 
addition, other important absorption bands at 1620, 1243 and 745 cm'' were attributed 
to C=C, C-0 and C-Cl, respectively. Further evidence for the formation of compound 
110 was well supported by its ' H NMR and '^C NMR spectra. The ' H NMR spectrum 
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of the compound exhibited a one-proton singlet at S 5.40 for C6-H and another one-
proton broad multiplet centered at S 3.81 was assigned to C3-«H (axial, W '2 = 17 
Hz). Another singlet for one proton at c) 3.1 was assigned to C3'-H. Angular and side-
chain methyl protons were observed at t)' 1.18 (CIO-CH3), 0.70 (CI3-CH3), 0.-)2 and 
0.85 for other methyl protons. '^ C NMR spectrum of the compound also supported the 
proposed structure and displayed characteristic signals at S 167.1 for CHCOCH3, 
161.3 for OCOCH, 159 for C7, 114 for Ca, 64 for C'3 and 52 for C3, in addition to the 
signals of cholestane series. The mass spectrum was also in good agreement with its 
molecular formula which exhibited strong molecular ion peak at m/z 502/ 504. 
On account of the above evidences, the compound 110 can be suitably 
characterized as 3P-chloro-3'-acetyl-3',6'-dihydro-cholest-6-eno-[5, 7- d e]-2H-pyran-
2-one 
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The catalytic performance ofchitosan in the synthesis of steroidal pyranone 
The catalytic system is influenced by various reaction parameters, such as amount of 
the catalyst employed, effect of catalyst and solvent system. Therefore, in our initial 
investigation to establish the optimum reaction conditions 3/?-acetoxy-cholest-5-en-7-
one and ethyl acetoacetate in methanol were selected as model substrates. We have 
applied a wide range of basic catalysts such as piperidine, NaOMe, pyridine, 
triethylamine and chitosan to improve the yield for the specific synthesis of 
derivatives. As shown in Table 1, chitosan is superior to other catalysts in terms of 
reaction time and yield. 
Table 1. Comparison of the efficiency ofchitosan on the model reaction. 
Entry 
1 
2 
3 
4 
5 
Catalysts 
Piperidine 
NaOMe 
Pyridine 
Triethylamine 
Chitosan 
Time (h) 
20 
32 
25 
36 
16 
Yield (%)" 
60 
43 
50 
34 
73 
Yields are related to isolated pure products. 
We screened the reaction in various organic solvents in order to optimize the solvent 
using chitosan as catalyst. It is noteworthy to mention that the polar solvents 
(methanol and ethanol) afforded better yield than the non-polar ones and the best 
result was obtained in methanol (Table 2). We then tried to optimize the catalyst load 
for the formation of steroidal pyranone and we found that 20 mol% of the catalyst was 
sufficient to get optimum yield in less reaction time. Use of more than 20 mol% of the 
catalyst does not have any profound effect on the reaction rate as well as the yield. 
Table 2. Effect of various solvents on the model reaction. 
Entry 
1 
2 
3 
4 
5 
Solvent 
Acetonitrile 
Methanol 
DMSO 
Toluene 
Ethanol 
Time(h) 
26 
16 
22 
34 
20 
Yield (%) 
30 
73 
40 
22 
60 
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The mechanism for the fonnation of steroidal pyranone derivatives invohes the 
Michael addition of active methylene to conjugated ketone at the electrophilic alkene 
C, in nucleophilic addition type process, which undergoes subsequent mtramolecular 
cyclization to provide the desired product (Scheme 1). 
Scheme 1. Proposed mechanism of formation of 5a-cholest-6-eno-[5, 7- d e]-2H-
pyran-2-one derivatives catalyzed by chitosan. 
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Stereochem istry 
The stereochemical assignation of C5-C bond has been established on the 
basis of mechanism as well as on 'H and '^C NMR spectral analysis of the products. 
During the course of reaction, the nucleophilic attack of the reagent at C-5 does occur 
preferably from less hindered (a) side because of the steric encumbrance imposed by 
axial ifi) methyl group at C-10, resulting axial (a) position of C5-C bond and trans to 
ClO-axial methyl group (A/B ring junction trans). The determination of ring fusion 
stereochemistry in angularly methylated six-membered ring compounds is not an easy 
task by either chemical or physical methods, NMR spectroscopy may, however, 
greatly aid in the solution of this problem. '^C NMR values of C-19 and C-9 are 
strongly dependent on the ring fusion stereochemistry. The cis and trans steroids 
differ most significantly at C-19 and these signal will surely be of prime value to 
characterize the nature of the ring junction.'* In the aW-trans steroids, the C-19 
resonance is well separated from the majority of those of the other carbons. In the 
compounds (105-110), C-19 chemical shift values were observed in the range of 16-
18 ppm, which is consistent with values obtained for trans steroids " (A/B ring 
junction trans). Furthermore the half band width {W1/2) values of C3-axial proton in 
the ' H NMR spectra of the synthesized compounds clearly suggest that A/B ring 
junction is trans. 
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General 
Melting points were deten-nined on a Kofler apparatus and are uncon-ected. 
The IR spectra were recorded on KBr pellets with Interspec 2020 FT-IR Spectrometer 
spectro Lab and values are given in cm"'. ' H and '^ C NMR spectra were run in CDCI3 
on a Bruker Avance II 500 NMR Spectrometer at 500 MHz and 125 MHz, 
respectively. Chemical shifts {S) are reported in ppm relative to the TMS ('H NMR) 
and to the solvent signal ('^C NMR spectra). Mass spectra were recorded on a JEOL 
D-300 mass spectrometer. Thin layer chromatography (TLC) plates were coated with 
silica gel G and exposed to iodine vapors to check the homogeneity as well as the 
progress of reaction. Sodium sulfate (anhydrous) was used as a drying agent. 
Cholest-5-en-7-one (102): 
A solution of butyl chromate [t-butyl alcohol (60 mL), Cr03 (20 g), acetic acid 
(84 mL) and acetic anhydride (10 ml)]"*^  was added at 0 °C to a solution of choiest-5-
ene (8 g) in CCI4 (150 mL), acetic acid (30 ml) and acetic anhydride (10 mL>. The 
contents were refluxed for 3 h and then diluted with water. The organic layer was 
washed with sodium bicarbonate solution (5 %) and water and then dried over 
anhydrous sodium sulfate. Evaporation of the solvents under reduced pressure 
furnished cholest-5-en-7-one (63) which was recrystallized from methanol (3 1 g), 
m.p. 128 °C (reported, m.p. 125-129 °C).''^" 
3P-Acetoxycholest-5-en-7-one {103): 
A solution of butyl chromate [t-butyl alcohol (60 mL), CrOs (20 g), acetic 
acid (84 mL) and acetic anhydride (10 mL]'*^ was added at 0 °C to a solution of 3y5-
acetoxycholest-5-ene (8 g) in CCI4 (150 ml), acetic acid (30 ml) and acetic anhydride 
(10 mL). The contents were refluxed for 3 h and then diluted with water. The organic 
layer was washed with sodium bicarbonate solution (5 %) and water and then dried 
over anhydrous sodium sulfate. Evaporation of the solvents under reduced pressure 
furnished 3y9-acetoxycholest-5-en-7-one which was recrystallized from methanol (3.2 
g), m.p. 161-163 °C (reported, m.p. 164 "C).^^" 
3P-Chlorocholest-5-en-7-one (104): 
A solution of butyl chromate [t-butyl alcohol (60 mL), CrO^ (20 g), acetic acid 
(84 mL) and acetic anhydride (10 mL)]'*^ was added at 0 °C to a solution of 3/?-
chlorocholest-5-ene (8 g) in CCI4 (150 mL), acetic acid (30 mL) and acetic anhydride 
(10 mL). The contents were refluxed for 3 h and then diluted with water. The organic 
layer was washed with sodium bicarbonate solution (5 %) and water and then dr ed 
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over anhydrous sodium sulfate. Evaporation of the solvents under reduced pressure 
ftimished 3/9-chlorocholest-5-en-7-one which was recrystallized from methanol (3.4 
g), m.p. 144 °C (reported, m.p. 144-145 "C).^ **' 
General procedure for the synthesis of steroidal pyranone derivatives (105-110): 
A mixture of steroidal a,/9-unsaturated ketone (102-104) (1 mmol) and ethyl 
chloroacetate/ethyl acetoacetate (1 mmol) in methanol (30 mL) was refluxed for 10-
16 h in the presence of chitosan (20 mol%). After completion of reaction, as 
determined by TLC, chitosan was removed by filtration. The solvents were removed 
under pressure and the residue was taken in diethyl ether, washed with water, dried 
over anhydrous sodium sulfate Recrystallization from ethanol afforded the respective 
products (105-110). 
3'-Chloro-3',6'-dihydro-5a-cholest-6-eno-[5, 7- d e]-2H-pyran-2-one (105) 
Yields (76%); m.p. 124-126 °C; (Beilstein positive); Anal. Calcd for C29H45CIO2: C, 
75.34, H, 8.91; found; C, 75.54, H, 9.84; IR (KBr) v cm"' 1730 (OCOCCl), 1614 
(C=C), 1145 (C-0), 751 (C-Cl); 'H N M R (CDCI3, 500 MHz) 3 5.1 (s, IH, Ce-W), 4.3 
(s, IH, C3'-H), 1.19 (s, 3H, CIO-CH3), 0.75 (s, 3H, CI3-CH3), 0.91 and 0.85 (other 
methyl protons); '^ C NMR (CDCI3, 125 MHz) 6 162, 150, 122, 66, 56, 48, 45, 44, 43, 
40, 38, 37, 36, 35, 34, 31, 29, 28, 27, 26, 25, 24, 23, 22, 21, 20, 19, 16, 12; MS (EI): 
{m/z) 460/462 [M^] 
3'-Chloro-3',6'-dihydro-3P-acetoxy-5a-cholest-6-eno-[5, 7- d e]-2H-pyran-2-one 
(106) 
Yields (80%); m.p. 123-125 °C; (Beilstein positive); Anal. Calcd for C31H47CIO4: C, 
71.26, H, 8.98; found; C,71.28, H,8.99; IR (KBr) v cm' 1735 (OCOCCl), 1712 
(OCOCH3), 1615 (C=C), 1142 (C-0), 754 (C-Cl); ' H NMR (CDCI3, 500 MHz) 6 5.3 
(s, IH, Cs-H), 4.6 (m, IH, C3a-H, W Vi = 12 Hz, A/B trans), 4.4 (s, IH, Cs'-H ), 2.21 
(s, 3H, OCOCH3), 1.18 (s, 3H, CIO-CH3), 0.70 (s, 3H, CI3-CH3), 0.92 and 0.85 
(other methyl protons);'^C NMR (CDCI3, 125 MHz) 8 170, 161, 152, 120, 70, 68, 57, 
48, 43, 42, 40, 39, 36 , 35, 34, 33, 32, 31, 29, 28, 27, 26, 25, 24, 23, 22, 21, 20, 19, 
16, 12; MS (EI): {m/z) 518/520 [M^]. 
3P,3'-Dichloro-3',6'-dihydro-5a-cholest-6-eno-[5, 7-de]-2H-pyran-2-one (107) 
Yields (78%); mp. 122-124 °C; (Beilstein positive); Anal. Calcd for C29H44CI2O2: C, 
70.14, H, 8.90; found; C, 70.29, H, 8.95; IR (KBr) v cm"' 1732 (OCOCCl), 1612 
(C=C), 1140 (C-0), 749, 752 (2xC-Cl); ' H NMR (CDCI3, 500 MHz) 5 5.1 (s, IH, Ce-
H), 4.2 (s,lH, C3'-H ), 3.8 (m, IH, C3 a-H, W'/: = 12 Hz, A/B trans), 1.19 (s, 3H, 
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ClO-CHj), 0.75 (s, 3H, CI3-CH3), 0.92 and 0.86 (other methyl protons); ''C NMR 
(CDCI3, 125 MHz) S 162, 150, 122, 67, 59, 53, 49, 44, 43, 42, 41, 40, 37, 36 34, 33, 
32, 31, 29, 28, 27, 26, 25, 24, 23, 22, 19, 16, 12; MS (EI): (m/z) 494/496 [ M ' ] 
3'-Acetyl-3',6'-dihydro-cholest-6-eno-[5, 7- de]-2H-pyran-2-one (108) 
Yield (70%); mp. 170-172 °C; Anal. Calcd for C31H48O3: C, 79.44, H, 10.32; found; 
C, 79.42, H, 10.34; IR (KBr) vcm' 1720 (CHCOCH3), 1677(OCOCH), 162) {Q=^C), 
1246 (C-O); 'H NMR (CDCI3, 500 MHz) 6 5.31 (IH, s, Ce-H), 3.31 (IH, s. C'3-H), 
2.01 (3H, s, CHCOCH3), 0.70 (3H, s, CIO-CH3), 1.18 (3H, s, CI3-CH3), 0.92 and 
0.85 (other methyl protons); '^ C NMR (CDCI3, 125 MHz) 5 165, 160, 158, 116, 65, 
48, 41, Ai), 39, 38, 35, 34, 32,31, 30, 29, 28, 28, 21, 25, 25, 24, 22, 22, 22, 21, 21, 2], 
20, 18, 17; MS (EI): (m/z) 468 [M^]. 
3p-Acetoxy-3 '-acetyl-3', 6'-dihydro-cholest-6-eno-[5, 7- d e]-2H-pyran-2-one (109) 
Yield (73%); m.p. 176-178 °C; Anal. Calcd for C33H50O5: C, 75.25, H, 9.57; found; 
C, 75.21, H, 9.54; IR (KBr) v cm"' 1743 {3/3-AcO), 1715 (CHCOCH ). 1673 
(OCOCH3), 1622 (C=C), 1245 (C-O); ' H NMR (CDCI3, 500 MHz) S 5.21 (IH. s, G,-
H), 4.80 (IH, m, C3a-H, W'/i = 16 Hz), 3.21 (IH, s, C'3-H), 2.03 (3H, s, OCOCH^), 
2.01 (3H, s, CHCOCH3), 1.18 (3H, s, CIO-CH3), 0.70 (3H, s, CI3-CH3), 0.97 and 
0.82 (other methyl protons); '^ C NMR (CDCI3, 125 MHz) S 170, 168, 163, 157, 112, 
72, 64, 48, 41, 40, 39, 38, 35, 34, 32, 31, 30, 29, 28, 28, 28, 27, 25, 24, 22, 22, 22, 21, 
21, 21, 20, 18, 17; MS (EI): (m/z) 526 [W]. 
3/}-Chloro-3 '-acetyl-3', 6 '-dihydro-cholest-6-eno-[5, 7- d e]-2H-pyran-2-one ( U 0) 
Yield (71%), mp. 165-167 °C; (Beilstein positive); Anal. Calcd for C3iH47C]03: C, 
74.00, H, 9.42; found; C, 74.02, H, 9.44; IR (KBr) v cm"' 1718 (CHCOCH3), 1675 
(OCOCH), 1620 (C=C), 1243 (C-O), 745 (C-Cl); ' H NMR (CDCI3, 500 MHz) S 5.40 
(IH, s, C6-H), 3.81 (IH, m, C3a-H, WVi = 17 Hz), 3.10 (IH, s, C'3-H), 2.0] (3H, .s, 
CHCOCH3), 1.18 (3H, s, CIO-CH3), 0.70 (3H, s, CH-CHj), 0.92 and 0.85 (other 
methyl protons); '^C NMR (CDCI3, 125 MHz) d \61, 161, 159, 114, 64, 52. 48, 41, 
40, 39, 38, 35, 34, 32, 31, 30, 29, 28, 28, 27, 25, 24, 22, 22, 22, 21, 21, 21, 20. i 8, 17; 
MS (EI): {m/z) 502/ 504 [M^ ]. 
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CeAPTEE-5 

The pyrazolone system (1), consists of a monounsaturated five membered ring 
with two adjacent nitrogen atoms and a carbonyl group. Knorr, "' first synthesized 
compounds containing this system in 1883 by the reaction of ethyl acetoactate with 
phenyl hydrazine, which yielded l-phenyl-3-methyl-5-pyrazolone (2). Knorr 
introduced the name to denote that the nucleus was derived from pyrrole by 
replacement of a carbon by nitrogen. They synthesized many members of this class 
and systematically investigated their properties. 
-CH3 
O-^ N  
C6H5 
(1) (2) 
The first steroidal compound with pyrazole moiety was reported in 1938 by 
Ruzicka et al.'^ and only a single derivative, cholest-4-eno-[3,2- c]-pyrazole-.5-
carboxylic acid (3), was mentioned. 
C«H 
HOOCH2C, 
gnn 
(3) 
After a considerable span of time, much attention has been paid by a number 
of organic chemists towards the synthesis of several pyrazolone derivatives. The 
compounds containing pyrazolone ring system can be synthesized by different routes 
and here we have summarized only important examples, as below. 
Kumaravel and Vasuki^  synthesized 2-amino-4-(5-hydroxy-3-methyl-l//-
pyrazol-4-yl)-4//-chromene-3-carbonitrile derivatives 6 (a,b) by a four component 
reaction between hydrazine hydrate, ethyl acetoacetate (4), 2-hydroxybenzaldebydes 5 
(a,b) and malononitrile in water at ambient temperature. 
N-NK 
,OH O O 
•^ ^ ^ OCH2CH3 
(4) 
CN-CH2-CN 
H2N-NH2 
(5) (6) 
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R R 
(a) 2-CH3 (a) 2-CH3 
(b) 2-OCH3 (b) 2-OCH3 
Bicu et al}^ synthesized pyrazolones containing a phenothiazine unit (8), the 
synthesized compound also evaluated for its antiproliferative activity. 
H,C 
N 
N' ^b 
O. 
ethyl acetoacetate / '^i-s^^ 
S 
(8) 
Bavatenko and coworkers^ reported substituted pyrazoles 10 (a-d) by 
cyclizing aryl hydrazones 9 (a-d), under Vilsmeier conditions. 
O CHO 
O Ar 
Ph' y N DMF-POCl3^  j ^ _ j ^ 
CH3 Ar 
(9) (10) 
Ar Ar 
(a) C6H5 (a) C6H5 
(b) 4-FC6H4 (b) 4-FC6H4 
(c) 4-CH3C6H4 (c) 4-CH3C6H4 
(d) 4-CH3OC6H4 (d) 4-CH3OC6H4 
Isloor and co-workers^ reported that the reaction of substituted hydrazines 
11 (a-g) with ethyl acetoacetate in absolute alcohol yielded corresponding substituted 
pyrazolones 12 (a-g). 
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H.C 
^ - H N - N H 2 o o 
0^ /CH, 
(11) 
Ar 
(a) C6H5 
(b) 2,4-Dinitrophenyl 
(c) 4-ChlorophenyI 
(d) 4-OCH3C6H4 
(e) Biphenyl 
(f) 2,4-Dichlorophenyl 
(g)4-SCH3C6H4 
H.C 
(12) 
Ar 
(a) C6H5 
(b) 2,4-Dinitrophenyl 
(c) 4-Chlorophenyl 
(d) 4-OCH3C6H4 
(e) Biphenyl 
(f) 2,4-Dichlorophenyl 
(g) 4-SCH3C6H4 
Silverman et al^ synthesized 5-((4-Chlorophenylthio)methyl)-l//-pyrazoI-
3{2H)-one (16) by the reaction of 4-Chlorothiophenol (13) with ethyl 4-
chloroacetoacetate (14) following by the treatment of the product 15 with hydrazine 
hydrate. 
CI r\ -SH CI 
(13) (14) (15) 
01 f\ 
NH2NH2 
o 
/ NH 
(16) 
JO Pawar and Borse reported 4-n-aIkylsubstituted pyrazoles (23-28), trom 
phenylhydrazones (17-20), semicarbazones (21) and azines of 2-n-acyl-5-
chlorophenoles (22) by monoformylation and cyclization by using one mole of the 
Vilsmeier-Haack reagent (DMF-POCI3). 
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on N -NHR-
H, ^ DMF/POCI3 
(17) 
(18) 
(19) 
(20) 
(21) 
(22) 
(28) 
R ' 
CH3 
C2H5 
(CH2)2 
(CH2)2 
CH3 
H 
CH3 
-CH3 
-CH3 
R^ 
Ph 
Ph 
Ph 
Ph 
CONH2 
l-(3'-Chloro-5 
l - (3 ' 
(23) 
(24) 
(25) 
(26) 
(27) 
R' 
CH3 
C2H5 
(CH2)2-CH3 
(CH2)2-CH3 
CH3 
R^ 
Ph 
Ph 
Ph 
Ph 
CONH2 
'-hydroxy-phenyl) propene 
-Cloro-5 '-hydro xy-phenyl) propa m-l-one 
Sridhar and Perumal reported the conventional and microwave synthesis of 
l-//-pyrazole-4-carboxylic acid esters 30 (a-h) by the reaction of hydrazones of/?-
ketoesters 29 (a-h) with Vilsmeier reagent. 
R' R^ 
R'-
(a) 
(b) 
(c) 
(d) 
(e) 
(f) 
(g) 
(h) 
COOCHzR^ 
(29) 
R' 
CH3 
CH3 
CH3 
CH3 
C6H5 
Ceiis 
4-CIC6H4 
4-CIC6H4 
-NO2 
DMF-POCI3 
reflux or MW] 
R^ 
H 
NO2 
H 
NO2 
H 
NO2 
H 
NO2 
R' 
H 
H 
CH3 
CH3 
CH3 
CH3 
CH3 
CH3 
R'' 
(a) 
(b) 
(c) 
(d) 
(e) 
(0 
(g) 
(h) 
r 
N N - ^ V 
COOCHzR^ 
(30) 
R' 
CH3 
CH3 
CH3 
CH3 
C6H5 
C6H5 
4-CIC6H4 
4-CIC6H4 
J>-N02 
R^ 
H 
NO2 
H 
NO2 
H 
NO2 
H 
NO2 
R^ 
H 
H 
CH3 
CH3 
CH3 
CH3 
CH3 
CH3 
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Venkata and Rao'~ synthesized 4-arylidene-3-methyi-l-(4-arylth azol-2-yl)-
l//-pyrazol-5(4//)-ones 32 (a-d) using ethylacetoacetate and aryl aldehydes 31 (a-d). 
Q O 
OCH2CH3 + 
CHO 
•^  AcOH/AcONa 
(31) 
^ M 
o 
R ' ^ ^ 
(32) 
R' 
(a) H 
(b) H 
(c) H 
(d) H 
R^ 
H 
H 
H 
H 
R' 
N(CH3)2 
N(CH3)2 
CH3 
OCH3 
R 
H 
H 
H 
H 
Dhar and Bhat'^ obtained 3,5-diphenyl-pyrazoles (36), from chalcoiies (33), 
by the reaction of hydrazine hydrate on chalcone-epoxide (34), followed by 
simultaneous dehydration in presence of catalytic amount of cone. H2SO4 m acetic 
acid. 
O O 
(35) (36) 
Kidwai and coworkers''* synthesized 4-methyl-2-[3'-substituted-pheny]-4'-
formylpyrazolyl] quinoline 38 (a-d), by the reaction of hydrazones of methyl 
quinoline 37 (a-d), with DMF and POCI3 under microwave irradiation of 3-4 min 
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CH, 
R 
N NHN = C 
CH 
\\ / 
(37) 
(a) 
(b) 
(c) 
(d) 
R 
H 
4-Cl 
4-CH3 
4-Br 
DMF/POCI3 
N N N 
(a) 
(b) 
(c) 
(d) 
(38) 
R 
H 
4-Cl 
4-CH3 
4-Br 
3-Aryl-4-fon-nyl-l[3(2-ch]orophenyl)-8-naphthyridin-2-yl] pyrazoles 40 (a-d) 
were yielded when hydrazones 39 (a-d) were subjected to microwave irradiation'^ in 
the presence of Vilsmeier-Haack reagent. 
CK 
NH. 
N=Ar 
POCl3-DMF/Siq2 
MWI 
(39) 
(a) 
(b) 
(c) 
(d) 
Ar 
CeHs 
4-CH3C6H4 
4-CH3OC6H4 
4-CIC6H4 
CHO 
(40) 
(a) 
(b) 
(c) 
(d) 
Ar 
C6H5 
4-CH3C6H4 
4-CH3OC6H4 
4-CIC6H4 
Condensation of 2-hydrazino-3-(4-niethoxyphenyl)-l,8-naphthyridine (41) 
with arylidene acetophenones 42 (a,b), in glacial acetic acid under microwave 
irradiation afforded the corresponding 2-(3,5-diaryl-2-pyrazolin-l-yl)-3-(4-methoxy-
phenyl)-l,8-naphthyridines 43 (a-b), which on oxidation with CAN in methanol under 
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phenyl)-!,8-naphthyridines 43 (a-b), which on oxidation with CAN in methanol under 
MWI furnished 2-{3,5-diarylpyrazol-l-yl)-3-(4-methoxyphenyl)-l,8-naphth\Tidines 44 
(a,b). '^ 
(a) 
(b) 
OCH, 
O 
II 
+ QH5-CH=CH-C-Ar 
(42) 
CH3COOH 
» 
MWI 
OCH, 
Ar 
(a) C6H5 
(b) 4-CH3OC6H4 
(a) 
(b) 
Ar 
C6H5 
4-CH3OC6H4 
Giacomelli et al}'' prepared a variety of 3-aryl-4-formyI pyrazoles 47 (a-f) by 
reaction of 1 molar equivalent of ketone hydrazones 45 (a-f), with 2,4,6-trichloro-
[1,3,5] triazine (TCT) in DMF at room temperature and subsequent neutralization with 
Na2C03(15%). 
R^  
^ / ^ TCT/DMF CI f \ NasCOj 
HN »- \ ,N 
'1 '1 
R' R' 
V H 
.N 
R^  
N 
A' 
(45) (46) (47) 
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R' R^ R ' R^ 
(a) C6H5 
(b) C6H5 
(c) C6H5 
(d) C6H5 
(e) C6H5 
(f) CeHs 
2-CH3C6H4 
3-CH3C6H4 
4-CH3C6H4 
4-HOC6H4 
4-CIC6H4 
(a) 
(b) 
(c) 
(d) 
(e) 
(0 
CfeHs 
C6H5 
CgHs 
C6H5 
C6H5 
CftHj 
C6H5 
Z-CH3C6H4 
3-CH3C6H4 
4-CH3C6H4 
4-HOC6H4 
4-CIC6H4 
18 Perumal et al. synthesized novel 2-aryl-5-methyl-2,3-dihydro-l//-3-
pyrazolones (50) by reaction of phenylhydrazine, ethyl acetoacetate aromatic 
aldehydes 49 (a-f) and 2-naphthoI (48). 
ArCHO ethyl acetoacetate 
PhNFfNH, A/ O HO' 
(48) (49) (50) 
R 
(a) 4-O2NC6H4 
(b) 2-O2NC6H4 
(c) 4-CIC6H4 
(d) C6H5 
(e) 4-PrC6H4 
(f) 4-MeOC6H4 
R 
(a) 4-O2NC6H4 
(b) 2-O2NC6H4 
(c) 4-CIC5H4 
(d) C6H5 
(e) 4-PrC6H4 
(f) 4-MeOC6H4 
Perumal and Selvi^' synthesized 4-ethoxy-4//-benzopyrano [4,3- c] pyrazoles 
52 (a-f) from o-hydroxyacetophenone-2,4-dinitrophenylhydrazones 51 (a-f), under 
the Vilsmeier conditions. 
75 
O^N 
(51) 
NO2 
DMF/POCI3 
r.t„ 4 h 
(52) 
(a) 
(b) 
(c) 
(d) 
(e) 
(f) 
R' 
H 
H 
H 
H 
H 
OCH3 
R^ 
H 
OCH3 
CH3 
CI 
OH 
H 
(a) 
(b) 
(c) 
(d) 
(e) 
(f) 
R' 
H 
H 
H 
H 
H 
OCH3 
R^ 
H 
OCH3 
CH3 
CI 
OH 
H 
Substituted hydrazones of 2-acetyl-3-phenylindoles 53 (a-c) on treatment with 
2 moles of Vilsmeier-Haack reagent followed by alkaline hydrolysis furnished 2-(4-
formyl-3-pyrazolyl)-3-phenylindoles 54 (a-c). 20 
CHO 
(53) 
R 
(54) 
R 
(a) H (a) H 
(b) C6H5 (b) C6H5 
(C) SO2C6H4CH3 (C) SO2C6H4CH, 
Singh et al^^ reported the synthesis of pyrazolo [3,2- c] cholest-4-ene (56) and 
[r//]-5'-(methylthio) pyrazolo [3,2- c\ cholest-4-ene (58) from 2-ethoxymethylene-
cholest-4-en-3-one (55) and bis(methylthio) methylene cholest-4-en-3-one (57), 
respectively, by the reaction of hydrazine hydrate in ethanol under reflux conditions. 
76 
C.HsOHC 
;i%iiin Ut»>'^ 
;,vV^ MeS 
MeS 
'-^ HN 
C2H5OH, reflux 
C2H5OH, reflux 
(57) (58) 
i 2 2 Clinton et al. reported that treatment of 17a-methylandrostan-17y9-ol-3-one 
(59) with ethyl formate and sodium methoxide gave 2-hydroxymethyIene derivative 
(60) which on condensation with hydrazine gave 17y9-hydroxy-17-a 
methylandrostano [3,2- c] pyrazole (61). Similar treatment of 2-hydroxymethylene-
17a-methylandrost-4-en-17/ff-oI-3-one (62), fbrnished I7y?-hydroxy-methylene-17a-
methylandrost-4-eno [3,2- c] pyrazole (63). In the same way, the homologous 17y5-
hydroxy-17a-methylandrost-4,6-dieno [3,2- c] pyrazole (65), was obtained from 64. 
CH3 
OH 
OHCH 
l5 j I NH2NH, HN 
(59) (60) (61) 
*- HN 
HOHC 
(62) 
(64) 
NH2NH2 
(63) 
(65) 
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Hirschmann and coworkers" reported several [3,2- c] pyrazoles related to 
Cortisol, 16a-methylcortisol and 4,5a-dihydrocortisol. The Cortisol sidf chain of 
compound 66 was protected by fonnation of thebismethylenedioxy (DMD) derivative 
(67), for the synthesis of pyrazoles related to 16a-methylcortisol. The conpound 67 
was allowed to react with ethylformate in benzene in the presence of sodium hydride 
to give 2-hydroxymethylene derivative (68). The compound 68 was subjected to 
condense with hydrazine and methyl hydrazine to yield the respective; [3,2- c] 
pyrazoles 69 and 70, respectively. While treatment of compound 68 with phenyl 
hydrazine gave pyrazoles 71 along with minor product 72. 
(66) 
CH2OH H,C-
(67) (68) 
(69) (70) 
(68) (71) 
(major) 
(72) 
(minor) 
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Berbalk and his coworkers"'^  in 1982 reported that the epoxyandrostane 73 
(a,b) underwent formolysis to give phenyl acetylandrostane 74 (a,b) which on further 
cyclocondensation with hydrazine hydrate afforded androstano-pyrazoles 75 (a,b). 
(73) (74) 
(a) 
(b) 
R 
OAc 
OH 
R' 
H 
H 
(a) 
(b) 
R 
OAc 
OH 
R 
H 
H 
CH,Ph 
(75) 
(a) 
(b) 
R 
OAc 
OH 
R' 
H 
H 
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Bonn and Dodson" carried out the hydrazine reduction of 16a, 17a-epoxy-
pregnenolone (76) to obtain 3/?-hydroxyandrost-5-ena[16,17- c]-5'-iTiethylpyrazole 
(77) along with the two isomeric allylic alcohols, 5,17 [20]-(c/5)-pregnadiene-3/?,166(-
diol (78) and 5,17 [20]-(/ra«5)-pregnadiene-3^,16a-diol (79). 
HO 
(76) (77) 
NH 
+ 
(78) (79) 
80 
^ ^i&euMo^ 
As a part of our continuing effort towards the synthesis of modifiec steroids, 
which are expected to be biologically active, the flision of heterocycles to steroids 
often led to a change in physiological activities or appearance of new interesting 
biological behavior. Thus, several steroidal heterocycles have been obtained 
exhibiting activity like potential inhibitors of cytochrome P450 enzynie 
aromatage,^ '^'^ ^ with their subsequent clinical application in the treatment ot estrogen 
dependent breast cancer. Pyrazolones constitute a class of compounds associated with 
wide spread popularity in the field of medicine, " and agrochemistry, "" as evident 
from number of reports covering their preparations and uses. Many of these were 
found to possess antimicrobial, anti-inflammatory, hypotensive, hypocholesverolemic 
and diuretic activities.^'"^^ The therapeutic importance of modified steroids"*^ 
encouraged us to synthesize steroidal pyrazolones. The substrates selected tor initial 
studies include 5a-cholestan-6-one (90)'*° 3y5-acetoxy-5a-cholestan-6-one (91)^' and 
3y?-chloro-5a-cholestan-6-one (92).'*^ The products obtained have been characterized 
on the basis of their elemental analysis and spectral (IR, ' H N M R , '^C N M R and MS) 
studies. 
81 
NH2NHCOCH2CN/Et3N 
C2H5OH, reflux 
(90-92) (93-95) 
X 
(80) H 
(81) OAc 
(82) CI 
X 
(83) H 
(84) OAc 
(85) CI 
Synthesis, evaluation and docking studies on steroidal pyrazolones as anticancer and 
antimicrobial agents. Shamsuzzaman, Ashraf Mashrai, A. Ahmad, A. M. Dar, H. 
Khanam, M. Danishuddin and A. U. Khan 
Med. Chem. Res. (2014) 23:348-362 
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Reaction of 5a-cfiolestan-6-one (80) with cyanoacetohydvazide: 6-(5'-Amino-3'-
oxo-dihydro -4H-pyrazol-4'-ylidine)-5a-cholestane (83): 
To a solution of steroidal ketone 80 (I mmol) in ethanol (15 mL), 
cyanoacetohydrazide (1 mmol) and few drops of triethyl amine were added. The 
reaction mixture was refluxed for 24 h. After completion of the reaction it was usually 
worked up. Recrystallization from methanol provided a single product 83, n.p. 134-
135 °C. 
C2H5OH, reflux, 24 h 
(80) (83) 
Characterization of compound 83 as 6-(5'-amino-3'-oxo-dihydro-4H-pyrazol-4'-
ylidine)-5a-cholestane 
The elemental analysis of compound 83 corresponded to the molecular 
formula C30H49N3O. The IR data provided evidence for the formation of the expected 
product. The compound showed intense bands in the region of 3385 and 3230 cm"' 
due to NH and NH2 stretching vibrations, respectively. In addition, other important 
absorption bands at 1691, 1657 and 1622 cm"' were attributed to C=0, C=N and C=C 
stretchings, respectively. Further evidence for the formation of compound 83 was well 
supported by its 'H N M R and '^C NMR spectra. Its ' H N M R spectrum exhibited one-
proton singlet at d 8.9 for NH (exchangeable with D2O) and another two-proton 
singlet at 2.6 for NH2 (exchangeable with D2O). Angular and side-chain methyl 
protons were observed at 5 1.19 (CIO-CH3), 0.75 (CI3-CH3), 0.96 and 0.83 for other 
methyl protons. '^ C NMR spectrum of the compound also supported the proposed 
structure and displayed characteristic signals aid 173 for CO, 150 for C=N, 140 for 
Ce and 119 for C'4, in addition to the known signals of cholestane series. The mass 
83 
spectrum was also in good agreement with its molecular fomiula which exhibited a 
prominent molecular ion peak at m/z 467. 
On account of the above descriptive discussion, the compound 83 can be 
suitably characterized as 6-(5'-amino-3'-oxo-dihydro-4H-pyrazol-4'-ylidine)-5a-
cholestane. 
Reaction of 3P-acetoxy-5a-cholestan-6-one (81) with cyanoacetohydrazide: 3fi-
A cetoxy-6-(5 '-amino-3 '-oxo-dihydro-4H-pyrazol-4 '-ylidine)-5a-cholestane (84): 
To a solution of steroidal ketone 81 (1 mmol) in ethanol (15 mL), equimolar 
quantity of cyanoacetohydrazide and few drops of triethyl amine were added then the 
reaction mixture was refluxed for 19 h. After completion of the reaction and usual 
work up, a single product 84, m.p. 159-160 °C, was obtained. 
NH,NHCOCH,CN/Et,N 
C2H5OH, reflux, 19 h H C-C-
(81) 
N-NH 
(84) 
Characterization of compound 84 as 3fi-acetoxy-6-(5'-amino-3'-oxo-dihydro-4H-
pyrazol-4'-ylidine)-5a-cholestane 
The compound 84 was correctly analyzed for formula C32H51N3O3. The IR 
analysis of the compound showed intense bands in the region of 3390 and 3210 cm'' 
due to NH and NH2 stretching vibrations, respectively. In addition, other important 
absorption bands at 1763, 1689, 1655, 1628 and 1240 cm"' were attributed to C=0 
(ester), C=0, C=N, C=C and C-0 stretchings, respectively. Further evidence for the 
formation of structure 84 was well supported by its 'H N M R and '^ C NMR spectra. 
The 'H NMR spectrum of the compound exhibited one-proton singlet at 6 8.6 for NH 
(exchangeable with D2O) while a two proton singlet at 2.5 was assigned to NH2 
(exchangeable with D2O). A broad multiplet centered at d 4.7 was assigned to C3-aH 
84 
(axial, WA = 15 Hz) and a three-proton sharp singlet at 2.03 was attributed to 
OCOCH3. Angular and side-chain methyl protons were observed at 1.19 (ClO-CH,), 
0.75 (CI3-CH3), 0.97 and 0.83 for other methyl protons. '^ C NMR spectrum of the 
compound also supported the proposed structure and displayed characteristic signals 
at d' 171 for CO, 167 for CONH and 154 for C=N, 145 for C(, and 118 for C'4, in 
addition to the expected signals of cholestane series. The mass spectrum was also in 
agreement with its molecular formula which exhibited a strong molecular ioii peak at 
m/z 525. 
On account of the above discussion, the compound 84 can be suitably 
characterized as 3[i-acetoxy-6-(5 '-amino-3 '-oxo-dihydro-4H-pyrazol-4 '-ylidine)-5a-
cholestane. 
Reaction of 3fi-chloro-5a-cholestan-6-one (82) mth cyanoacetohydrazide: 3ft-
Chloro-6-(5'-amino-3 '-oxo-dihydro-4H-pyrazol-4 '-ylidine)-5a-choIestane (85): 
To a solution of steroidal ketone 82 (1 mmol) in ethanol (15 mL), 
cyanoacetohydrazide (1 mmol) few drops of triethyl amine were added. The reaction 
mixture was refluxed for 18 h. After completion of reaction, Usual work up and 
recrystallization, it provided a single product 85, m.p. 147-148 °C. 
NH2NHCOCH2CN /EtjN 
-* 
CHjOH, reflux, 18 h 
(82) 
Characterization of compound 85 as 3ft-chloro-6-(5'-amino-3'-oxo-dihydro-4H-
pyrazol-4'-ylidine)-5a-cholestane 
The elemental analysis of compound 85 corresponded to the molecular 
formula C30H48N3CIO (Beilstein positive). The IR data provided evidence for the 
formation of the expected structure. The compound showed intense bands in the 
region of 3380 and 3226 cm'' due to NH and NH2 stretching vibrations, respectively. 
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Other important absorption bands at 1686, 1650, 1625 and 756 cm' were attributed to 
C=0, C=N C=C and C-Cl stretchings, respectively. Further evidence for the 
formation of this steroidal derivative was well supported by its 'H N M R and '""C 
NMR spectra. The ' H NMR spectrum of the compound exhibited one-proton singlet 
at S 8.7 for NH (exchangeable with D2O) while as a two-proton singlet at 2.6 for NH2 
(exchangeable with D2O). A one-proton broad multiplet centered at S 3.9 was 
assigned to C3-aH (axial, W'A = 17 Hz). Angular and side-chain methyl protons were 
observed at J 1.19 (CIO-CH3), 0.75 (CI3-CH3), 0.97 and 0.80 for other methyl 
protons. '^ C NMR spectrum of the compound also supported the proposed structure 
and displayed characteristic signals at S 169 for CO, 149 for C=N, 142 for Co, 118 for 
C'4 and 60 for C3, in addition to the normal signals of cholestane series. The mass 
spectrum was also in good agreement with its molecular formula which exhibited a 
strong molecular ion peak at m/z 501/499. 
On account of the above descriptive discussion, the compound 85 can be suitably 
characterized as 3p-chloro-6-(5'-amino-3 '-oxo-dihydro-4H-pyrazol-4'-ylidine)-5a-
cholestane. 
86 
The reaction seems to proceed by following mechanistic pathway presented in 
Scheme 1. A mechanistic rationale includes condensation between steroidal ketones 
and cyanoacetohydrazide leading to the fonnation of steroidal cyanoacetohydrazide, 
which later involves the nucleophilic attack of nitrogen to the C=N changing it to 
C=NH that later causes the closure of the heterocyclic ring hence leading to the 
formation of pyrazolones. 
r. NC-CH;-C0-NH-NH2 
EtjN 
LN-NH 
Scheme 1. Mechanism for the formation of steroidal pyrazolones 
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xjberi/m/erital 
General 
Melting points were determined on a Kofler apparatus and are uncorrected. 
The IR spectra were recorded on KBr pellets with Interspec 2020 FT-IR Spectrometer 
spectro Lab and values are given in cm"'. 'H and '•'C NMR spectra were rur in CDCI3 
on a Bruker Avance II 500 NMR Spectrometer at 500 MHz and 125 MHz, 
respectively. Chemical shifts (6) are reported in ppm relative to the TMS ( H NMR) 
and to the solvent signal ('^C NMR spectra). Mass spectra were recorded on a JEOL 
D-300 Mass Spectrometer. Thin layer chromatography (TLC) plates were coated with 
silica gel G and exposed to iodine vapors to check the homogeneity as well as the 
progress of reaction. Sodium sulfate (anhydrous) was used as a drying agent. 
SP-Chlorocholest-S-ene: 
Freshly distilled SOCI2 (20 mL) was added gradually to cholesterol (25 g) at 
r.t. A vigorous reaction ensured with evolution of gaseous products. When the 
reaction slackened, the mixture was gently heated at temperature 50-60 °C on water 
bath for 1 h and then poured into water with constant stirring. The yellow solid thus 
obtained was filtered under suction and washed several times with ice-cold water and 
air dried. Recrystallization from acetone gave 3y9-chlorocholest-5-ene (20 g), n .p. 95-
96 °C (reported, m.p. 96-97 "C)."*^  
Cholest-5-ene: 
3y?-Chlorocholest-5-ene (10 g) was dissolved in warm amyl alcohol (230 mL) 
and sodium metal (20 g) was added in small portions to the solution with continuous 
stirring over a period of 8 h. The reaction mixture was warmed occasionally. When all 
the sodium metal was dissolved, methanol was added and the reaction mixture was 
poured into water, acidified with dilute HCl and then allowed to stand overnight. A 
white crystalline solid thus obtained was filtered under suction and washed 
thoroughly with water and air dried. The crude material was recrystallized from 
acetone to provide cholest-5-ene as cubes (8.3 g), m.p. 88-89 °C (reported m.p. 89-91 
6-Nitrocholest-5-ene: 
A suspension of finely powdered cholest-5-ene (6.0 g), in glacial acetic acid (50 
mL) was stirred at room temperature for 5 min. Fuming nitric acid (15 mL; d, 1.52) 
was rapidly added. Sodium nitrite (3 g) was added gradually over a period of 1 h with 
stirring and sfirring was continued for 2 h. The temperature of the reaction mixture 
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was kept between 20-25 °C by external cooling. Cold water was added and a yellow 
solid thus obtained was filtered under suction, washed thoroughly with water and air 
dried. Recrystallization from methanol furnished 6-nitrocholest-5-ene, m.p. 119-120 
°C (reported m.p. 120-121 °C).^' 
5a-Cholestan-6-one (80): 
6-Nitrocholest-5-ene (6 g) was dissolved in glacial acetic acid (200 mL) by 
heating and to this solution zinc dust (12 g) was added in small portions. After the 
initial exothermic reaction had subsided, the suspension was heated under reflux for 4 
h, and water (12 mL) was added during the course of reaction. The solution was then 
filtered and the residue was washed with 40 mL warm acetic acid. To the filtrate 
water was added till turbidity developed and it was allowed to stand overnight at room 
temperature. The crystalline material thus separated was filtered under suction and 
washed thoroughly with water in order to remove zinc acetate. The organic solid was 
air dried and its recrystallization fi-om methanol afforded 5a-cholestan-6-one (90), 
m.p. 96-98 °C (reported m.p. 98-100 °C).'"^ 
3(i-A cetoxych olest-5-ene: 
A mixture of cholesterol (100 g), pyridine (150 mL, freshly distilled over 
KOH) and freshly distilled acetic anhydride (100 mL) was heated on a water bath for 
2 h. The reaction mixture was poured into ice cold water and solid mass thus obtained 
was filtered under suction, washed thoroughly with water until free from pyridine and 
then air-dried. Recrystallization of the crude product from acetone gave 3y5-
acetoxycholest-5-ene (95 g), m.p. 114 °C (reported, m.p. 115-116 °C).'*' 
3P-Acetoxy-6-nitrocIiolest-5-ene: 
To a cooled mixture of 3;ff-acetoxycholest-5-ene (10 g) and cone, nitric acid 
(250 mL), sodium nitrite (10 g) was gradually added with constant stirring over a 
period of about 45 minutes. Afler complete addition of sodium nitrite stirring was 
continued for additional 2 h. Cold water (300 mL) was added to reaction mixture, 
yellow solid material separated out. The whole mass was extracted with diethyl ether. 
The ethereal layer was washed with water, NaHCOa solution (5%) (until washings 
become pink), water and dried over anhydrous sodium sulfate. Removal of the 
solvents provided the nitro compound as an oil which was crystallized from methanol 
(6.5 g), m.p. 104 °C. (reported m.p. 102-104 "C).'" 
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3/i-A cetoxy-5a-cholestan-6-one (81): 
3y5-Acetoxy-6-nitrocholest-5-ene (6.0 g) was dissolved in glacial icetic acid 
(120 mL) by warming the mixture and zinc dust (12.0 g) was added in small portions 
with shaking. The suspension was heated under reflux for 4 h and water (i:', mL) was 
added at regular intervals during the course of reaction. The hot solution was filtered, 
cooled to room temperature and diluted with large excess of ice-cold vater and 
extracted with diethyl ether. The ethereal solution was washed with water, NaHC03 
solution (5%), again with water and dried over anhydrous sodium sulfate. E\ aporation 
of solvents provided the acetoxy ketone as an oil which was crystallized from 
methanol (4.2 g) m.p. 128-129 °C (reported m.p. 127-128 °C).^' 
3P-Chloro-6-nitrocholest-5-ene: 
To a well stirred mixture of 3;^-chlorocholest-5-ene (14 g), glacial acetic acid 
(100 mL) and fulming nitric acid (28 mL; d, 1.52) at temperature below 2C C, was 
added sodium nitrite (3 g) gradually over a period of 1 h. After the complete addition 
of sodium nitrite, the mixture was further stirred for 2 h. Now ice-cold water was 
added to it. The yellowish solid thus separated was filtered, washed with cold water 
and air dried. TTie crude product was recrystallized from methanol to give 3/^-chloro-
6-nitrocholest-5-ene, m.p. 150-52 °C (reported m.p. 153 "C)."*^  
3P-Chloro-5a-cholestan-6-one (82): 
A mixture of 3>5-chloro-6-nitrocholest-5-ene (8 g) and glacial acetic acid (160 
mL) was heated just to get a clear solution. The zinc dust (16 g) was added giadually 
in small portions with constant shaking. The suspension was heated under reflux for 4 
h and water (16 mL) was added at regular intervals during the course of reaction. The 
hot solution was filtered and the filtrate was diluted with large excess of ioe-cold 
water. The organic matter was extracted with diethyl ether and ethereal layer was 
washed successively with water, sodium bicarbonate solution (5 %) and again with 
water and dried over anhydrous sodium sulfate. Evaporation of the solvents furnished 
the ketone as an oil which was crystallized fi-om methanol (5.8 g), m.p. 128-129 °C 
(reported m.p. 127-128 °C).^^ 
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General procedure for the synthesis of steroidal pyrazolone derivatives (83-85): 
To a solution of steroidal ketones (80-82) (1 mmol) in absolute ethanol (15 
mL), cyanoacetohydrazide (1 mmol) was added followed by the addition of few drops 
of triethyl amine. The reaction mixture was refluxed for 18-24 h. The progress of 
reaction was monitored by TLC. After completion of reaction the solvent was 
removed under reduced pressure. Now it was taken in diethyl ether, washed with 
water and dried over anhydrous sodium sulfate. Removal of solvents gave the crude 
product which was recrystallized from methanol to furnish corresponding 6-(5'-
amino-3 '-oxo-dihydro-4//-pyrazol-4'-ylidine)-5«-cholestane derivatives (83-85). 
6-(5'-Amino-3'-oxo-dihydro-4H-pyrazol-4'-yUdine)-5a-cholestane (83) 
Yield (75%); m.p. 134-135 °C; Anal. Calcd for C30H49N3O: C, 77.04, H, 10.56, N, 
8.98; found; C, 77.05, H, 10.52, N, 8.95; IR (KBr) v cm '^ 3385, 3230 (NH, NH2), 
1691 (CONH), 1657 (C=N), 1622 (C=C), 1378 (C-N); 'H N M R (CDCI3, 500 MHz) S 
8.9 (s, IH, CON//, exchangeable with D2O), 2.3 (s, 2H, N//2. exchangeable with 
D2O), 2.0 (dd, IH, J =1.55, 4.52 Hz, C5-H), 1.19 (s, 3H, Cxo-CHj), 0.75 (s, 3H, C13-
CH3), 0.96 and 0.83 (other methyl protons); '^C NMR (CDCI3, 125 MHz) 6 173, 150, 
140, 119, 56, 56, 54, 42, 40, 39, 38, 37, 36, 36, 36, 34, 32, 30, 28, 28, 27, 27, 26, 25, 
24, 23, 23,19,14, 13; MS (EI): {m/z) 467 [M^]. 
3p-Acetoxy-6-(5'-amino-3'-oxo-dihydro-4H-pyrazol-4'-ylidine)-5a-cholestane (84) 
Yield (80%) m.p. 159-160 °C; Anal. Calcd for C32H5,N303: C, 73.10, H, 9.78, N, 
7.99; found; C, 73.12, H, 9.81, N, S.O; IR (KBr) v cm"' 3390, 3210 (NH, NH2), 1736 
(OCOCH3), 1689 (CONH), 1655 (C=N), 1628 (C=C), 1376 (C-N), 1240 (C-O); 'H 
NMR (CDCI3, 500 MHz) S 8.6 (s, IH, CON//, exchangeable with D2O), 4.7 (m, IH, 
Csa-H, W '/2=\5 Hz, axial), 2.5 (s, 2H, N//2 exchangeable with D2O,), 2.3 (dd, IH, J 
=7.55, 4.52 Uz,C5-H), 2.03 (s, 3H, OCOC//3), 1.18 (s, 3H, C10-C//3), 0.70 (s, 3H, C13-
C//3), 0.97 and 0.83 (other methyl protons); '^ C NMR (CDCI3, 125 MHz) J 171, 167, 
154, 145, 118, 75, 56, 56, 54, 42, 40, 39, 38, 37, 36, 36, 36, 34, 32, 30, 28, 28, 27, 26, 
25, 24, 23, 23, 22, 19, 14, 13; MS (EI): (m/z) 525 [M^]. 
3p-Chloro-6-(5'-amino-3 '-oxo-dihydro-4H-pyrazol-4'-ylidine)-5a-cholestane (85) 
Yield (78%) m.p. 147-148 °C; (Beilstein positive); Anal. Calcd for C30H48N3CIO: C, 
71.75, H, 9.63, N, 8.37; found; C, 71.79, H, 9.59, N, 8.34; IR (KBr) v cm"' 3380, 3226 
(NH, NH2), 1685 (CONH), 1650 (C=N), 1625 (C=C), 1371 (C-N), 756 (C-CI); 'H 
NMR (CDCI3, 500 MHz) 8.7 (s, IH, CON//, exchangeable with D2O), 3.9 (m, IH, 
C3a-H, WV2 = \1 Hz, axial), 2.6 (s, 2H, N//2, exchangeable with D2O), 2.3 (dd, IH, J 
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=7.55, 4.52 Hz A-H) , 1.19 (s, 3H, C10-C//3), 0.75 (s, 3H, C13-C//3). 0.9 " and 0.80 
(other methyl protons); '^ C NMR (CDCI3, 125 MHz) S 169, 149, 142, 118, 60.2, 56. 
56, 54, 42, 40, 39, 38, 37, 36, 36, 36, 34, 32, 30, 28, 28, 27, 26, 25, 24.8, .l?.S. 2M. 
19.9, 14.08, 13; MS (EI): {m/z) 501/499 [M^]. 
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CHAPTER-

Thiazolidinones and their derivatives display a large variety of activities such 
as antibiotic, diuretic, organoleptic, tuberculostatic, antileukemic and antiparasitical.'" 
Thiazolidinones (1) are classified as five membered heterocyclic ccmpounds 
containing one nitrogen, one sulfiar and three carbon atoms including a carbonyl 
group. Our continuous interest in the synthesis of steroidal compounds promjited us to 
prepare new steroidal thiazolidinone derivatives from steroidal ketones and 
simultaneously study the biological behavior like antimicrobial, anticancer and 
antioxidant activity. 
o 
(1) 
Moawad et al.^ reported that reaction of Schiff base (3) with mercajitoacetic 
acid in dry benzene afforded thiazolidinone (4). Schiff base (3) was obtained by the 
condensation of 3,4-xylene sulfonate ester of/j-hydroxy benzaldehyde (2) with p-
amino benzoic acid. 
CH. 
CHj 
p-am'mo benzoic acid 
CHO \\ / - C H = N - ( ^ C O O H 
(2) 
mercaptoacetic acid 
(3) 
SO3—<( J>—CH-N—<( \cOO\\ 
(4) 
Gursoy et al. prepared new thiazolidinone (6) by the reaction of quinazoline 
derivative (5) with mercaptoacetic acid. 
95 
SCH,CONHNHC-NH, 
II 
S 
QHj 
N SCH^COHNHN 
O 
(5) (6) 
Ansari et al.^ synthesized 4-thiazolidinone (9) starting form chalcone (7), by 
two different routes as shown in the following scheme. 
o 
\\ / 
(7) 
HSCH2COOH 
(NH4)2C03 HSCH2COOH 
H2 / = x HSCH^COOH 
^'--Vy-A-c-f-\_>ci —-^ CI 
S NH V _ c o O H 
0 
(NH4)2C03 \\ //^r"V-\\ //^ '^ O 
-COOH 
(9) (8) 
El-masry et al.^ reported that condensation of compound 10 with aromatic and 
heterocyclic aldehydes in absolute ethanol afforded the corresponding Schiff bases 
11). The cyclocondensation of substituted Schiff bases with mercaptoacetic acid/ 
thiolactic acid afforded the corresponding thiazolidinones 12 and 13. 
^ \ RCHO 
CH2CH2CONHNH2 
(10) 
SHCH2COOH 
N 
1> 
N^ CH2CH2CONHN= CHR 
(11) 
CH-, 
SHCHCOOH 
^ 
N 
CHjCHjCONHN f^ 
(12) 
^ 
N 
CH2CH2CONHN 
6 
R 
S 
CH3 
(13) 
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CI 
HJ, AJ 
Anthonsen e/ fl/7 synthesized 2-imino-3-(4-phenylthiazol-2-yl)-thiazohdin-4-
ones (16) via the key intermediate, 2-amino-4-phenylthiazoles (14) which was 
subjected to with chloroacetyl chloride to produce 2-chloro-acetaniido-4-
phenylthiazole (15) following its treatment with potassium thiocyanate in relluxing 
acetone to afford the required product 16. 
0 ^ , 0 S 
/ C U .C + NH-,/*--
NH3 H2O X = CI, Br, I 
Ph N CICOCH2CI ' ' V N ^ KSCN , ' ' V N O 
(14) (15) (16) 
Ocal et al.^ synthesized substituted 4-thiazolidinones (18) by the reaction of 
aldimine (17) with mercaptoacetic acids which were obtained by the condensation of 
pyrrole-2-carbaldehyde with aromatic amine. 
I 
H 
(17) 
R = H, CH 3 
Abbady et al.'^ obtained 4-acetylthiosemicarbazone-4-acetyldiphenyl sulfone 
(19) and 4-acetylthiosemicarbazone-4-acetyldiphenyl sulfide (20) which on further 
reaction with ethylchloroacetate in the presence of fused AcONa gave 4-(4"-
thizoHdinone-2"-acetylazino)-4'-acetyldiphenyl sulpfone (21) [X = SO2] and 4-(4"-
thizolidinone-2"-acetylazino)-4'-acetyldiphenyl sulfide (22) [X = S], respectively. 
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s 
C = N - N H - C - N H 2 
I 
(19) 
ethyl chloroacetate 
AcONa 
H3C-C—(; /H-S—(N, / > — C = N - N H - C - N H 2 
ethyl chloroacetate 
AcONa 
(21), (22) 
CH, 
(20) 
Parekh et al}^ prepared substituted Schiff bases (24) by the treatment of 2-
amino-4-(a-methoxyiminocarbomethox>Tnethyl)-thiazole (23) with aromatic 
aldehyde. The compound 24 on fiirther reaction with mercaptoacetic acid and methyl 
substituted mercaptoacetic acid in dry benzene furnished desired thiazolidinones (25) 
and (26), respectively. The products were evaluated for their in vitro growth inhibiting 
activity against several microbes. Some of them showed significant anti-tubercular 
and antiftingal activity. 
H2N 
CH3 
CH3 
I 
CH, 
(23) 
HSCH2COOH 
CH3 
0 ^ 0 
S 
(25) 
:y^A 
R = Ar 
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Monforte et alV reported the synthesis of 2,3-diaryl-1.3-thiazold n-4-ones 
(29) by reacting an aromatic aldehyde (28) with an equimolar amount oi (hetero) 
aromatic amine (27) in the presence of an excess of mercaptoacetic acid. The 
microwave-irradiation dramatically shortened the reaction time, affording the desired 
products in high yields. 
?4 R' R^  
HSCH2COOH 
R 2 ^ Y ^ N 
(27) (28) (29) 
R' = Me, OMe, Br X - CH, N 
R^=H, Me Y = CH,N 
R^=C1, F 
R ^ - H , Me 
R^=C1, F 
Terzioglu and Glu'^ synthesized the target compounds, 2-(3-ethyi-4(3//)-
quainazolinone-2-ylmercaptoacetylhydrazono)-3-alkyl/aryl-5-methyl-4thiazolidmones 
(31) and 2-arylimino-3-(3-ethyl-4(3//)-quinazolinone-2-ylmercaptoa-cetylaniino)-5-
methyl-4-thiazolidinones (32) by the cyclization of 3-ethyl-4(3//)-quinazolinone-2-
ylmercaptoacetyl)-4-alkyl/arythiosemicrabazides (30) with ethyl-2-bromopropionate 
in presence of anhydrous sodium acetate in absolute ethanol. 
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N 
1 H ^ 
H H 
CHjBrCHCOOEt 
CHjCOONa 
abs.ethanol 
\ N 
H // 
O / 
o 
R=CH3,C6H|, 
Altintas et al}^ synthesized 5-(N,N-disubstitutedaminomethyl-2-[(4-
carbethoxymethylthiaxol-2-yl)imino] 4-thiazolidinones compound 35 by refluxing 4-
carbethoxymethyl-2-[(a-chloropropoinyl/a-bromobutyryl/a-chloro-(-
phenyl)acetyl)amino] thiazoles (34) with ammonium thiocyanate. The product (35) 
also evaluated for antibacterial and antifungal activities. 
C^HsOCOHjC R'CHXCOX CsHjOCOH^C 
y-N *• jr-^ R' 
^S" NH2 
(33) (34) 
NH4SCN 
^-
CH2O+ R^H 
C2H5OCOH2C 
nj 
R ' = C H 3 , C 2 H 5 , C 6 H 5 
R 2 = — N O — N 
X = CI, Br 
CH2R^ 
(35) 
,CH3 
/ \ CH3 C2H5 ^ 
\J - N -N -N > 
^ ' CH3 ' C2H5 , \ — / 
too 
Sriram et al.''^ reported the synthesis of l,3-thiazoHdin-4-ones (38) b) reacting 
substituted benzaldehyde (36) with equimolar amount of an appropriate si bstituted 
aromatic amine (37) in the presence of an excess of mercaptoacetic acid in toluene 
under microwave irradiation. Unlike the conventional methods (48 h, 3()-70 %), 
microwave-assisted reactions were very facile (6-8 min) and provided very good 
yields (64-82 %). [Ar = 4-F-C6H4, R = 4-Cl, 2-Cl] 
R 
HSCH2COOH 
Ar-NH, 
Toluene 
MWl 
(37) (38) 
Arya et al}^ prepared spiro [indole-thiazolidines] (41) by the multicoinponent 
condensation between indole-2,3-dione (39), aromatic amine (40) and marcaptoacetic 
acid using montmorllonite KSF as solid support in 85-90 % yield in 4-5 mm under 
MW conditions. 
0 
MW 
NH, 
KSF 
HSCH2COOH 
\V 
-N 
O 
(39) 
X = H, 5-Cl, 5-CH3 
Y = OCH3 
(40) (41) 
Desai et al}^ synthesized 4-thiazolidinones (43) in a good yield from the 
heterocyclization reaction of 2-(benzothiazol-2-ylthio)-N'-benzylideneacetohydrazide 
(42) with mercaptoacetic acid in DMF in the presence of catalytic amount of 
anhydrous ZnCl2 under microwave irradiation. 
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N /=\ R 
^SCH2CONHN=CH- \\ / / 
(42) 
SHCH7COOH 
" ^ ^ SCH-,CONHN- CH 
= \ ^ 
O 
s ^^  // 
R = 4-NO2, CH3 (43) 
11 
Nagarajan synthesized £'-thiazolidinone (46) by the cycHzation of acetylene 
dicarboxylic ester (44) with thiocarbamoyl derivative (45). 
COjMe 
+ PhNH-C-NH2 / \ „ 
CO,Me ^ ^ CO2CH3 
(44) (45) (46) 
Sahu et al}^ reported that condensation of substituted benzaldehydes (47) with 
primary aryl amines (48) gave a series of Schiff bases (49) which, on reaction with 
mercaptoacetic acid, resulted in the formation of the corresponding 4-thiazoldinones 
(50). 
<V />CHO + Ar-NH2 V />-CH=N-Ar 
R 4 _ / EtOH R-^ ^ ^ 
(47) (48) (49) 
HSCH2COOH 
O 
R 
CH-N-Ar 
(50) 
Ar = 4-NO2, Phenyl, Naphthyl 
R = 2-OH, 4-N(CH3)2, 4-NO2, 4-Cl and 4-OCH3 
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Shah and Desai''' synthesized 2-(substituted phenyl)-3-[4-(2,4-di;hloro-."S-
fluorophenyl)-6-(2-thienyl)pyriiTiidine-2-yl-ureido] SHI methyl carboxy ricthyl-4-
thiazolidinones (54) starting with compound 51 and employing the following reaction 
scheme. 
F 
" A CI 
methyl chloroformate 
hydrazine hydrate 
X 
HSCHCOOH 
Y 
O 
(53) 
RC^HO 
NH NH>H, 
Y (52) O 
R CI N ^ N 
NH NH-N I 
Y V^x 
(54) O O 
R = aryl 
X = H, CH3, CH2COOH 
Terioglu et al?'^ synthesized series of 5-nitro-3-[(5-nonsubstituted/mtthyl-4-
thiazolidinone-2-ylidene) hydrazono]-l//-2-indolinones (56) by reaction of 5-nitro-l//-
indole-2,3-dione-3-thiosemicarbazone (55) with ethyl bromoacetate or ethyl 2-
bromopropionate. 
O7N 2«j--NH-C-NH2 
H 
(55) 
- N = 
O 
O 
R 
N 
H 
(56) 
R = H, CH3 
71 
Cacic et al. reported the cyclizaiton of thiosemicarbazide (57) with 
chloroacetylchloride in chloroform which afforded thiazolidinone derivative (58 . 
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HO 
NH-N N 
O ^ O 
(57) 
o ^o 
(58) 
\\ / / 
Mir et al.'" reported a rapid and easy solvent free one-pot synthesis of 5-
arylidene-2-imino-4-thiazolidinones (61) by condensation of the thiourea derivatives 
(59) with chloroacetic acid and aldehydes (60) under microwave-irradiation. 
S R2CHO CICH;C00H 
R'HN-^ NHPh 
(59) (60) (61) 
R ' = Ph, 4-Methylpyridin-2-yl 
R^  = 
OMe NMe2 NMe, 
Cao et al?^ reported the reaction of l,4,5,6-tetrahydro-6-pyridazinone-3-
carboxylic acid hydrazides (62) with aromatic aldehydes to afforded hydrazones (63). 
Hydrazones (63) which on reaction with mercaptoacetic acid in DMF in the presence 
of anhydrous ZnCb afforded 1,3-thiazolidinone derivative (64). 
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o 
0=*;^  //—C-NHNH. 
HN-N 
RCHO 
(62) 
O 
O ^ //-C-NHN=CH-R 
HN-N 
(63) 
HSCH7COOH 
o o< s 
0\ //-C-NHN-CR 
HN-N R 
(64) 
R = C6H5, 4-MeOC6H5, 4-NMe2C6H5, 2-NO2C6H4, 3-NO2C6H4, 3-OMe-4-OFC6H3 
Rollas and Kucukguzel"'* synthesized 4-thiazolidinones (66) by reacting 
hydrazones (65) with mercaptoacetic acid/thiolactic acid. 
0 o. 
Ph-C-NH N=CH-CH3 
(65) 
O 
Ph-C-NH N-CH-CH3 
(66) 
Turgut et al?^ prepared 4-thiazoHdinones (69) by the Katti carbodiimide 
(DCC) mediated one-pot three component condensation reaction of substituted 
aromatic amines (68), substituted aldehyde (67) and mercaptoacetic acid. 
CH3O, 
o^:^H^ CH3 
CH30 
SHCH2C00H 
X—(x /^-NH2 -CH3O W // 
CH30 
(67) (68) 
X = CH3, CI, OC6H5, OCH3, OC2H5 
(69) 
Shiradkar^^ reported that various phenyl-thiourea derivatives (70) on treatment 
with ethyl chloraoacetate (71) and ftised sodium acetate in absolute ethanol gave 2-
phenylimino-4-thiazolidinones(72). 
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Ph 
pu_NH ..L, / \ A CHjCOONa J~^^ 
n O ^-^^ "^  
S 
(70) (71) (72) 
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Ameta e/ a/, reported a fast and facile procedure for the synthesis of 
pyridothiazolidinone (76) starting from dihydropyridine (73). Oxidation of (73) with 
nitrating mixture (HNO3/H2SO4) produced the anticipated 2,6-dimethylpyridine 
derivatives (74), which were subsequently condensed thiosemicarbazide in ethanol to 
produce the key intermediate 2,2-[4-(4-substitutedphynely)-2,6dimethylpyridine-
3,5di-yl]-dicarbonyl dihydrazine carbothioamides (75). Compound (75) finally 
provided (76) on reacting with CICH2COOH and CHsCOONa. Their reactions were 
carried by conventional as well as microwave method. The potent antimicrobial 
effects of the synthesized compounds were also investigated. 
^ Ar O O 
.CH3 
HNO:;, H:,Sp4 
thiosemicarbazide " 2 ^ HN^ 
C N 
H3C 
II 
8-10 min S 
(75) 
9 Ar O 
ClCH,COOH. s . .N^ ^ L X A -N S 
CHjCOONa ( r N )f ^ ^ J > 
6-8.3 min V ^ H " A A . Q ^ N 
13V 
3 min „ , , , -^  . . , , 
J H3C N CH3 ^ H 
(76) 
Ar = 4-F-C6H4, 4-CI-C6H4, 4-OCH3C6H4, 4-NO2-C6H4, CeHj 
Yan et al?^ reported the construction of 4-thiazolidnone ring (79) by a three 
component reaction of fluorous benzaldehydes (78), an amine and mercaptoacetic 
acid. Compound 78 was readily prepared from 77. 
106 
CHO 
K2CO3/DIVIF 
O 
CgFiySOjF QF.y-S-O' 
(77) 
R ' = H, OMe 
R^ = n-Butyl, 4-Me-Ph 
O R 
(78) 
CHO 
R--NH2 
SHCH2COOH o 
c,F,7-s-cy 
o 
Talesara et al}'^ synthesized 2-amino-5-(4'-pyridyl)-l,3,4-thiadiazole (81) by 
cyclization of isonicotinoylthiosemicarbazide (80) with cone, sulfuric acid. When 81 
was refluxed with various aldehydes [Ar-CHO] it gave the corresponding arylidene 
derivatives (82) which on fiarther treatment with mercaptosuccinic acid furnished 
thiazolidinone derivatives (83). Another thiazolidinone derivative, 
isonicotinoylhydrazido-l,3-thiazolidinone (84), was obtained by the treatment of 80 
with chloroacetic acid in the presence of sodium acetate. [Ar = 4-OCH3C61H4. 3,4,5-
OCH3C6H2, 3-NO2C6H4, 4-NO2C6H4, 4-(CH3)2NHC6H4, C6H5, C4H30(2-fliryl)]. 
rV. 
N ^ NH2 
(80) 
CICH,CCK)H 
O 
N 
.N, 
H 
O 
(81) 
mercaptosuccinic 
acid 
(82) 
(84) 
Literature has revealed that very few steroidal thiazolidinones hava been 
prepared and studied so far. Shafiullah and Ali'''^  reported the synthesis and mass 
spectral studies of the spiro thiazolidinones (85) and (86). Steroidal thiazolidinones'' 
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of cholestane series (87) and (88) were also prepared by cyclising the respective 
thiosemicarbazones with CICH2COOH. 
(85) (86) 
AcO 
H N — r = N - N 
O 
(87) (88) 
Our lab^ ^ prepared 3-diazo(4'-thiazolidinone)cholest-4-en (90) from cholest-4-
en-3-one (89) in two steps reaction. 
HN—ri=N-N 
(89) (90) 
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Thiazolidinones have been reported to show versatile phamiacological 
activities. They have been reported as COX-1 inhibitor, anti-intlairniatory, 
antiprohferative,'-'''^^' antihistaminic," anti-HIV,"'**'^ '^  hypnotic,""' ana.\sthetic,'*' 
antifungal,''^ anthelmintic'*^ and antiviral'*'* agents as well as CNS'*^  s imulants. 
Thiazolidinones and their derivatives'*^ exhibit unusually high activitv against 
Mycobacterium tuberculosis. Recently, a number of thiazolidinones derivatives 
found to exhibit highly potent and selective anti-Platelet activating factor activity both 
in vitro and in vivo.'^^ 2-Arylimino-4-thiazolidinone derivatives have also showed 
antibacterial,'*^"'*^ antiftingal,^ *^ anticonvulsant^''^^and anticancer^^ activities. 
Furthermore, most of the 4-thiazolidinones and their benzylidene derivatives display a 
large variety of activities such as antibiotic, diuretic, organoleptic, tuberculoststic, 
antileukemic and antiparasital/'*' The pharmacological properties of 4-
thiazolidinones encouraged our interest in synthesizing several new compounds 
featuring various heterocyclic rings, attached to 4-thiazolidinone moiety. For a long 
time imines have been used successfully in the synthesis of nitrogen containing 
heterocycles.^^ As a part of our aim to search for biologically active heterocycles 
containing sulftir and nitrogen, we have undertaken the synthesis of some steroidal 
thiazolidinones eg. 5a-cholestan-((5i?)-5;?/>o-6,3'-amino-r,3',4'-thiazolidinone (94), 
3y5-acetoxy-5a-cholestan-(6/?)-5p/ro-6,3'-amino-r,3',4'-thiazolidinone (95) and 3ft-
chloro-5a-cholestan-(6j'?)-5;p/ro-6,3'-amino-r,3',4'-thiazolidinone (96) starting from 
5a-choIestan-6-one (91), 3y9-acetoxy-5c[-cholestan-6-one (92) and 3/?-chloro-5a-
cholestan-6-one (93). The structure of newly synthesized compounds lias been 
assigned on the basis of elemental analysis and spectral (IR, ' H N M R , "^C N M R , MS) 
studies. 
109 
NH2NH2,HSCH2COOH 
DCC, C^Hft, reflux 
X 
H (91) 
OAc (92) 
CI (93) 
X 
H (94) 
OAc (95) 
CI (96) 
no 
Reaction of 5a-cholestan-6-one (91) with hydrazine hydrate and mercuptoacetic 
acid: 5a-Cholestan-(6R)'Spiro-6,3 '-amino-1 ',3 ',4'-thiazolidinone (94): 
A mixture of steroidal ketone 91, hydrazine hydrate and mercaptoacetic acid 
in benzene was refluxed for 5 h in the presence of DCC in. After usual work up and 
recrystallization provided a single product 94, m.p. 128-130 °C, was obtained 
NH2NH2, HSCH2COOH 
DCC, CftHft, reflux, 5 h 
(91) (94) 
Characterization of compound 94 as 5a-cholestan-(6R)-spiro-6,3'-amino-l',3',4'-
thiazolidin one: 
The elemental analysis of the compound 94 corresponded to the molecular 
formula C29H50N2OS. The IR data provided evidence for the formation of the 
expected product. The compound showed intense band in the region of 3215 cm"' due 
to NH2 stretching vibrations. In addition, other important absorption bands at 1645, 
1229 and 674 cm" were attributed to C=0, C-N and C-S stretchings, respectively. 
Further evidence for the formation of compound 94 was well supported by its ' H 
NMR and '^C NMR spectra. The 'H N M R spectrum of the compound exhibited two 
singlets integrating for two protons each at <5 8.11 (exchangeable with D2O) for NH2 
and 3.36 for methylene protones of thiazolidinone ring. Angular and side-chain 
methyl protons were observed at 8 1.19 (CIO-CH3), 0.75 (CI3-CH3), 0.91 md 0.85 
for other methyl protons. '^C NMR spectrum displayed characteristic signals at 6 173 
for C=0, 38 for methylene carbon of thiazolidinone ring and 67 for Ce, in addition to 
the usual signals of cholestane series. The mass spectrum was also in agreement with 
its molecular formula which exhibited a strong molecular ion peak at m/z 41 A. 
On account of the above descriptive discussion, the compound 94 can be 
suitably characterized as 5a-cholestan-(6R)-spiro-6,3'-amino-l',3',4'-thiazolid:none. 
I l l 
Reaction of 3li-acetoxy-5a-cholestan-6-one (92) with hydrazine hydrate and 
mercaptoacetic acid: 3p-Acetoxy-5a-cholestan-(6R)-spiro-6,3 '-amino-1 ',3 ',4'-
thiazolidinone (95): 
A mixture of steroidal ketone 92, hydrazine hydrate and mercaptoacetic acid 
in the presence of DCC was refluxed in benzene for 6 h. Usual work up provided a 
single product 95, m.p. 132-134 °C. 
o 
ir 
H3C--C-0 
DCC. CftHfi, reflux, 6 h 
O 
II 
(92) (95) 
Characterization of compound 95 as 3P-acetoxy-5a-cholestan-(6R)-spiro-6,3'-
amino-1 ',3 ',4'-thiazolidinone: 
Compound 95 was correctly analyzed for C31H52N2O3S. The IR data suggested 
evidence the formation of the expected product. The compound showed intense band 
in the region of 3218 cm"' due to NH2 stretching vibrations. In addition, other 
important absorption bands at 1763, 1648, 1234 and 680 cm' were attributed to C=0 
(ester), C=0, C-N and C-S stretchings, respectively. Further evidence for the 
formation of compound 95 was well supported by its ' H N M R and '"'C NMR spectra. 
The ' H NMR spectrum of the compound exhibited two singlets integrating for two 
protons each at 5 8.2 (exchangeable with D2O) for NH2 and at 3.38 for methylene 
protons of thiazolidinone ring. A one-proton broad multiplet centered at 6 4.7 was 
assigned to C3-aH (axial, WA = 15 Hz) and a sharp singlet for three acetoxy group 
protons appeared at 2.03. Angular and side-chain methyl protons were observed at 
1.19 (CIO-CH3), 0.75 (CI3-CH3), 0.91 and 0.85 for other methyl protons. '^ C NMR 
spectrum of the compound also supported the proposed structure by displaying 
characteristic signals at <5 176 for C=0, 172 for C3, 40 for methylene carbon of 
thiazolidinone ring and 69 for Ce, in addition to the usual signals of cholestane 
nucleus. The mass spectrum was also found in good agreement with its molecular 
formula which exhibited a strong molecular ion peak at m/z 532. 
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On account of the above evidences, the compound 95 can be suitably 
characterized as 3P-acetoxy-5a-cholestan-(6R)-spiro-6,5 '-amin,)- /', i', 4 '-
thiazolidinone. 
Reaction of 3p-chloro-5a-cholestan-6-otie (93) with hydrazine hydrate and 
mercaptoacetic acid: 3P-Chloro-5a-cholestan-(6R)-spiro-6,3'-amino-l ',3',4'-
thiazolidinone (96): 
A mixture of steroidal ketone 93, hydrazine hydrate and mercaptoacetic acid in 
the presence of DCC was refluxed in benzene for 5.5 h. After usual work up. a single 
product 96, m.p. 136-138 °C was obtained. 
NH2NH2, HSCH-,COOH 
DCC, CgHg, reflux, 5.5 h p . 
(93) 
Characterization of compound 96 as 3fi-chloro-5a-cholestan-(6R)-spiro-6,3'-
amino-1', 3',4'-thiazolidinone: 
The elemental analysis of compound 96 corresponded to the molecular 
formula C29H49CIN2OS (Beilstein positive). The IR data provided evidence for the 
formation of the expected structure. The compound showed intense band in the region 
of 3220 cm" due to NH2 stretching vibrations. In addition, other important absorption 
bands at 1649, 1235, 776 and 683 cm"' were attributed to C=0, C-N, C-Cl and C-S 
stretchings, respectively. Further evidence for the formation of compound 96 was well 
supported by its ' H N M R and '^C NMR spectra. The ' H N M R spectrum of the 
compound exhibited two singlets at (5 8.13 (exchangeable with D2O) for NH2 and at 
3.4 for methylene protones of thiazolidinone ring. A one-proton broad rnultiplet 
centered at S 3.9 was assigned to C3-aH (axial, W'/2=^\l Hz), Angular and side-chain 
methyl protons were observed at 1.19 (CIO-CH3), 0.75 (CI3-CH3), 0.91 and 0.85 for 
other methyl protons. '^ C NMR spectrum of the compound also supported the 
proposed structure and displayed characteristic signals at ^ 174 for C=0, 50 for C3, 39 
for methylene carbon of thiazolidinone ring and 68 for Co, in addition to the signals of 
13 
cholestane series. The mass spectrum was also in good agreement with its molecular 
formula which exhibited a strong molecular ion peak at miz 508/510. 
On account of the above evidences, the compound 95 can be suitably 
characterized as 3fi-chloro-5a-cholestan-(6R)-spiro-6,3'-cimino-l',3',4'-thiazolidinone. 
The tentative mechanism for the formation of thiazolidinones have been proposed in 
schemel. 
N-NH2 
HSCH2COOH 
DCC 
Scheme 1. Proposed mechanism of formation of 5a-cholestan-(6i^)-spiro-6,3'-
amino-^,3',4'-thiazoIidinone derivatives 
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Stereo ch em istry 
The stereoselectivity of steroidal thiazolidinone can be explained by 
considering that there is a considerable amount of steric hindrance to ring-closure 
from one side of the ring at C-6 which might be explained on the basis that during 
cyclization the thiazolidinone ring closes at C-6, by the attack of sulfur of 
mercaptoacetic acid moiety, preferentially from the front (J3, axial) side s<) that the 
NNH2 has an equatorial orientation (a) to avoid 1,3-diaxial interactiors, giving 
minimum steric hindrance and maximum stability. This is further supported by the 
fact that during cyclization the nitrogen already attached to C-6 is moved towards the 
back (a, equatorial) side to reduce the steric hindrance, and leaving the front (J3, axial) 
side for the attack of nucleophile to close the thiazolidinone ring at C-6. Therefore the 
only product of this reaction with R stereochemistry at C-6 was selectively obtained. 
The dreiding models also suggest the attack of sulfur from the /?-side whii;h pushes 
the nitrogen to the less hindered «-side. Hence the formulation of the compound as 6R 
is preferred over its isomer 6S. On the basis of these models it is suggested that the 
same should also be kinetically favorable. 
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General 
Melting points were determined on a Kofler apparatus and are uncorrected. 
The IR spectra were recorded on KBr pellets with Interspec 2020 FT-IR Sj^ectrometer 
spectro Lab and values are given in cm''. ' H and '^C NMR spectra were run in CDCI3 
on a Bruker Avance II 500 NMR Spectrometer at 500 MHz and 125 MHz, 
respectively. Chemical shifts {S) are reported in ppm relative to the TMS ( 'H NMR) 
and to the solvent signal ('^C NMR spectra). Mass spectra were recorded on a JEOL 
D-300 mass spectrometer. Thin layer chromatography (TLC) plates were coated with 
silica gel G and exposed to iodine vapors to check the homogeneity as well as the 
progress of reaction. Sodium sulfate (anhydrous) was used as a drying agent 
5a-Cholestan-6-one (91): 
6-Nitrocholest-5-ene (4 g) was dissolved in warm glacial acetic acid (80 mL) 
and zinc dust (8 g) was gradually added with shaking. The mixture was heated under 
reflux for 4 h and water (8 mL) was added during the course of reaction. Zinc dust 
(unreacted) was removed by filtration. To the filtrate, water was added till turbidity 
developed and it was allowed to stand overnight at room temperature. The solid 
material thus separated was filtered under suction and washed thoroughly u ith water 
in order to remove zinc acetate. The organic solid was air dried and then recrystallized 
from methanol (2.4 g), m.p. 96-98 °C (reported m.p. 98-100 °C)." 
3P-Acetoxy-Sa-cholestan-6-one{91): 
3y9-Acetoxy-6-nitrocholest-5-ene (6.0 g) was dissolved in glacial acetic acid 
(120 mL) by warming the mixture and zinc dust (12.0 g) was added in small portions 
with shaking. The suspension was heated under reflux for 4 h and water (12 mL) was 
added at regular intervals during the course of reaction. The hot solution was filtered, 
cooled to room temperature and diluted with large excess of ice-cold water and 
extracted with diethyl ether. The ethereal solution was washed with water, NaHCO:! 
solution (5%), again with water and dried over anhydrous sodium sulfate. Evaporation 
of solvents provided the acetoxy ketone as an oil which was crystallized from 
methanol (4.2 g) m.p. 128-129 °C (reported m.p. 127-128 °C).^ * 
3p-Chloro-5a-cholestan-6-one (93): 
A mixture of 3yff-chloro-6-nitrocholest-5-ene (8 g) and glacial acetic acid (160 
mL) was heated just to get a clear solution. The zinc dust (16 g) was added gradually 
in small portions with constant shaking. The suspension was heated under refluK for 4 
h and water (16 mL) was added at regular intervals during the course of reaction. The 
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hot solution was filtered and the filtrate was diluted with large excess of ice-cold 
water. The organic matter was extracted with diethyl ether and ethereal layer was 
washed successively with water, sodium bicarbonate solution (5 %) and again with 
water and dried over anhydrous sodium sulfate. Evaporation of the solvents furnished 
the ketone as an oil which was crystallized from methanol (5.8 g), m.p. 128-129 °C 
(reported m.p. 129 °C).^^ 
General procedure for the synthesis of steroidal thiazolidinone derivatives (94-96): 
A mixture of steroidal ketone (91-93) (1 mmol), hydrazine hydrate (1 mmol) 
and mercaptoacetic acid (3.0 mmol) and DCC (1.2 mmol) were refluxed in benzene 
(15 mL) for 5-6 h. The progress of the reaction was monitored by TLC. After 
completion of the reaction, the DCC was removed by filtration, and the solvent was 
removed under reduced pressure. The residue was taken in diethyl ether, washed with 
water and dried over anhydrous sodium sulfate. Removal of solvent gave the crude 
product which was recrystallized from methanol to obtain the corresponding pure 
product (94-96). 
5a-Cholestan-(6R)-spiro-6,3'-amino-l',3',4'-thiazolidinone (94) 
Yield (78%); m.p. 128-130 °C; Anal. Calcd for C29H50N2OS: C, 73.36; H, 10.61; N, 
5.90; found; C, 73.34, H, 10.65, N, 5.92; IR (KBr) v cm' 3215 (NH2), 1645 (C=0), 
1229 (C-N), 647 (C-S); 'H N M R (CDCI3, 500 MHz) c) 8.11 (s, IH, NH2), 3.36 (s, 2H, 
CH2), 1.19 (s, 3H, CIO-CH3), 0.85 (s, 3H, CI3-CH3), 0.91 and 0.85 (other methyl 
protons); '^ C NMR (CDCI3, 125 MHz) d 173, 67, 62, 56, 54, 50, 48, 43, 41, 40, 39, 
38, 37, 35, 29, 28, 27, 26, 25, 24, 23, 22, 21, 21, 20, 20, 18, 19, 16; MS (EI): {m/z) 
474 [M*] 
3p-Acetoxy-5a-cholestan-(6R)-spiro-6,3'-amino-l',3',4'-thiazolidinone{9S) 
Yield (79%); m.p. 132-134 °C; Anal. Calcd for C31H52N2O3S: C, 69.88; H, 9.84; N, 
5.26; found; C, 69.84, H, 9.45, N, 5.22; IR (KBr) v crrr' 3218 (NH2), 1736 
(OCOCH3), 1648 (C=0), 1234 (C-N), 1234 (C-O), 680 (C-S); ' H NMR (CDCI3, 500 
MHz) d 8.11 (s, IH, NH2), 4.7 (m, IH, C3a-H, W'/2=\5 Hz, axial), 3.36 (s, 2H, CH2), 
2.03 (s, 3H, OCOCH3), 1.19 (s, 3H, CIO-CH3), 0.85 (s, 3H, CI3-CH3), 0.91 and 0.85 
(other methyl protons); '^C NMR (CDCI3, 125 MHz) d 176, 172, 69, 62, 56, 54, 50, 
49, 43, 41, 40, 39, 38, 37, 35, 30, 29, 28, 27, 26, 25, 24, 23, 22, 21, 21, 20, 20, 18, 19, 
16; MS (EI): {m/z) 532 [M^] 
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3p-Chloro-5a-cholestan-(6R)-spiro-6,3'-amino-1 ',3',4'-thiazoUdinone (96) 
Yield (77%); m.p. 136-138 °C; (Beilstein positive); Anal. Calcd for C79H4QCIN2OS: 
C, 68.40; H, 9.70; N, 5.50; found; C, 68.37, H, 9.76, N, 5.54; IR (KBr) v cm ' 3220 
(NH2), 1649 (C=0), 1235 (C-N), 776 (C-Cl), 683 (C-S); 'H N M R (CDCh, 500 MHz) 
6 8.13 (s, 1H,NH2), 3.9 (m, IH, C3a-H, W Vi^M Hz, axial), 3.4 (s, 2H, CH.), 1.19 (s, 
3H, CIO-CH3), 0.85 (s, 3H, CI3-CH3), 0.91 and 0.85 (other methyl protons); '^ C 
NMR (CDCI3, 125 MHz) S 174, 67, 68, 56, 54, 50, 49, 43, 41, 40, 39, 38, n, 35, 30. 
29, 28, 27, 26, 25, 24, 23, 22, 21, 20, 20, 18, 19, 16; MS (EI): (w/z) 508/510 [M^ ] 
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The global production of new drugs has increased in the last decades, and 
although many of the products have been beneficial for mankind, many cf them are 
also toxic and can accumulate within organisms.' In the global drug market, steroid 
drugs rank second only after antibiotics.^ Steroids have been a prime focus of research 
due to their fascinating structural framework and their excellent ability tc penetrate 
cell membranes and bind to the nuclear and membrane receptors. Even a small 
change in steroid moiety can elicit an extensive biological response. All ihese facts 
have attracted medicinal chemists and biochemists to explore these af^er nodifying 
them suitably to induce various pharmacological properties. Steroids represent 
constituents of biomembranes and hormones, fulfil protective functions, stimulate 
plant growth, etc. Many representatives of this group are widely used in medicine as 
essentials of anti-inflammatory, anabolic and contraceptive drugs"* some of them are 
extremely toxic against tumor cells and show antimicrobial and other effects. 
Heterocyclic analogs of steroids are of interest for the study of structure activity 
relationship.^ They have an important practical value in the development of novel 
pharmacological agents for regulating and maintaining biochemical homeostasis m 
man and domestic animals. Attention to heterosteroid is caused by the fact that these 
compounds proved to be interesting fi-om the biological activity point of ^ lew and 
moreover are convenient intermediates in the synthesis of numerous polyfimctional 
compounds. The Heterocyclic analogs appended to the steroid nucleus were 
positioned on the a face and the P face of the steroid to test their ability to coordinate 
the heme iron of the P450 enzyme complex.* The position of the heterocycle with 
respect to the steroid skeleton was determined to be important for optimum affinity 
and in general, compounds with the heterocycle attached to a trigonal centre at C-17. 
had the best affinity for CI 7(20) lyase.^ The invesfigation of new modified steroid 
derivatives condensed with various heterocyclic rings has been given great attention."^ 
The addition of heterocyclic rings to steroids often leads to a change of their 
physiological activity and the appearance of new interesting pharmacological and 
biological properties," especially antiinflammatory,'^ antineoplastic' and 
antiandrogenic activity.'"* The treatment of infectious diseases still remains an 
important and challenging problem. The search of novel antimicrobial agents is field 
of current and growing interest and many compounds have been synthesized to this 
aim. Their clinical use has been limited by their relatively high risk of toxicity. 
bacterial resistance and/or pharmacokinetic deficiencies. A major research emphasis 
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to counter this growing problem is the development of antimicrobials structurally 
unrelated to the existing molecules. One possibility to achieve this goal is the 
combination of a steroid molecule with structural elements possessing appropriate 
biological activities . The advantage of employing hydrophobic steroid units is their 
ability to interact with cell membranes and thus pave the way for biological activity of 
such hybrid molecules. Steroidal containing heterocycles were reported to be 
biologically active, here we are mentioning some reports by different workers for the 
biological evaluation of heterosteroids. Steroids heterocycles containing pyrazole (1), 
isoxazole (2), thiazole (3), pyrane (4) and pyridine ring (5) were reported to be active 
against some bacteria and fungi.'^ 
-R 
(1) (2) 
N-NHC0CH2-<( J 
(3) 
(5) 
Q 
(4) 
N-N /)—NH2 
O CN 
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C27 steroidal saponins (6) and steroidal sapogenins (7) isolated from several 
monocotyledons plants were found to be effective against a class of fungi. 17 
Glc(t-4)Fu-0 
^O. 
Glc 
(6) 
Saleem et al. synthesized cholest-5-en-7-thiazolo[4, 5- h\ quinoxaline-2-}l 
hydrazone derivatives (8-10) and reported them as promising antibacterial agents. 
•^  1 ^ N 
N 
X 
(8) H 
(9) AcO 
(10) CI 
124 
Saleem et al. reported the synthesis of different steroidal thiazolo 
quinooxaline (11-13) derivatives as antibacterial agents against E. coli. The 
antibacterial activities of these compounds were evaluated by disk diffusion method 
against the culture of E. Coli and the results were compared with the standard drug 
Amoxicillin. 
X 
(11) H 
(12) AcO 
(13) CI 
N 
Stigmest-6-en-7,5 a thiourea (14-15) and stigmest-6-en-7,5 a urea (16-17) 
derivatives of steroids were found to be effective against a class of bacteria.^" 
C)oH|9 
(14) 
(15) 
(16) 
(17) 
X 
AcO 
CI 
AcO 
CI 
R 
S 
s 
0 
0 
x ^ ^ ^ 
> 
r 1 " 
H H 
JH NH 
If 
R 
Several steroidal thiosemicarbazone derivatives (18) were also reported to be 
active against some bacteria. The antibacterial activity was first tested in vitro by disk 
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diffusion assay against two Gram-positive and two Gram-negative bacteria, and then 
the minimum inhibitory concentration (MIC) of compounds was detennined.' 
X' ^ " ^ N-NH-C-NH, 
X 
(18) H 
(19) AcO 
(20) CI 
i 2 2 Banday et al. reported the synthesis of different steroidal pyrazoHne (21-30) 
derivatives as anticancer agents. 
O, 
(21) 
(22) 
(23) 
R 
\\ / / 
^ / 
HO 
\\ / / 
(26) 
(27) 
(28) 
^ // 
OMe 
^ // 
\\ / / -OMe 
(24) 
(25) 
(29) — ^ 
CI 
(30) // W 
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2'-amino-5a-cholest-6-eno [6, 5- d] oxazole derivatives (31-33) have found to 
be active against some class of microbial steroids.^^ 
H,N 
X 
(31) H 
(32) AcO 
(33) CI 
Shamsuzzaman et al?'^ reported the synthesis of various steroidal pyrazolines 
(34-36) as antimicrobial agents. 
H2N-C 
X 
(34) H 
(35) AcO 
(36) CI 
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Biological evaluation of steroidal pyrazoline derivatives 70-75 
(Refer to Chapter-1 for their synthesis and characterization) 
Rule of Five and bioactivity score 
Calculated physicochemical properties of the synthesized compoands are 
shown in Table 1. The data showed one violation of Lipinski rules for compounds 70-
73 due to a calculated Clog P value above the limit of 5 and two violations in 
compounds 74 and 75 due to the same reason and the molecular mass above 500 
(Table 1). On the basis of the above results we can say that the synthesized 
compounds adhere to Lipinski's "Rule of Five" and the exceptions to the Lipinskis 
rule of five are known and involve drugs that are transported across membranes by 
carrier proteins, such as antibiotic erythromycin. 
Table 1. Calculated physicochemical properties of steroidal pyrazolines 70-75 
Comp. 
70 
71 
72 
73 
74 
75 
Clog P; expi 
Mwt 
398.67 
456.70 
433.11 
474.76 
532.80 
509.21 
•essed as th 
ClogP 
10.68 
7.45 
8.578 
11.526 
10.38 
11.51 
s logarithm 
HBD 
of its pari 
HBA 
1 
3 
1 
1 
3 
1 
tition coe 
TPSA 
22.31 
22.31 
43.61 
21.31 
21.31 
42.31 
"ficient bet' 
No. violations 
1 
1 
1 
1 
2 
2 
iveen n-octanol 
a n d w a t e r log(Coctano|/Cwater) 
HBD; Hydrogen bond donor (expressed as the sum of OH and NH) 
HBA; Hydrogen bond acceptor (expressed as the sum of O and N atoms) 
TPSA; Topological polar surface area (defined as a sum of surfaces of polar atoms 
in a molecule) 
The bioactivity score of the compounds 70-75 was also calculated for six 
criteria, GPCR ligand activity, ion chaimel modulation, kinase inhibition activity, 
protease inhibitor, enzyme inhibitor and nuclear receptor ligand activity. As we know 
for organic molecules if the bioactivity score is more than 0.00 then the compound is 
active but if it is between -0.50 to 0.00 then the compound is moderately active and if 
the compound has less than -0.50 then it is inactive compound. As we can see in 
Table 2 our synthesized compounds showed good bioactivity score. 
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Table 2 
Comp. 
70 
71 
72 
73 
74 
75 
. Bioactivity score 
GPCR 
ligand 
-0.21 
-0.20 
-0.20 
-0.15 
-0.15 
-0.14 
; of steroidal pyrazolines 
Ion 
channel 
-0.21 
-0.10 
-0.25 
-0.20 
-0.22 
-0.24 
Modulator 
Kinase 
-0.73 
-0.72 
-0.75 
-0.70 
-0.70 
-0.71 
70-75. 
Protease 
inhibitor 
-0.20 
-0.08 
-0.25 
-0.17 
-0.08 
-0.12 
Nuclear 
Receptor 
ligand 
0.23 
0.23 
0.17 
0.14 
0.13 
0.09 
Enzyme 
inhibitor 
-0.04 
0.03 
-0.04 
0.01 
0.05 
0.01 
Anticancer activity 
Steroidal pyrazolines (70-75) were evaluated for cytotoxicity in a panel of 
selective human cancer cell lines using the MTT assay. The panel of cancer cells 
encompassed HepG2 (from hepatocellular carcinoma), A549 (from lung 
adenocarcinoma epithelium), SW480 (from colon adenocarcinoma), HeLa (from 
cervical carcinoma) and HL60 from (promyelocytic leukaemia). Doxorubicin and 
Cytarabine were used as cytotoxic drugs of reference. It's clear from IC50 values 
(Table 3) that all the compounds showed impressive activity against tested cancer cell 
lines. Compound 70 was found to be potential inhibitor of cell death against all cancer 
cell lines except HL60. Compound 71 was specific to HepG2 (IC5o= 17.04) while 
compounds 72-75, showed marked inhibitory activity against HL60 (IC5o= 14.29), 
SW480 (1C50=12.17), HepG2 (IC5o=19.24) and SW480 (1C50=16.25) respectively. To 
confirm the cytotoxicity the synthesized compounds 70-75 were also tested with non-
cancer cell lines PMBC during which none of the compounds were found toxic, all 
the compounds showed IC5o> 60 fimol L~'. This also suggests that the steroidal 
pyrazoline derivatives can be used specifically for the treatment of cancer cells 
without showing toxicity to the non-cancer cells (Table 3). 
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Table 3. Anticancer activity of steroidal pyrazolines 70-75. 
Comp 
70 
71 
72 
73 
74 
75 
Doxorubicin 
Cytarabine 
SW480 
11.97±0.2 
28.01±0.4 
26.21±0.3 
12.17±0.2 
28.01±0.4 
16.25±0.4 
10.9±0.4 
16.05±0.2 
A549 
11.05±0.2 
28.21±0.3 
33.52±0.6 
13.43±0.2 
28.21±0.3 
30.32±0.6 
15.01±0.3 
14.12±0.6 
HepG2 
25.03±0.5 
17.04±0.2 
38.14±0.2 
25.03±0.5 
19.24±0.2 
28.24±0.2 
13.5±0.3 
13.04±0.4 
HeLa 
16.32±0.3 
>50 
22.13±0.5 
16.32±0.3 
20.43±0.2 
22.03±0.5 
13.52±0.3 
14.32±0.2 
HL60 
>50 
23.15±0.2 
14.29±0.6 
32.42±0.2 
23.15±0.2 
17.10±0.6 
9.52±0.2 
10.09±0.2 
PMBC 
()5 
(t4 
65 
(.3 
69 
65 
Antimicrobial Activity 
The synthesized compounds 70-75 were screened for their >? vitro 
antimicrobial activities against Gram-positive and Gram-negative bacterial strains and 
were found to possess activities against the bacteria listed in Tables 4 and •S. All of 
the compounds present excellent activities against Gram-positive bacteria, exhibiting 
MIC values of 25-100 ^ig/mL. On the other hand, all the derivatives possess moderate 
to excellent antimicrobial activities against Gram-negative strains. Among the 
synthesized compounds it was clear that compound 70 showed very good antibacterial 
activity nearly equivalent to that of standard drug Ciprofloxacin. For assaying 
antiftingal activity, different fiingal strains like Candida albicans, Asperergillus 
fumigatiis, Pencillium marneffei and Trichophyton mentagrophytes were chosen. The 
antiftingal screening data showed moderate to good ftingal inhibition (Tables 6 and 
7). Among the screened compounds, compound 70 and 73 were found to have good 
zones of inhibition. The MFC of all the compounds was two or three folds higlier than 
the corresponding MIC results. 
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Table 4. 
Comp. 
70 
71 
72 
73 
74 
75 
Standard 
DMSO 
Antibacterial activity (zones 
Gram posit 
S. Pyogenes 
16.9±0.3 
15.7±0.2 
14.1±0.5 
15.6±0.3 
13.6±0.3 
13.U0.5 
23.0±0.2 
-
i of inhibition) of steroidal pyrazolines 70-75. 
Diameter of zone of inhibition (mm) 
tive bacteria 
MRS A* 
18.9±0.4 
15.2±0.5 
14.7±0.2 
16.9±0.4 
12.2±0.2 
15.7±0.2 
22.0±0.2 
-
P. aeruginosa 
19.2±0.3 
17.1±0.3 
15.9±0.6 
15.2±0.3 
14.3±0.3 
14.9±0.6 
32.0±0.3 
-
Gram negative bacteria 
K. pneumoniae 
15.8±0.3 
15.2±0.4 
13.1±0.6 
12.8±0.3 
14.2±0.4 
13.1±0.6 
19.0±0.2 
E. coli 
16.3±0.6 
\5.\±0.2 
13.9±0.4 
14.3±0.6 
9.1 ±0.2 
12.9±0.4 
27.0±0.2 
-
Positive control (standard); Ciprofloxacin and negative control (DMSO) measured by the Halo 
Zone Test (Unit, mm); * Methicillin resistant Staphylococcus aureus (MRSA +Ve). 
Table 5. MIC and MBC results of steroidal pyrazolines 70-75 against bacterial 
strains. 
Comp. 
70 
71 
72 
73 
74 
75 
Standard 
CA; Candi 
Gram positive bacteria 
S.Pyogenes 
MIC 
50 
50 
25 
50 
50 
50 
12.5 
da albi 
MBC 
100 
100 
100 
100 
100 
100 
12.5 
cans, A 
MRSA* 
MIC 
50 
50 
12 
50 
50 
25 
6.25 
"; Aspei 
MBC 
100 
>100 
50 
100 
>100 
50 
12.5 
-gillusfh 
p. aeruginosa 
MIC 
50 
50 
25 
50 
50 
50 
12.5 
tmigatus 
MBC 
100 
50 
50 
100 
50 
100 
25 
, TM; Tri 
Gram negative bacteria 
K. pneumonia 
MIC 
50 
100 
12 
50 
100 
50 
6.25 
chophyto 
MBC 
>100 
>100 
50 
>100 
>100 
>100 
25 
n mentag 
E. coli 
MIC 
50 
100 
25 
50 
100 
50 
6.25 
rophyte 
MBC 
>100 
>100 
>100 
>100 
>100 
>100 
12.5 
y, PM; 
Penicillium marneffei. Positive control (standard); Fluconazole and negative control (DMSO) 
measured. 
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Table 7. MIC and MFC of of steroidal pyrazolines 70-75 against tlingal s rains 
Comp. 
70 
71 
72 
73 
74 
75 
Standard 
CA 
MIC 
12 
25 
50 
12 
25 
50 
6.25 
MFC 
50 
100 
100 
50 
100 
100 
25 
AF 
MIC 
25 
50 
50 
12 
50 
50 
12.5 
MFC 
100 
100 
100 
100 
100 
100 
12.5 
TM 
MIC 
50 
100 
100 
50 
50 
100 
6.25 
MFC 
100 
100 
>100 
100 
100 
>100 
25 
PM 
MIC 
12 
50 
100 
25 
50 
100 
12.5 
MFC 
no 
100 
>100 
100 
100 
> 00 
It-
(Standard); Fluconazole; CA; Candida albicans, AF; Aspergillus fiimigatiis, TM; 
Trichophyton mentagrophytes, PM; Penicillium mamejfei. MIC ()ag/ml) = minimum 
inhibitory concentration, i.e the lowest concentration of the compound to inhibit the growth of 
fungus completely; MFC (ng/ml) = minimum fungicidal concentration, i.e., the lowest 
concentration of the compound for killing the fungus completely. 
In vitro antioxidant activity 
The in vitro antioxidant activity and scavenging effects of steroidal 
pyrazolines 70-75 were evaluated by using different reactive species assay containing 
DPPH radical scavenging activity. The free radical scavenging activity of all the 
synthesized compounds were evaluated through their ability to quench the DPPH 
using ascorbic acid as reference. The potencies for the antioxidant activity of the 
synthesized compounds to the reference drug are shown in Table 8. In general all the 
synthesized compounds were less potent than the reference. Among the synthesized 
compounds, compounds 70 and 72 exhibited a slightly better antioxidant activity than 
the other compounds. 
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Table 8, The antioxidant activity data of steroidal pyrazolines 70-75' 
Comp. 
70 
71 
72 
73 
74 
75 
Standard 
control" 
25 jiig/mL 
15.8±0.5 
14.8±0.7 
14.2±0.2 
19.2±0.2 
13.3±0.4 
18.1±0.2 
36.0±0.3 
-
% inhibition 
50 ^g/mL 
23.7±0.3 
11.6±0.5 
18.3±0.4 
21.1±0.3 
]7.5±0.4 
19.7±0.2 
37.0±0.2 
-
75 ^g/mL 
15.6±0.6 
16.6±0.8 
22.6±0.2 
11.7±0.3 
16.6±0.8 
12.6±0.2 
44.0±0.3 
-
100 ^g/mL 
24.5±0.4 
21.9±0.9 
25.5±0.3 
14.5±0.4 
12.9±0.9 
15.8±0.2 
SO.OtO.S 
-
"Values represent the mean ± standard error mean (SEM) of three experiments. 
"Tvfo inhibition, standard: ascorbic acid. 
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Biological evaluation of steroidal pyranone derivatives 105-110 
(Refer to Chapter-2 for their synthesis and characterization) 
Rule of Five and bioactivity score 
The synthesized steroidal pyranones 105,107 and 108 showed one violation of 
Lipinski rules for compounds due to a calculated Clog P value above the limit of 5 
and two violations in the rest of compounds (106, 109 and 110) due to she same 
reason and the molecular mass above 500 (Table 9). On the basis of these rosults we 
can say that the synthesized compounds adhere to Lipinski's Rule. 
Table 9. Calculated physicochemical properties of steroidal pyranones 105-110 
Comp. 
105 
106 
107 
108 
109 
110 
Mwt 
461.12 
534.19 
495.56 
468.71 
526.7 
503.16 
ClogP 
8.518 
8.544 
9.518 
9.092 
7.951 
8.925 
HBD 
0 
0 
0 
0 
0 
0 
HBA 
2 
4 
2 
3 
5 
3 
TPSA 
20.31 
20.31 
46.61 
22.32 
22.32 
48.61 
No. violations 
1 
2 
1 
1 
2 
2 
Clog P; expressed as the ogarithm of its partition coefficient between n-octanol 
a n d w a t e r log(CoctanQ|/Cwater) 
HBD; Hydrogen bond donor (expressed as the sum of OH and NH) 
HBA; Hydrogen bond acceptor (expressed as the sum of O and N atoms) 
TPSA; Topological polar surface area (defined as a sum of surfaces of polar atoms 
in a molecule) 
The bioactivity score of the compounds (105-110) was also calculated for six 
criteria, GPCR ligand activity, ion channel modulation, kinase inhibition activity, 
protease inhibitor, enzyme inhibitor and nuclear receptor ligand activity Table 10. 
The results show that these compounds have good bioactivity score. 
Table 1 
Comp. 
105 
106 
107 
108 
109 
110 
0. Bioacti^ 
GPCR 
ligand 
0.03 
0.03 
0.04 
-0.07 
-0.05 
-0.07 
aty score o 
Ion 
channel 
-0.01 
-0.03 
-0.05 
-0.03 
-0.10 
-0.09 1 
"steroidal pyranones 105-1 
Modulator 
Kinase 
-0.57 
-0.56 
-0.59 
-0.72 
-0.70 
-0.77 
Protease 
inhibitor 
0.13 
0.16 
0.07 
0.04 
0.08 
-0.00 
10. 
Nuclear 
receptor 
ligand 
0.34 
0.35 
0.28 
0.28 
0.30 
0.22 
Enzyme 
inhibitor 
0.26 
0.32 
0.11 
0.24 
0.29 
0.21 
134 
Anticancer activity 
Steroidal pyranones were evaluated for cytotoxicity in a panel of selective 
human cancer cells using the MTT assay (Table 11). The panel of cancer cells 
encompassed HepG2 (from hepatocellular carcinoma), A549 (from lung 
adenocarcinoma epithelium), SW480 (from colon adenocarcinoma), HeLa (from 
cervical carcinoma) and HL-60 from (promyelocytic leukaemia). Doxorubicin and 
Cytarabine were used as cytotoxic drugs of reference. Anticancer potency of the 
compounds was indicated by IC50 values that were calculated by hnear regression 
analysis of the concentration-response curves obtained for each compound. 
Compound 105 was found to be most active among all the synthesized compounds 
against almost all the cancer cell lines while compounds 106, 108, 109 and 110 were 
found more potential to HeLa (IC5o=16.32), HeLa (IC5o=16.32), HepG2 (IC5o=19.24) 
and HepG2 (ICso^lS.H), respectively. 
To confirm the cytotoxicity, the synthesized compounds were also tested with 
non-cancer cell lines PMBC during which none of the synthesized compounds were 
found toxic, all the compounds showed IC5o> 60 |.imolL~'. 
Table 11. Anticancer activity of steroidal pyranones 105-110. 
Comp 
105 
106 
107 
108 
109 
110 
Doxorubicin 
Cytarabine 
SW480 
18.27±0.2 
29.21±0.5 
26.61±0.6 
42.27±0.2 
38.01±0.2 
25.15±0.4 
10.9±0.4 
15.01±0.3 
A549 
19.15±0.2 
19.11±0.8 
23.22±0.2 
33.43±0. 
29.11±0 
27.22±0.6 
13.5±0.3 
16.05±0.2 
HepG2 
15.03±0.5 
37.24±0.2 
27.34±0.5 
25.13±0.5 
19.24±0.2 
18.14±0.5 
14.12±0.6 
13.04±0.4 
HeL 
16.32±0.3 
16.32±0.3 
22.23±0.6 
16.32±0.3 
22.43±0.2 
29.03±0.8 
13.52±0.3 
14.32±0.2 
HL60 
19.61±0. 
43.45±0.2 
24.19±0.7 
32.42±0.2 
23.45±0.2 
27.10±0. 
9.52±0.2 
10.09±0.2 
PMBC 
69 
68 
64 
63 
69 
68 
-
-
Antimicrobial A ctivity 
The synthesized compounds 105-110 were also screened for their in vitro 
antimicrobial activities against Gram-positive and Gram-negative bacterial strains and 
were found to possess activities against the microorganisms listed in Tables 12 and 
13. All of the compounds present excellent activities against Gram-positive bacteria, 
exhibiting MIC values of 25-100 |ig/mL. On the other hand, all the derivatives 
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possess moderate to excellent antimicrobial activities against Gram-negative strains. 
Among the synthesized compounds it was clear that compound 107 showed \eiy good 
antibacterial activity nearly equivalent to that of standard drug Ciprotlox.icin. For 
assaying antifungal activity, different fungal strains like Candida albicans, 
Asperergillus fumigatus, Pencillium marneffei and Trichophyton mentagmphytcs 
were chosen. The antifungal screening data showed moderate to good fungal 
inhibition (Tables 14 and 15). Among the screened compounds, 107 and 109 vvere 
found to have good zones of inhibition. The MFC of all the compounds was two or 
three folds higher than the corresponding MIC results. 
Table 12. Antibacterial activity (zones of inhibition) of steroidal pyranones 
105-110. 
Diameter of zone of inhibition (mm) 
Comp. 
105 
106 
107 
108 
109 
110 
Standard 
DMSO 
Gram positive bacteria 
S. Pyogenes 
13.5±0.5 
12.3±0.2 
17.1 ±0.5 
17.2±0.3 
12.6±0.3 
18.2±0.9 
23.0±0.2 
-
MRS A* 
18.1±0.4 
15.2±0.5 
13.7±0.2 
15.9±0.4 
11.2±0.2 
18.2±0.1 
22.0±0.2 
" 
Gram negative bacteria 
P. aeruginosa 
19.2±0.3 
17.1±0.3 
13.9±0.6 
18.2±0.3 
11.3±0.3 
17.9±0.6 
32.0±0.3 
-
K pneumoniae 
15.8±0.3 
15.2±0.4 
10.1±0.6 
]1.3±0. 
12.1±0.4 
17.1±0.2 
]9.0±0.2 
E. coli 
16.5±0.6 
15.l±0.2 
13.')±0.4 
i4.;;±o.5 
19.; ±0.2 
16.9±0.2 
27.C»±0.2 
-
Positive control (standard); Ciprofloxacin and negative control (DMSO) measured by the 
Halo Zone Test (Unit, mm); * Methicillin resistant Staphylococcus aureus (MRSA +Ve) 
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Table 13. MIC and MBC results of steroidal pyranones 105-110 against bacterial 
strains. 
Comp. 
105 
106 
107 
108 
109 
110 
Standard 
Gram positive bacteria 
S. Pyogenes 
MIC 
50 
50 
25 
50 
50 
50 
12.5 
MBC 
100 
100 
100 
100 
100 
100 
12.5 
MRS A* 
MIC 
50 
50 
12 
50 
50 
25 
6.25 
MBC 
100 
>100 
50 
100 
>100 
50 
12.5 
Gram negative bacteria 
P. aeruginosa 
MIC 
50 
50 
25 
50 
50 
50 
12.5 
MBC 
100 
50 
50 
100 
50 
100 
25 
K. pneumonia 
MIC 
50 
100 
12 
50 
100 
50 
6.25 
MBC 
>100 
>100 
50 
>100 
>100 
>100 
25 
E. coli 
MIC 
50 
100 
25 
50 
100 
50 
6.25 
MBC 
>\00 
>100 
>100 
>100 
>100 
>100 
12.5 
(Standard); Ciprofloxacin; MIC (^g/ml) = minimum inhibitory concentration, i.e the 
lowest concentration of the compound to inhibit the growth of bacteria completely; 
MBC (^g/ml) = minimum bacterial concentration, i.e., the lowest concentration of the 
compound for killing the bacteria completely; * Methicillin resistant Staphylococcus 
aureus (MRSA +Ve). 
Table 14. Antifiingal activity of steroidal pyranones 105-110. 
Diameter of zone of inhibition (mm) 
Comp. 
105 
106 
107 
108 
109 
110 
Standard 
DMSO 
CA 
29.2±0.2 
22.1±0.2 
26.4±0.4 
25.6±0.2 
22.8±0.6 
20.8±0.8 
30.0±0.2 
-
AF 
22.7±0.1 
21.7±0.3 
19.9±0.6 
21.7±0.3 
22.5±0.3 
18.9±0.6 
27.0±0.2 
' 
TM 
20.6±0.6 
14.6±0.2 
18.9±0.5 
14.6±0.2 
12.6±0.1 
18.9±0.2 
24.0±0.3 
PM 
19.5±0.4 
16.5±0.1 
11.8±0.2 
14.5±0.4 
13.5±0.1 
11.4±0.2 
20.0±0.5 
CA; Candida albicans, AF; Aspergillus fumigatus, TM; Trichophyton 
mentagrophytes, PM; Penicillium mameffei. Positive control (standard); Fluconazole 
and negative control (DMSO) measured. 
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Table 15. MIC and MFC ot of steroidal 
Comp. 
105 
106 
107 
108 
109 
110 
Standard 
CA 
MIC 
12 
25 
25 
12 
25 
50 
6.25 
MFC 
50 
100 
100 
50 
100 
100 
25 
pyranones 105-110 against fungal strains. 
AF 
MIC 
25 
50 
50 
12 
50 
50 
12.5 
MFC 
100 
100 
100 
100 
100 
100 
12.5 
TM 
MIC 
50 
100 
10 
50 
50 
100 
6.25 
MFC 
100 
100 
50 
100 
100 
>100 
25 
PM 
MIC j MFC 
12 ' 100 
50 100 
100 >100 
25 100 
50 100 
100 >100 
12.5 25 
(Standard); Fluconazole; CA; Candida albicans, AF; Aspergillus fiimigatus, TM; 
Trichophyton mentagrophytes, PM; Penicillium marneffei. MIC (fjg/ml) = niinimum 
inhibitory concentration, i.e the lowest concentration of the compound to inhibit the 
growth of fiingus completely; MFC (|jg/ml) = minimum fungicidal concentration, i.e., 
the lowest concentration of the compound for killing the fungus completely. 
In vitro antioxidant activity 
The in vitro antioxidant activity and scavenging effects of steroidal pyranone 
derivatives were evaluated by using different reactive species assay containing DPPH 
radical scavenging activity. The free radical scavenging activity of all the synthesized 
compounds were evaluated through their ability to quench the DPPH' using ascorbic 
acid as reference. The compounds 108 exhibited a slightly better antioxidant activity 
than the rest of compounds as shown in Table 16. 
Table 16. The antioxidant activity data of steroidal \ 
Comp. 
105 
106 
107 
108 
109 
110 
Standard 
Control' 
25 ^g/mL 
17.1±0.4 
15.8±0.2 
18.2±0.7 
28.2±0.6 
15.3±0.2 
19.2±0.5 
36.0±0.3 
-
% inhibition 
50 ^g/mL 
22.5±0.3 
21.6±0.5 
18.2±0.4 
20.1 ±0.3 
19.5±0.4 
25.7±0.2 
37.0±0.2 
-
Dyranones 105-110^. 
75 ^g/mL 
25.6±0.3 
19.6±0.5 
21.6±0.1 
31.7±0.2 
16.6±0.7 
12.6±0.5 
44.0±0.3 
-
100 ^g/niL 
21.5±0.4 
20.9±0.9 
15.5±0.3 
34.5±0.4 
22.9±0.9 
25.8±0.2 
50.0±0.5 
-
Values represent the mean ± standard error mean (SEM) of three experiments. 
HO inhibition, standard: ascorbic acid. 
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Biological evaluation of steroidal pyrazolone derivatives 83-85 
(Refer to Chapter-3 for their synthesis and characterization) 
Rule of Five and bioactivity score 
The compound 83 showed one violation of Lipinski rules due to a calculated 
Clog P value above the limit of 5 and two violations in compounds 84 and 85 due to 
the same reason and the molecular mass above 500. On the basis of these results we 
can say that the synthesized compounds adhere to Lipinski's "Rule of Five" (Table 
17) 23 
Table 17. Calculated physicochemical properties of steroidal pyrazolone derivatives 
83-85 
Comp. 
83 
84 
85 
Mwt 
467.742 
525.778 
502.187 
ClogP 
7.979 
7.298 
7.832 
HBD 
3 
3 
3 
HBA 
4 
6 
4 
TPSA 
71.777 
98.082 
71.777 
No. 
violations 
1 
2 
2 
Clog P; expressed as the logarithm of its partition coefficient between n-octanol 
a n d w a t e r log(Coctano|/Cwater) 
HBD; Hydrogen bond donor (expressed as the sum of OH and NH) 
HBA; Hydrogen bond acceptor (expressed as the sum of O and N atoms) 
TPSA; Topological polar surface area (defined as a sum of surfaces of polar atoms 
in a molecule) 
The bioactivity score of compounds 83-85 was also calculated for GPCR 
ligand activity, ion channel modulation, kinase inhibition activity, protease inhibitor, 
enzyme inhibitor and nuclear receptor ligand activity. As we know for organic 
molecules if the bioactivity score is more than 0.00 then the compound is active but if 
it is between -0.50 to 0.00 the compound is moderately active and if the compound 
has less than -0.50 it is considered as inactive compound. Therefore the result (Table 
18) showed that compounds 83-85 had good bioactivity score. 
Table \l 
Comp. 
83 
84 
85 
1. Bioactivity score 0 
GPCR 
ligand 
0.00 
-0.00 
-0.04 
Ion 
channel 
0.06 
-0.08 
-0.02 
f steroidal pyr 
Modulator 
Kinase 
-0.12 
-0.12 
-0.05 
azolones 83-
Protease 
inhibitor 
0.09 
-0.01 
0.0 
•85. 
Nuclear 
receptor ligand 
-0.05 
-0.07 
-0.05 
Enzyme 
inhibitor 
0.27 
0.19 
0.21 
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Anticancer activity 
Steroidal pyrazolones (84-86) were evaluated for anticancer activity against 
selective human cancer cells using the MTT assay (Table 19). The panel of cancer 
cells encompassed HepG2, A549, SW480, HeLa and HL-60. Doxoruoicin and 
Cytarabine were used as cytotoxic drugs of reference. The compound 84 showed 
potential activity with minimum IC5o=11.67 (SW480), 16.32 (HeLa), 19.61 (A549) 
fimol L~' while compound 85 showed minimum IC5o=17.04 (HepG2) and 18.01 
(SW480)nmolL~'. 
Table 19. Anticancer activity of steroidal pyrazolone derivatives 83-85 against 
cancer and non-cancer cells. 
PMBC: 
64 
69 
67 
Comp. 
83 
84 
85 
Doxorubicin 
Cytarabine 
SW480 
26.21±0.3 
11.67±0.2 
18.01±0.4 
10.9±0.4 
15.01±0.3 
A549 
33.52±0.6 
19.05±0.2 
29.2I±0.3 
13.5±0.3 
16.05±0.2 
HepG2 
38.14±0.2 
25.03±0.5 
17.04±0.2 
11.52±0.6 
13.04±0.4 
HeLa 
22.03±0.5 
16.32±0.3 
>50 
12.52±0.3 
14.32±0.2 
HL60 
14.09±0.6 
>50 
' 23.15±0.2 
9.52±0.2 
10.09±0.2 
To confirm their cytotoxicity the compounds 83-85 were also tested with non-
cancer cell lines PMBC during which none of these compounds were found toxic, all 
the compounds showed IC5o> 60 {amol L"'. This also suggested that the sreroidal 
pyrazolone derivatives can be used specifically for the treatment of cancer cells 
without showing toxicity to the normal cells (Table 19). 
Antimicrobial A ctivity 
The compounds 83-85 were evaluated for their in vitro antimicrobial activities 
against Gram-positive and Gram-negative bacterial strains and were found to piossess 
activities against the microorganisms listed in Tables 20 and 21. All Df the 
compounds presented excellent activities against Gram-positive bacteria, exhibiting 
MIC values of 25-100 |xg/mL suggesting that the presence of amino group may lead 
to the biologically activity of the compounds. In addition to this, all the deriv atives 
also show moderate to excellent antimicrobial activity against Gram-negative strains.. 
Among these compounds it was clear that compound 83 showed very good 
antibacterial activity neariy equivalent to that of standard drug Ciprofloxacin. 
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Table 20. Antibacterial activity (zones of inhibition) of steroidal pyrazolones 83-85. 
Diameter of zone of inhibition (mm). 
Comp. Gram positive bacteria Gram negative bacteria 
83 
84 
85 
Standard 
DMSO 
S. Pyogenes 
I6.9±0.3 
15.7±0.2 
14.1 ±0.5 
23.0±0.2 
! MRS A* 
15.9±0.4 
15.2±0.5 
14.7±0.2 
22.0±0.2 
-
P. aeruginosa 
19.2±0.3 
17.1±0.3 
15.9±0.6 
32.0±0.3 
" 
K. pneumoniae 
15.8±0.3 
15.2±0.4 
13.1±0.6 
19.0±0.2 
-
E. coli 
16.3±0.6 
15.1 ±0.2 
13.9±0.4 
27.0±0.2 
-
Positive control (standard); Ciprofloxacin and negative control (DMSO) measured by 
the Halo Zone Test (Unit, mm); * Methicillin resistant Staphylococcus aureus (MRSA 
+Ve). 
Table 21 
1 
Comp. 
83 
84 
85 
Standard 
(Standarc 
MIC and MBC results of steroidal pyrazolones 83-85 against 
strains. 
Gram positive bacteria 
S. Pyogenes 
MIC 
50 
50 
50 
12.5 
); Cipr 
MBC 
100 
100 
100 
12.5 
ofloxaci 
MRSA* 
MIC 
25 
50 
50 
6.25 
n;MIC 
MBC 
50 
100 
>100 
12.5 
: (ug/m 
bacterial 
Gram negative bacteria 
P. aeruginosa 
MIC 
50 
50 
50 
12.5 
1) = mil 
MBC 
100 
100 
50 
25 
nimum i 
Kpneumonia 
MIC 
50 
50 
100 
6.25 
nhibito 
MBC 
>100 
>100 
>100 
25 
ry concen 
E. coli 
MIC 
50 
50 
100 
6.25 
tration, 
MBC 
>100 
>100 
>100 
12.5 
i.e the 
lowest concentration of the compound to inhibit the growth of bacteria completely; 
MBC ()Jg/ml) — minimum bacterial concentration, i.e., the lowest concentration of the 
compound for killing the bacteria completely; * Methicillin resistant Staphylococcus 
aureus (MRSA +Ve). 
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For assaying antifungal activity, different ftingal strains like Candida albicans, 
Asperergillus fumigatiis, Pencillium marneffei and Trichophyton mentagrophytes 
were chosen. The antifiingal screening data showed moderate to good fungal 
inhibition (Tables 22 and 23). 
Table 22. Antifungal activity of steroidal pyrazolones 83-85. 
Comp. 
83 
S4 
85 
Standard 
DMSO 
Diameter of zone of inhibition (mm) 
CA 
27.8±0.2 
25.8±0.2 
20.9±0.4 
30.0±0.2 
-
AF 
22.7±0.3 
20.7±0.3 
14.9±0.3 
27.0±0.2 
-
TM 
18.6±0.6 
17.6±0.6 
12.8±0.5 
24.0±0.3 
-
I'M 
I6.5±0.4 
14.5±0.4 
12.8±0.5 
20.at0.5 
-
CA; Candida albicans, AF; Aspergillus fiimigatus, TM; Trichophyton 
mentagrophytes, PM; Penicillium marneffei. Positive control (standard); Fluconazole 
and negative control (DMSO) measured. 
Among the screened compounds, 84 and 85 were found to have good zones of 
inhibition. The compound 83 showed maximum inhibition against C. albicans and 
Trichophyton mentagrophytes strains, while compound 83 was more effective by 
showing maximum inhibition against C. albicans, Aspergillus fumigatus and 
Penicillium marneffei strain. The MFC of all the compounds was two or three folds 
higher than the corresponding MIC results. 
Table 23. MIC and MFC of steroic 
Comp. 
83 
84 
85 
Standard 
CA 
MIC 
25 
25 
50 
6.25 
MFC 
50 
100 
100 
25 
al pyrazolones 83 
AF 
MIC 
25 
50 
50 
12.5 
MFC 
100 
100 
100 
12.5 
-85 against fungal strains 
TM 
MIC 
50 
50 
100 
6.25 
MFC 
100 
100 
>100 
25 
PM 
MIC 
25 
50 
100 
12.5 
MFC 
100 
100 
>100 
25 
(Standard); Fluconazole; CA; Candida albicans, KY; Aspergillus fumigatus, TM; 
Trichophyton mentagrophytes, PM; Penicillium marneffei. MIC (^g/ml) = minimum 
inhibitory concentration, i.e the lowest concentration of the compound to inhibit the 
growth of fungus completely; MFC (|Jg/ml) = minimum fungicidal concentration, i.e., 
the lowest concentration of the compound for killing the fungus completely. 
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The deduced patterns of antimicrobial activity of the newly synthesized steroidal 
pyrazolones are in the following order: antifungal > antibacterial. 
In vitro antioxidant activity 
The in vitro antioxidant activity and scavenging effects of steroidal pyrazolone 
derivatives 83-85 were evaluated by using different reactive species assay containing 
DPPH radical scavenging activity. The free radical scavenging activity of these 
compounds were evaluated through their ability to quench the DPPH* using ascorbic 
acid as reference. The potencies for the antioxidant activity of the compounds to the 
reference drug are shown in Table 24 
Table 24. The antioxidant activity data of steroidal pyrazolone; 
Comp. 
83 
84 
85 
Standard 
Control" 
25 ^g/InL 
16.1±0.2 
14.2±0.2 
18.2±0.5 
36.0±0.3 
-
% inhibition 
50 ^g/mL 
21.5±0.3 
18.9±0.2 
22.2±0.5 
37.0±0.2 
75 ^g/mL 
24.6±0.5 
14.6±0.2 
10.6±0.5 
44.0±0.3 
; 83-85 \ 
100 ^g/mL 
21.3±0.2 
21.9±0.8 
24.8±0.2 
50.0±0.5 
-
^Values represent the mean ± standard error mean (SEM) of three experiments. 
^o inhibition, standard: ascorbic acid. 
In general, all the synthesized compounds (83-85) were less potent than the reference. 
Molecular Docking 
Molecular docking of compounds 83-85 with S12 protein (PDB ID: IFJG) 
In order to know the exact interactions of the compounds 83-85 docking 
studies were carried out. Figures 1 depicts the comparison of binding of these 
compounds with the Ciprofloxacin binding site. Although the compounds 83, 84 and 
85 had no hydrogen bonds with the S12 protein but have hydrophobic interactions 
with the S12 protein. 
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Figure 1 (a). All the three molecules (83-85) docked in the binding site of S12 
protein. 
\,.^ 
fcr 
Figure 1 (b). (Ligplot) The interaction plot of all the three molecules (83-85) 
with the binding site of S12 protein 
The top score pose was selected for each compound and their results are 
shown in Table 25 and compared with Ciprofloxacin, which was redocked with the 
target protein using the same protocol. Among these three compounds, compound 83 
showed strong molecular interactions within active site of SI2 with 56.78 (JOLD 
fitness score as compared to other compounds 84, 85 and reference drugs having 
54.45, 52.62 and 55.45 fitness scores, respectively. Compound 83 was also found to 
have highest number of hydrophobic contacts (twenty six) as compared to other novel 
compounds and reference drug Ciprofloxacin. 
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Table 25. The ligand molecules with number of molecular interactions and the scores 
for strength of binding with S 12 protein of £". coli. 
i Com p. 
1 
83 
S4 
85 
Ciprofloxacin 
GOLD 
fitness 
score 
56.78 
54.45 
52.62 
55.45 
Residues 
involved in 
Hydrogen 
bonding 
NA 
NA 
NA 
Lys47, 
Pro94 
Residues involved 
in Hydrophobic 
interaction 
Val43,Lys46,Val55 
,Leu93J'ro94,Val9 
6 
Val43, Pro45, 
Lys46,Pro94 
Vai43,Lys46,Val55 
,Leu93, 
Pro94,Val96 
Val43, Lys46, 
Lys47,Leu93, 
Val96 
H-bond 
Range(A) 
NA 
NA 
NA 
2.6-2.9 
Hydrophobic 
Interaction 
Range (A) 
3.24-3.90 
3.17-3.90 
3.12-3.87 
3.2-3.80 
It was evident from Figures 1 that for each compound, the binding site and 
hydrogen-bonding interactions was found varied. It was interesting to observe that 
even though the core structure of all the compounds was same, the degree of 
interaction and binding location were found to be almost similar. The binding sites of 
the compounds were found to be in close proximity to the binding site of 
Ciprofloxacin. The variation in the bioactivity is mainly attributed to the difference in 
their binding site. For instance, the activity studies showed that compounds 83-85 
showed comparable results with Ciprofloxacin in the case of F. aeruginosa. It may be 
due to the fact that their binding site is close to the Ciprofloxacin binding site. 
The mode of action of compounds 83-85 with active site ofCYP 51 ofC. albicans 
(PDBID:1E9X) 
The results show that the overall trend of the interaction energies of all the 
derivatives is in good qualitative agreement with the in vitro antifungal activities. 
Among these three compounds, compound 83 showed strong molecular interactions 
within active site of CYP 51 of C. albicans with 48.10 GOLD fitness score as 
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compared to other compounds 84, 85 and reference drugs having 38.37, 40.81 and 
47.68 fitness scores respectively. Compound 83 also found to have highest number of 
hydrophobic contacts as compared to other novel compounds and reference drug 
Fluconazole (Figures 2). 
Figure 2 (a). The three molecules 83-85 docked in the binding site of Cytochrome 
P451 of C albicans. 
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"T ^^ 
lucon«jot« 
Figure 2 (b). The interaction plot of compounds 83-85 with the binding site residues 
of Cytochrome P451 of C. albicans. 
The compound 83 docked within the active site with one hydrogen bond and 
twenty eight hydrophobic interaction with rang of 3.24-3.9A (Table 26). In case of 
compound 83, the pyrazolone ring forms H-bonding interactions with the residues 
Glul33 in the S4 subsite. The binding mode of these derivatives with the active site of 
Cytochrome P450 provides reasonable explanation for their antifungal activities. The 
antifungal activities of all the compounds are comparable to the control Fluconazole. 
The results shown in Table 26 also suggest that the appropriate length of the 
substituent on the derivatives is also important for antifungal activities. The S4 sub 
site is a hydrogen bond donor and acceptor region, which interacts with the oxygen of 
the pyrazolone ring. 
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Table 26. The ligand molecules with number of molecular interactions and he scores 
for strength of binding with Cytochrome P451 of C. albicans. 
Comp. 
83 
84 
85 
Fluconazole 
GOLD 
fitness 
score 
48.10 
38.37 
40.81 
47.68 
Residues 
involved in 
Hydrogen 
bonding 
Glul33 
NA 
NA 
Arg446 
Residues involved 
in Hydrophobic 
interaction 
Alal31,Glyl32,Glul3 
3,Glu416, 
Glu418,Arg444, 
Arg446 
Alal31,Glyl32,Glul3 
3,Glu416, 
Arg444, Arg446 
Alal31,Glyl32,Glul3 
3,Glu416, 
Phe417,Glu418,Arg44 
4, Arg446 
Alal31,Glyl32,Glul3 
3,Glu416, 
Arg444, Arg446 
H-
bond 
Range 
(A) 
2.85 
NA 
NA 
2.96-
3.90 
Hydrophobic 
Interaction 
Range (A) 
^.24-3.90 
3.11-3.81 
3.12-3.87 
3.43-3.82 
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Biological evaluation of steroidal thiazolidinone derivatives 94-96 
(Refer to Chapter-4 for their synthesis and characterization) 
Rule of Five and bioactivity score 
The synthesized compounds 94-96 showed only one violation from rules of 
five for compound 94 due to a calculated Clog P value above the limit of 5 and two 
violations for compounds 95 and 96 due to the same reason and the molecular mass 
above 500. On the basis of these results we can say that the synthesized compounds 
reasonably follow Lipinski's "Rule of Five" (Table 27)." 
Table 27. Calculated physicochemical properties of steroidal thiazolidinone 
derivatives 94-96. 
Comp. 
94 
95 
96 
Mwt 
474.80 
532.8 
509.24 
ClogP 
8.08 
7.41 
7.90 
HBD 
2 
2 
2 
HBA 
3 
4 
' 
TPSA 
46.332 
72.405 
46.332 
No. violations 
1 
2 
2 
The bioactivity score of the compounds 94-96 was also calculated for six 
criteria, GPCR ligand activity, ion channel modulation, kinase inhibition activity, 
protease inhibitor, enzyme inhibitor and nuclear receptor ligand activity. Normally for 
organic molecules if the bioactivity score is more than 0.00 then the compound is 
active but if it is between -0.50 to 0.00 then the compound is moderately active and if 
the compound has less than -0.50 then it is inactive compound. The results (Table 28) 
of compounds 94-96 showed good bioactivity score. 
Table 28. Bioacl 
Comp. 
94 
95 
96 
GPCR 
ligand 
-0.08 
-0.04 
-0.04 
ivity score 
Ion 
channel 
-0.12 
-0.07 
-0.17 
of steroidal t 
Modulator 
Kinase 
-0.66 
-0.65 
-0.71 
liazolidinones 94-96. 
Protease 
inhibitor 
0.10 
0.17 
0.05 
Nuclear 
receptor 
ligand 
0.05 
0.11 
-0.01 
Enzyme 
inhibitor 
0.15 
0.23 
0.13 
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Anticancer activity 
Steroidal thiazolidinones were evaluated for cytotoxicity in a panel of selective 
human cancer cells using the MTT assay (Table 29). The panel of cancer cells 
encompassed HepG2 (from hepatocellular carcinoma), A549 (from lung 
adenocarcinoma epithelium), SW480 (from colon adenocarcinoma), Ht;La (from 
cervical carcinoma) and HL-60 from (promyelocytic leukaemia). Doxonibicin and 
Cytarabine were used as cytotoxic drugs of reference. The compound 96 showed 
potential activity with minimum IC5o= 12.03±0.5 (HeLa) and 14.09±0.6 (HL-60) lamol 
-I 
Table 29. Anticancer activity of steroidal thiazolidinones 94-96 
Comp. 
94 
95 
96 
Doxorubicin 
Cytarabine 
SW480 
10.9±0.4 
15.67±0.2 
28.0I±0.4 
25.11 ±0.3 
15.01±0.3 
A549 
19.05±0.2 
29.21 ±0.3 
32.52±0.6 
13.5±0.3 
I6.05±0.2 
HepG2 
15.03±0.5 
27.04±0.2 
38.14±0.2 
11.52±0.6 
13.04±0.4 
HeLa 
26.32±0.3 
15.03±0.5 
12.03±0.5 
12.52±0.3 
14.32±0.2 
against cancer cells. 
HL60 
24±0.3 
13.25±0.2 
14.09±0.6 
9.52±0.2 
10.09±0.2 
PMBC 
67 
69 
68 
-
' 
To confirm the cytotoxicity, the synthesized compounds (94-96) were also 
tested with non-cancer cell lines PMBC during which none of these compounds were 
found toxic, all the compounds showed IC5o> 60 pmolL"'. 
Antimicrobial Activity 
The steroidal thiazolidinones were screened for their in vitro antimicrobial 
activities against Gram-positive and Gram-negative bacterial strains and were found 
to possess activities against the microorganisms listed in Tables 30 and 31. All of the 
compounds present excellent activities against Gram-positive bacteria, exhibiting 
MIC values of 25-100 i^g/mL. On the other hand, all the derivatives possess moderate 
to excellent antimicrobial activities against Gram-negative strains. Since the 
antibacterial activity were found almost same whatever the derivative used, 
suggesting that the mechanism of action of these compounds is depending on the class 
of bacteria considered. Among these compounds it was clear that compound 94 
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showed very good antibacterial activity nearly equivalent to that of standard drug 
Ciprofloxacin. 
Table 30. Antibacterial activity (zones of inhibition) of steroidal thiazolidinones 
94-96. 
Diameter of zone of inhibition (mm). 
Comp. 
94 
95 
96 
Standard 
DMSO 
Gram positive bacteria Gram negative bacteria 
S. Pyogenes 
20.4±0.4 
19.1 ±0.4 
19.2±0.3 
23.0±0.2 
-
MRS A* 
18.2±0.4 
16.6±0.4 
17.1±0.4 
22.0±0.2 
-
P. aeruginosa 
30.2±0.4 
28.3±0.4 
29.1±0.4 
32.0±0.3 
-
K. pneumoniae 
17.2±0.4 
15.5i0.4 
17.1±0.3 
19.0±0.2 
-
E. coli 
24.6±0.4 
21.7±0.4 
23.1±0.3 
27.0±0.2 
-
Positive control (standard); Ciprofloxacin and negative control (DMSO) measured by 
the Halo Zone Test (Unit, mm). 
Table 31. MIC and MBC results of steroidal thiazolidinones 94-96 against bacterial 
strains. 
Comp. 
94 
95 
96 
Standard 
(Standard) 
Gram positive bacteria Gram negative bacteria 
S. Pyogenes 
MIC 
100 
50 
50 
12.5 
; Ciprc 
MBC 
>100 
100 
100 
12.5 
)floxaci 
MRS A* 
MIC 
50 
50 
25 
6.25 
ii;MIC 
MBC 
>100 
100 
50 
12.5 
(Hg/ml 
P. aeruginosa 
MIC 
50 
50 
50 
12.5 
) = min 
MBC 
>100 
100 
100 
25 
imum in 
K. 
pneumonia 
MIC 
50 
50 
25 
6.25 
libitorv 
MBC 
>100 
100 
50 
25 
' concen 
E. coli 
MIC 
50 
50 
25 
6.25 
tration, 
MBC 
>100 
100 
50 
12.5 
i.e the 
lowest concentration of the compound to inhibit the growth of bacteria completely; 
MBC (|jg/ml) = minimum bacterial concentration, i.e., the lowest concentration of the 
compound for killing the bacteria completely; * Methicillin resistant Staphylococcus 
aureus (MRSA +Ve). 
For assaying antifungal activity, different fungal strains such as Candida 
albicans, Asperergillus fumigatus, Pencillium marneffei and Trichophyton 
mentagrophytes were chosen. The antifungal screening data showed moderate to good 
antifungal activity (Tables 32 and 33). 
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Table 32. Antifungal activity of steroidal thiazolidi nones 94-96. 
Diameter of zone of inhibition (mm) 
Comp. 
94 
95 
96 
Standard 
DMSO 
CA 
25.8±0.2 
24.8±0.1 
21.9±0.4 
30.0±0.2 
-
AF 
22.7±0.3 
21.7±0.3 
16.7±0.5 
27.0±0.2 
-
TM 
16.3±0.5 
16.6±0.2 
14.9±0.3 
24.0±0.3 
-
PM 
]4.5±0.1 
1 7.5±0.3 
1 i.8±0.2 
2().0±0.5 
' 
CA; Candida albicans, AF; Aspergillus fumigatus, TM; Trichophyton 
mentagrophytes, PM; Penicillium marneffei. Positive control (standard); Fluconazole 
and negative control (DMSO) measured. 
Among the screened compounds, 94 and 96 were found to have good zones of 
inhibition. The compound 94 showed maximum inhibition against C. albicans and 
Trichophyton mentagrophytes strains, while compound 96 was more effective by 
showing maximum inhibition against C. albicans, Aspergillus fumigatus and 
Penicillium marneffei strain. The MFC of all the compounds was two or three folds 
higher than the corresponding MIC results. 
Table 33. 
Comp. 
94 
95 
96 
Standard 
MIC and MFC of steroidal thiazolidinones 94-96 against 
CA 
MIC 
25 
50 
25 
6.25 
MFC 
100 
100 
50 
25 
AF 
MIC 
50 
50 
25 
12.5 
MFC 
100 
100 
100 
12.5 
TM 
MIC 
50 
100 
50 
6.25 
MFC 
100 
>100 
100 
25 
ftingal strains. 
PM 
MIC 
50 
100 
25 
12.5 
MFC 
100 
>100 
100 
125 
(standard); Fluconazole; CA.; Candida albicans, AF; Aspergillus fumigatus, TM; 
Trichophyton mentagrophytes, PM; Penicillium marneffei. MIC (^g/ml) = minimum 
inhibitory concentration, i.e the lowest concentration of the compound to inhibit the 
growth of fiingus completely; MFC (^g/ml) = minimum fungicidal concentration, i.e., 
the lowest concentration of the compound for killing the fungus completely. 
152 
In vitro antioxidant activity 
The in vitro antioxidant activity and scavenging effects of steroidal 
thiazolidinones were evaluated by using different reactive species assay containing 
DPPH radical scavenging activity. The free radical scavenging activity of all the 
synthesized compounds were evaluated through their ability to quench the DPPH* 
using ascorbic acid as reference. The potencies for the antioxidant activity of the 
synthesized compounds to the reference drug are shown in Table 34. 
Table 34. The antioxidant activity data of steroidal thiazolidinones 94-96° 
Comp. 
94 
95 
96 
Standard 
Control" 
25 ^ g^/mL 
27.1±0.4 
14.8±0.2 
18.2±0.7 
36.0±0.3 
-
% inhi 
50 ^g/mL 
22.5±0.3 
11.6±0.5 
18.2±0.4 
37.0±0.2 
-
)ition 
75 ^g/mL 
25.6±0.3 
12.6±0.5 
21.6±0.1 
44.0±0.3 
100 }ig/mL 
21.5±0.4 
10.9±0.9 
15.5±0.3 
50.0±0.5 
-
Values represent the mean ± standard error mean (SEM) of three experiments. 
"^0 inhibition, standard: ascorbic acid. 
Among these compounds, compound 94 exhibited a slightly better antioxidant activity 
than 95 and 96. 
Molecular Docking 
Molecular Docking of compounds 94-96 with SI2 protein (PDB ID: IFJG) 
The potent activity of steroidal thiazolidinones as new antimicrobial agents, 
prompted us to study the docking of these derivatives inside the active site of SI2 
protein. X-ray study of S12 with divergent inhibitors showed that the binding pocket 
of the protein included the following residues Arg 89, Lys 46, Lys 47 and Lys 91 as 
shown in Figures 3. The top score was selected for each compound and the results 
were shown in Table 35 and also compared with Ciprofloxacin, which was redocked 
with the target protein using the same protocol. It was evident from the Figures 3 
that for each compound, the binding site was found to be the same. It was interesting 
to observe that even though the core structure of all the compounds was same, the 
degree of interaction and binding location were found to be different for these 
compounds. The binding sites of the compounds were found to be in close proximity 
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to the binding site of Ciprofloxacin. The variation in the bioactivity is mainly 
attributed to the difference in their binding pattern. 
Figure 3 (a). The three molecules (94-96) docked in the bindmg site of S12 protein. 
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Figure 3 (b). The interaction plot of all the three molecules (94-96) with the binding 
site residues of S12 protein 
Table 35. The ligand molecules with number of molecular interactions and the scores 
for strength of binding with S12 protein. 
Comp. 
94 
95 
96 
Ciprofloxacin 
GOLD 
fitness 
score 
31.4 
14.88 
20.83 
50.31 
Hydrogen Bond 
Interaction 
3, Cys 90, His 
132, His 136 
4, Glu 42, Cys 
90, His 132, His 
136 
3, Cys 90, His 
132, His 136 
1, His 101 
Lipophilic 
Interaction 
8, He 44, Arg 
66, Glu 88, 
Gly 89, Arg 
97, Leu 125, 
He 128, Cys 
129 
7, He 44, Arg 
66, He 86, 
Glu 88, Leu 
125, Cys 
129, Glu 133 
5, Glu 42, 
Gly 43, He 
44, Leu 91, 
Arg 97 
4; Lys 97, 
Ala 256, Cys 
394, Val 395 
Non 
Bonded 
Interaction 
24 
25 
18 
22 
XScore 
(kcal/mol) 
-6.83 
-6.81 
-6.77 
-8.06 
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Molecular docking of compounds 94-96 with active site of CYP 51 of C. albicans 
(PDBID:1E9X) 
The binding site of Fluconazole (ligand present in the template) is used as the 
active site in the Cytochrome P450-14DM model (Figures 4). The results show that 
the overall trend of the interaction energies of all the derivatives is in good qualitative 
agreement with the in vitro antifungal activities. Among the synthesized compounds, 
compound 94 had maximum negative Glide score as well as maximum binding 
energy with the active site of C>'tochrome P450 14DM of C. albicans (Table 36). 
These compounds also showed better bioactivity results as compared to standard 
Fluconazole. 
'^•\ 
!!% £'' :/"<<^ 
.7 
•--• 
Figure 4 (a). All the molecules (94-96) docked in the binding site of CYP 51 protein. 
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Figure 5 (b). The interaction plot of all the molecules (94-96) with the binding site 
CYP 51 protein. 
Table 36. The ligand molecules (94-96) 
the scores for strength of bine 
Comp. 
94 
95 
96 
Fluconazole 
GOLD 
fitness 
score 
48.2 
41.16 
43.23 
36.71 
Hydrogen 
Bond 
Interaction 
1, Gin 72 
1, Ala 73 
NIL 
NIL 
with number of molecuh 
ing with CYP51 protein. 
Lipophilic 
Interaction 
l l ,Ala73, Lys74, 
Tyr 76, Met 79, Thr 
80, Phe 83, Lys 97, 
Phe 255, Ala 256, Leu 
321,Cys394 
7, Gin 72, Tyr 76, Phe 
78, Phe 83, Lys 97, 
His 259, Leu 321 
13, Gin 72, Ala 73, 
Tyr 76, Met 79, Thr 
80, Phe 83, Lys 97, 
Ala 256, His 259, Leu 
321, Leu 324, Phe 
387, Gly 388 
6; Tyr 76, Met 79, 
Phe 255, Ala 256, His 
259, Leu 321 
IT interactions and 
Non-Bonded 
Interaction 
22 
29 
32 
24 
XScore 
(kcal/mol) 
-5.89 
-5.97 
-6.17 
-7.35 
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Rule of Five and bioactivity score 
The physicochemical parameters including octanol partition coefficients 
(CLogP), Mwt, HBD, HBA and IPSA as well as bioactivity score were calculated 
using molinspiration server (http://www.molinspira tion.com/cgi-binyproperties) and 
ChemAxon (chemicalize.org). 
Anticancer activity 
Cell lines and culture conditions 
Human cancer cell lines SW480 (human colon adenocarcinoma cells), HeLa 
(human cervical cancer cells), A549 (human lung carcinoma cells), HepG2 (human 
hepatic carcinoma cells), and HL-60 (human leukaemia) were taken for the study. 
Doxorubicin and Cytarabine were used as cytotoxic drugs of reference. SW480, 
A549, HL60 and HepG2 cells were grown in RPMI 1640 supplemented with 10 % 
fetal bovine serum (FBS), lOU penicillin and 100 ^ig/mL streptomycin at 37 °C with 5 
% CO2 in a humidified atmosphere. HeLa cells were grown in Dulbecco's modified 
Eagle's medium (DMEM) supplanted with PCS and antibiotics as described above for 
RPMI 1640. Fresh medium was given every second day. Cells were passaged at 
preconfluent densifies using a solufion containing 0.05 % trypsin and 0.5 mM IDTA. 
Blood peripheral mononuclear cell isolation (PBMC) 
Fresh blood (20-15 mL) was kindly provided by the Blood Bank Jawahar Lai 
Nehru Medical College, AMU Aligarh. The blood sample was diluted with the same 
volume of phosphate buffered saline (PBS) (1.5 KH2PO4, 6.5 Na2HP04, 137 NaCl, 
and 2.7 mM KCI; pH 7.4). Then the diluted blood sample was carefully layered on 
Ficoll-Histopaque. The mixture was centrifliged at 400g for 30 min at 20-22 °C. The 
undisturbed lymphocyte layer was careftilly transferred out. The lymphocyte was 
washed and pelleted down with 3 v of PBS for twice and resuspended RPMI-1640 
media with antibiofic and antimycotic solution 10 %, v/v FCS. Cell counting was 
performed to determine the PBMC cell number with equal volume of trypan blue. 
Cell viability assay (MTT) 
The anticancer activity in vitro was measured using the MTT assay. 
Exponentially growing cells were harvested and plated in 96-well plates ct a 
concentration of IxlO'' cells/well. After 24 h incubation at 37 °Cunder a humidified 5 
% CO2 to allow cell attachment, the cells in the wells were respectively treated w ith 
target compounds at various concentrations for 48 h. The concentration of DMSO vas 
always kept below 1.25 %, which was found to be non-toxic to the cells. A solution of 
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3-(4,5-dimethylthizaol-2-yl)-2,5-diphenyltetrazoliuiTi bromide (MTT), was prepared 
at 5 mg/mL in phosphate buffered saline (PBS; 1.5 mM KH2PO4, 6.5 mM Na2HP04, 
137 mM NaCl, 2.7 mM KCl; pH 7.4). 20 i^ L of this solution were added to each well. 
*^ After incubation for 4 h at 37 °C in a humidified incubator with 5% CO2, the 
medium/MTT mixtures were removed, and the formazan crystals formed by the 
mitochondrial dehydrogenase activity of vital cells were dissolved in 100 |xL of 
DMSO per well. The absorbance of the wells was read with a microplate reader (Bio-
Rad Instruments) at 570 nm. Effects of the drug cell viability were calculated using 
cell treated with DMSO as control. 
Data analysis 
Cell survival was calculated using the formula: Survival (%) = [(absorbance of 
treated cells-absorbance of culture medium) / (absorbance of untreated cells -
absorbance of culture medium)] xlOO.^ ^ The experiment was done in triplicate and the 
inhibitory concentration (IC) values were calculated from a dose response curve. IC50 
is the concentration in '^iM' required for 50 % inhibition of cell growth as compared 
to that of untreated control. IC50 values were determined from the linear portion of the 
curve by calculating the concentration of agent that reduced absorbance in treated 
cells compared to control cells by 50 %. Evaluation is based on mean values from 
three independent experiments, each comprising at least six microcultures per 
concentration level. 
Antimicrobial Activity 
The synthesized compounds were screened for their in vitro antibacterial 
activities against the culture of Streptococcus pyogenes (ATCC-29213), 
Staphylococcus aureus (ATCC-25923), Pseudomonas aeruginosa (ATCC-27853), 
Escherichia coli (ATCC-25922) and Kliebsiella pneumoniae (Clinical isolate) by disk 
diffusion method.^^ The minimum inhibitory concentration (MIC) of all the 
compounds was determined. Ciprofloxacin (30 mg) was used as positive control, 
whereas DMSO poured disk was used as negative control and then minimum 
inhibitory concentration (MIC) was evaluated by the macro-dilution test using 
standard inoculums of 1-2 xlO/c.fu. mL"' (0.5 McFarland standards). Serial dilutions 
of the test compounds, previously dissolved in dimethyl sulfoxide (DMSO) were 
prepared to final concentrafions of 512, 256,128, 64, 32, 16, 8,4, 2 and 1 mgmL"'. To 
each tube was added 100 mL of 24 h old inoculums. The MIC, defined as the lowest 
concentration of the test compound which inhibits the visible growth after 18 h and it 
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was determined visually after incubation for 18 h, at 37 °C. The susceptibility of the 
bacteria to the test compounds was determined by the fonnation of an inhibitory zone 
after 18 h of incubation at 37 °C. The tests use DMSO and Ciprofloxacin ,is negative 
and positive controls, respectively. The in vitro antifungal activities of synthesized 
compounds were carried out using Candida albicans, Aspergillus fiimigatus, 
Trichophyton mentagrophytes and Pencillium marneffei (recultured) in DMSO by 
agar diffusion rnethod. The minimum inhibitory concentration (MIC) was 
determined by broth dilution technique as in antibacterial activity. The Inhibition 
zones of compounds were compared with Fluconazole used as standard drug. The 
nutrient broth which contained logarithmic serially two fold diluted amount of test 
compound and controls was inoculated with approximately 1.6-6 xlO cfu. mL" . 
The cultures were incubated for 48 h at 37 °C and the growth was monitored. 
Antioxidant activity 
The synthesized compounds were tested for their antioxidant property by 1,1-
diphenylpicrylhydrazyl (DPPH) method. Drug stock solution (1 mg/mL) was diluted 
to final concentration of 2, 4, 6, 8, 10 and 12 mg/mL in methanol. Methanolic DPPH 
solution (1 mL, 0.3 mmol) was added to 3.0 mL of drug solution of different 
concentrations. The tube was kept at an ambient temperature for 30 min and the 
absorbance was measured at 517 nm. The scavenging activity was calculated by the 
following formula: 
[ % i n h i b i t i o n = [(Acomrol -Asample/Acontrol XIOO)] 
where Acomroi is the absorbance of the L-ascorbic acid (Standard) and Asampie is the 
absorbance of different compounds. The methanolic DPPH solution (1 mL, 0.3 mM) 
was used as control. 
Docking study 
Protein and ligandpreparation 
The three dimensional structures of the targets were downloaded from protein 
databank. Hydrogen atom and MMFF partial charge were added to enzyme. Potential 
steric clashes and added hydrogen atoms were relaxed by using the minimization 
procedure. The minimization was performed by using a CHARMm force field with 
Dependent Dielectric implicit solvent model and conjugates gradient method. This 
process was carried out until the average absolute derivative of co-ordinates with 
respect to energy fell below the 0.1 kcal A"'. The two dimensional structures of 
ligands were prepared by using the ChemDraw Ultra 11.0 software integrated with 
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Cambridgesoft Software (Cambridgesoft Corporation).^" Further refinement of 
compounds was performed by using energy minimization protocol with cvff force 
field. 
Molecular Docking 
GOLD (Genetic Optimization for Ligand Docking) 5.0 was used for docking 
of the compounds dataset against selected targets in present study.^' Docking 
annealing parameters for van der Walls and hydrogen bonding were set to 5.0 and 2.5 
respectively. The parameters used for genetic algorithm were population size 100, 
selection pressure 1.2, number of operations 1,00,000, number of islands 5, niche size 
2, migrate 10, mutate 100 and cross-over 100. Interaction analyses were performed by 
using Ligplot figures of the complexes and prepared by using discovery studio 
visualizer.^^ 
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H I G H L I G H T S 
• 3(i-Acetoxy-6-nitrocholest-5-ene has been synthesized from 3fi-acetoxycholest-5-ene, 
. Structural assignment has been performed on the basis of FT-IR, FT-Raman, 'H NMR, '-^ C NMR. and X-ray crystallography. 
• Thermal, optical, microstructural and dielectrical properties have also been explored. 
. Thermal studies (TG-DTA-DSC) showed thermal stability and good crystalinity of the compound. 
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A B S T R A C T 
3p-Acetoxy-6-nitrocholest-5-ene (2) has been synthesized from 3p-acetoxycholest-5-ene {1\ We pro-
vided an analysis of the compound by means of FT-IR, FT-Raman, NMR and X-ray crystallography. In addi-
tion microstructural, thermal, optical and dielectrical properties were also investigared. The compound 2 
crystallizes in the monoclinic space group P2| with cell dimensions, a = 15.7729 (13) A, b = 9.8933 (8j A. 
c - 17.8070(14) A, a = 90.00, /( = 96.175(4), y^SO.OO. The powder X-ray diffraction (PXRD) of the com-
pound was recorded to ascertain phase homogeneity. The SEM micrograph showed the presence of brick 
shaped, elongated nitrocholestane particles with 177.12 x 25.53 x 5.69 (.tm dimensions. Thermogravi-
metric analysis showed stability of the compound up to 200 X.The dielectrical studies showed that with 
increase in frequency, the dielectric constant decreases and becomes almost constanr at high frequencies. 
© 2014 Elsevier B.V. All rights reserved. 
1. Introduction 
Steroids, a widespread class of natural organic compounds 
occurring in animals, plants and fungi, have shown great therapeu-
tic value for a broad array of pathologies. They comprise a wide 
repertoire of structurally related natural compounds with impor-
tant functions in vivo, such as physiological regulators, hormones, 
and provitamins. Steroids are representative of a rich structural 
molecular diversity and ability to interact with various biological 
targets and pathways. For the last seventy years the chemistry of 
steroids has provided one of the most interesting and thoroughly 
explored areas for organic chemists. The synthetic modification 
of naturally occurring steroids with the hope of improving phar-
macological essentials has resulted in the preparation and discov-
ery of a number of diverse pharmacologically active, potent, highly 
* Corresponding author. TeL:+91 9411003465. 
E-mail address.- sliamsuzzaman9#gmail.com ( Shamsuzzaman). 
^ These authors have contributed equally. 
tirtp:;7dx.doi.org;10.l016/j.molstruc.20i4.01.031 
0022-2860/© 2014 Elsevier B.V. All rights reserved. 
specific commercially important therapeutic agents i) - ]. More-
over steroids play an important biological role ind have occupied 
a prominent position in medicinal chemistry field. Steroids have al-
ways attracted considerable interest because of I heir biological sig-
naling molecules. Many representatives of this group are widely 
used in medicine as essentials of anti-inflammatory, diuretic, ana-
bolic, contraceptive, antiandrogcnic, progestational, anticancer and 
antimicrobial agents [4.51, The steroidal drugs are widely used in 
traditional medicines, such as antibacterium, hormone kind medi-
cation, etc. Some steroid compounds are known to exert hormone 
receptor-independent antiproliferative activity via the inhibition of 
angiogenesis, tubulin polymerization and the upregulation of 
apoptotic pathways 16-8). Cholesterol (Choi), a well known steroid, 
is ubiquitous in all living systems. Cholesterol is located in all 
membrane compartments at levels as high as 50-mole percent, 
which renders it the most prominent lipid in eukaryotic cells fM). 
Cholesterol, which is synthesized de novo and obtained from the 
diet, largely affects the biophysical properties of cellular mem-
branes and fijnctions in a variety of syntheric pathways, including 
Med Chem Res (2014) 23;348-362 
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Abstract A series of new steroidal pyrazolones have been 
synthesized, characterised and evaluated for their in vitro 
anticancer activity. They were tested against five cancer 
(SW480, HepG2, A549, HeLa and HL-60) cell lines. The 
synthesized compounds showed high selectivity and com-
pound 4 showed the strongest inhibitory activity against 
human SW480 (IC50 - H.67 ^mol L~') . In addition, the 
synthesized compounds were tested for their antimicrobial 
activity by disc diffusion assay and MIC by broth micro 
dilution method against Gram-positive, Gram-negative 
strains of bacteria as well as fungus strains and we found a 
correlation between the observed and predicted antimicro-
bial activities. Docking studies were performed to investi-
gate the hypothetical binding mode of the target compounds. 
This study provided a new molecular scaffold for the further 
development of anticancer as well as antimicrobial agents. 
Keywords Steroid • Pyrazolone Anticancer • 
Antimicrobial • Docking 
Introduction 
Steroids attract much attention in cell biology and patho-
physiology because of the wide range of biological 
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phenomena in which they are involved (Vejux and Lizard. 
2009). The involvement of steroids in anticancer promotion 
and suppression has been known for a long time. This 
involvement goes far beyond the steroidal sex hormones 
(Salvador et al., 201,3). Many anticancer steroids are 
enzyme inhibitors, such as aromatase and sulfatase inhib-
itors for breast cancer, 5 a-reductase inhibitors for the 
treatment of benign prostatic hyperplasia and CYP 17 
inhibitors for advanced prostate cancer therapy (Handratta 
et al., 2005). A variety of steroids with unusual and 
interesting structures have been synthesized and evaluated 
for their antitumor activity (Krstic'a et al., 2(X)7; Poza 
et al., 2007; Bansal and Guleria, 2(X)8; Koutsourea et al.. 
2008; Thibeault et al., 2(X)8). Among these steroids, 
nitrogen containing steroid derivatives have been shown to 
be more potent and have been used clinically for the 
treatment of cancer (Guama <?? a/., 1999; Ling <•/a/., 19"7). 
Among all the numerous antibiotics developed to date, few 
compounds possessing a steroid nucleus have been studied 
and the results clearly showed that these compounds 
exhibited a good antibacterial activity agamst several 
human pathogenic bacteria (Jayasinghe et al.. 199S; Atta 
et al., 1998). The potent mechanism of action of these 
compounds described by the interactions of amine groups 
with the negative phosphate groups of LPS displacing 
divalent cations such as Ca""*^  and Mg'"*^  (Nikaido, 19^6; 
Vaara, 199.3). Pyrazolones are important structural cores in 
many drug substances of medicinal fields. Heterocyclic 
nucleus containing pyrazolones are useful antipyretic and 
analgesic drugs (Himly et al., 2003), whilst edaravone 
(MCI-186) has been used for treating the br;iin (Kawai 
et al., 1997) and myocardial Lschemia (Wu et ai., 2(X)2). In 
addition, pyrazolones possess kinase inhibitory properties, 
particularly of enzymes which catalyze the phosphoryla-
tion of serine and threonine in proteins and also used for 
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Abstract In this study, we describe a green and simple procedure for biosynthesis of Z lO nanopar-
ticles using Candida albicans as eco-friendly reducing and capping agent. The synthesized ZnO nano-
particles were characterized by UV-vis spectroscopy, powder X-ray diffraction, scanning electron 
microscopy (SEM), transmission electron microscopy (TEM),photoluminescence (PL). Ihermo gravi-
metric analysis (TGA) and differential thermal analysis (DTA). The prepared nano-particles were 
used as catalyst for the fast and efficient synthesis of steroidal pyrazolines (4-9) from a. /J unsaturated 
steroidal ketones (1-3). The target molecules were obtained in good to excellent yields applying the 
current method. 
© 2013 Production and hosting by Elsevier B.V. on behalf of King Sand University. 
1. Introduction 
Green chemistry can be recognized as pioneering research, 
which widely reports intrinsic atom economy, energy savings, 
waste reduction, easy work ups and the avoidance of hazardous 
chemicals (Kumar et al., 2012). The development of a simple, 
eco-friendly reaction protocol for the synthesis of highly func-
tionalized compound libraries of medicinal motifs is an attrac-
tive area of research in both academia and the pharmaceutical 
industry (Domling, 2006). Nano-chemistry is an up growing re-
search area due to its imique properties (Xia ci al. 2003). The 
usage of nanomaterials as catalyst has gained a significant role 
in organic synthesis due to simple work-up procedure, environ-
mentally benign nature, reusability, low cost, and e isc of isola-
tion. Recently, nano-ciystaUine inorganic oxides exhibited 
enormous opportunities and attracted the interest of several re-
search groups because of their different topical characteristics 
and wide range of particle sizes (Hadjipanayis and Siegcl. 
1994). Of late, catalysis by nanomaterials has become an area 
of interest, as these materials exhibit better catalytic activity 
compared to their bulk sized counterparts (Beydoun et al., 
1999: Zhang et al., 2007). Zinc oxide as a non-toxic, inexpensive, 
and non-hygroscopic polar inorganic crystalline material is very 
economical, safe, and easily available Lewis acid catalyst, which 
has gained much interest in various organic translbrmaiions, 
1878-5352 © 2013 Production and hosting by ELsevier B.V. on behalf of King Saud University. 
http:vdx.doi.org/IO. 10l6.j.arabjc.2013.05.0()4 
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Abstract In this study, we describe a green and simple procedure for the synthesis of steroidal 2H-
pyrans 4-6 using chitosan as an eco-friendly heterogeneous catalyst. The synthesized compounds 
were characterized by IR, 'H NMR, ' ' C NMR, MS and analytical data. These compounds were 
tested in vitro against two cancer cell lines [HeLa (cervical) and Jurkat (leukemia)] and one normal 
cell line (PBMC). The compounds exhibited moderate to good activity against the two human can-
cer cell lines and were less toxic against the non-cancer cell line. In addition, the synthesized com-
pounds were tested for their in vitro antioxidant activity by l,l-diphenylpicrylhydraz\l method in 
which compounds 4 and 6 exhibited good antioxidant activity. This study provided a new molecular 
scaffold for the further development of anticancer as well as antioxidant agents. 
© 2013 King Saud University. Production and hosting by Elsevier B.V. All rithis reserved. 
1. Introduction 
Green chemistry can be recognized as a pioneering research, 
which widely reports intrinsic atom economy, energy savings, 
waste reduction, easy work ups and the avoidance of hazard-
ous chemicals (Kumar ct al., 2012). The progress of a simple 
and eco-friendly reaction protocol for the synthesis of highly 
functionalized compound libraries of medicinal motifs is an 
attractive area of investigation in both academia and the phar-
Corresponding author. Tel.: -f-91 941100,3465. 
E-mail address: shaniMi7yaman9c gmaii.cDin ( Shamsuzzaman). 
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maceutical industry (Doinlinu. 2006). Chitosan is 'eadily pre-
pared via aqueous alkali promoted hydrolysis of chitin. 
Being hydrophilic and possessing basic moieties Bide; and 
Birkholz. I99(i). chitosan has been utibzed as a heterogeneous 
eco-friendly basic catalyst for reactions carried out in prolic 
medium (Gomha and Riy;Klh. 2009). Steroids are an impor-
tant class of natural products which have high capability to 
penetrate cells and bind to nucleus and membrane receptors. 
They include great variations in structure and play a very 
important role in life (hcsti ct :il . 2007: Ifcro et •;! . 2()(^). 
The investigation of modified steroid derivatives condensed 
with different heterocyclic rings has drawn great attention 
(El-Far el al., 2009). Pyrans and their derivatives constitute 
an important class of organic compounds due to their attrac-
tive pharmacological and biological properties (Ci'c-n c( ,\ . 
lyyS; Ncmouchi ct al.. 2012). They are widely usee as antico-
agulant, anticancer, diuretic, spasmolitic and antiaraphylactin 
1018-3647 © 2013 King Saud University, Production and hosting by Elsevier B.V, AH rights reserved. 
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A B S T R A C T 
a-Selective epoxidation of 3p-chlorochoIest-5-ene and 3(i-acetoxycholest-5-ene has been performed 
with m-CPBA to synthesize 3P-chloro-5a,6a-epoxycholestane (1) and 3(5-acetoxy-S«.6a-epoxycholes-
tane (2). We provided an analysis of these compounds by means of Fl'-IR, FT-Raman 'H NMR, '^ C NMR, 
2D cosy, NOESV, UV-visible and X-iay cr-yslallography. The compound 1 crystallizes in the orthorhombic 
space group P2,2| 21 while compound 2 crystallizes in the monoclinic space group P2,. We compared the 
conformations of both compounds in solid state and in solution by calculation of dihedral angles and 
coupling constant values. The powder X-ray diffraction (PXRD) of the compound was recorded to 
ascertain the purity of the grown ciystals. Theimogravimetric analysis showed stability of the 
compounds up to 250 T. Moreover, the ICH rule has been applied to test the stability of two crystals, 
which showed significant stability. 
© 2013 Elsevier B.V. All rights reserved. 
1. Introduction 
Cholesterol is a tetracyclic lipid of biological importance since 
its discovei-y by Franijois Poulletier de la Salle in 1758. Since the 
last century cholesterol is known to be subject to oxidation leading 
to the formation of mono- or poly-oxygenation products called 
oxysterols. Oxysterols attract much attention in cell biology and 
pathophysiology because of the wide range of biological phenom-
ena in which they are involved. Oxysterols can be endogenously 
produced from cholesterol (Choi'') by enzymatic and nonenzy-
matlc oxidative processes or absorbed from diet sources [ 1 j . They 
participate in the biosynthesis of bile acids and steroid hormones, 
acting also as signaling lipids that regulate cholesterol biosynth-
esis, cellular cholesterol efflux, lipoprotein uptake, intracellular 
cholesterol trafficking [2J and have been related to neurodegen-
erative diseases, such as Alzheimer, Parkinson, and Multiple 
sclerosis [1 j . Most common oxysterols are known to interfere with 
the cell membrane structure and cellular receptors [3] to inhibit 
'Corresponding autiior. Mobile: +91 .9411003465. 
£-niai( addresses: sliams_chcm@'rediffniail.cora, 
shamsu22aman9(^ gmaii.cnm [Shamsuzzaman). 
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cholesterol |2,4) and DNA biosynthesis [51, and to induce cell 
death in different cell lines by apoptosis or necrosis j ' 
Among oxysterols, 5,6-epoxycholestanes have stimulated the 
interest of researchers some years after the photo-oxidation 
products of cholesterol were suspected to be involved in photo-
carcinogenesis 16|. Because of the presence of an oxirane group, it 
was supposed that 5,6-epoxycholestane could be electrophilic and 
behave like alkylating agents with direct carcinogenic properties. 
Recent data from literature mled out that 5,6-epoxycholestanes 
could be direct alkylating substances | 7 | and provides evidence 
that 5,6-epoxycholestanes may be involved in physiological pro-
cesses that result in metabolites with tumor promoter properties 
as well as to the production of steroidal alkaloids which are anti-
oncogenic. Ring B oxysterols were repotted to stimulate choles-
terol ester formation in cultured fibroblasts !S| and 5a,6a-epox-
ycholestane was shown to be the most potent allosteric activator 
for ACAT-1 (acyl-coA: cholesterol acyl transferase) whereas 5p,6(5-
epoxycholestane was found to be inefficient 9!. 't was found that 
5a,6a-epoxycholestane has tighter interactions with phospholi-
pids than 5p,6p-epoxycholestane and would se considered a 
better raft-stabilizing sterol [lOi. 5a,6a-Epoxycholestane was 
repotted to inhibit Topoisomerase (/ {(if. FDrfhcrmore, ring 
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The synthesis and anti-tumor activity screening of new steroidal derivatives (4-18) rontaining pharma-
cologically attractive pyrazoline moieties are performed. During in vitro anticancer evaluation, the newly 
synthesized compounds displayed moderate to good cytotoxicity on ceivical and leukemia cancer cell 
lines. In addition these compounds were found to be nontoxic to normal cell (PBMCs) {\C^n•• 50 (iM). 
The structure-activity relationship is also discussed. The most effective anticance'" compound 9 was 
found to be active with IC50 value of 10.6 |.iM. It demonstrated significant antiproliferative influence on 
Jurkat cell lines. The morphological changes and growth characteristics of HeLa cells treated with com-
pound 4 were analyzed by means of SEM. 
S 2013 Elsevier Inc. All rights reserved. 
1. Introduction 
Cancer is becoming the biggest health hazard for the world. 
Despite recent advances in early diagnosis, prevention and ther-
apy, cancer still affects millions of people worldwide and is one 
of the leading causes of death. In 2008, 7.6 million people died 
from cancer according to the World Health Organization (WHO) 
and without immediate action, the global number of deaths from 
cancer will increase by nearly 80% by 2030 [I |. Although cancer 
chemotherapy has established a new era of molecularly targeted 
therapeutics, the efficacy of the existing drugs for the treatment 
of various cancers is rather limited [21, and there is a need to devel-
op new therapeutic agents to overcome the limitations with the 
current therapy. That's why there is an intense effort in cancer 
research to design new, potent, selective and less toxic anticancer 
agents that are capable of rapid destruction of tumor vasculature 
leading to tumor necrosis and anti-tumor efficacy 13,4]. In vitro 
studies, using a variety of human cancer cell lines, have been em-
ployed to evaluate the effectiveness of new medicinal compounds 
against these cancers. 
Steroids are an important class of natural products which have 
high ability to penetrate cells and bind to nucleus and membrane 
* Corresponding author. Tel.: +91 9411003465. 
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receptors. They include great variations in structure and play a 
very important role in life [5,6;. Structurally diverse cytotoxic 
and cytostatic steroids are very relevant as lead compounds and 
molecular probes for anticancer drug discovery and cancer 
molecular mechanisms elucidation. The chemistry of steroids has 
motivated extensive investigation through decades and a compre-
hensive review on the syntheses of novel bioac five steroids has 
been recently published |7[. The investigation ot modified steroid 
derivatives condensed with various heterocyclic rings has drawn 
great attention [&]. A variety of steroids with unusual and interest-
ing structures have been synthesized and evaluated for their anti-
tumor [9,101, antimicrobial [11] and anti-parasitic activities 
Hybrid anti-cancer agents, which combine two active compounds 
in one. such as steroidal alkylators, contain steroidal moiety as bio-
logical vectors for anti-tumor agents in order to diminish toxicity 
and to enhance specificity, were recently demonstrated 11 i|. Such 
types of agents attain duplicate effects on cancer cells. These 
merged molecules may act on multiple therapeuiic targets and of-
fer the possibility of circumventing drug resistance. In addition, the 
hybrids may also minimize unwanted side effects and allow for 
synergic action [141. 
Pyrazolines present an interesting group of compounds, which 
has been known to possess wide spread pharmacological proper-
ties (15[. Recently, different authors worldwide hcfve reported anti-
tumor, antiproliferative or anticancer potenti.d of pyrazoline 
derivatives 116-18]. These derivatives are also we'l known for their 
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A B S T R A C T 
A novel expeditious and convenient synthesis of 5a(-cho]estano-(5,6-cl-isoxazolidin-5'-ones based on the 
reaction of 5ot-6-hydroxyim\nocholestanes with Vilsmeier-Haack reagent (DMF/POClj) 's described. The 
systems presented here, are novel scaffolds and have not been described before. Structuial assignment of 
newly synthesized compounds was performed by IR, 'H NMR, '^ C NMR, 2D 'H-'H COS\, MS and analyt-
ical data. 
© 2012 Elsevier Ltd. Al rights reserved. 
Isoxazolidinones are well-established building blocks in syn-
thetic organic chemistry. One of the reasons the isoxazolidinones, 
particularly 5-isoxazolidinones, are of considerable interest to or-
ganic chemists is that they are good precursors to unnatural p-ami-
no acids: these are, indeed, unmasked forms of 5-isoxazolidinones. 
TTiese structures exhibit a wide range of biological activities.''^ 
These type of compounds are an important class of heterocyclic 
structures, that can be applied in drug and pharmaceutical fields. 
These compounds have attracted scientific interest because of their 
potential cytotoxic, pro-apoptotic and antimicrobial capabilities.^ 
Furthermore, they can be used for the preparation of nucleoside 
analogues."* Nucleoside analogues have emerged in recent years 
as highly promising candidates for the development of new effi-
cient drugs against cancer and viral infections, particularly that 
of the HIV.'' Moreover, Parnafungins, natural products containing 
an isoxazolidinone ring, have been isolated from Fusarium laivarum 
and have been shown to be potent inhibitors of the fungal polyad-
enosine polymerase.'' Because of the importance of these scaffolds 
in synthetic organic chemist\-y and their usefulness as pharmaco-
logical molecules, much attention has been focused on their 
synthesis. 
Synthetic routes to them are numerous, including the enantio-
selective conjugate addition of hydroxylamines to pyrazolidinone 
acrylamides,^ propenoates,* crotonic acid esters" and o(,j}-unsatu-
rated-6-lactones."' The 1,3-dipolar cycloaddition of nitrones with 
ynolates to give isoxazolidinones has been developed quite re-
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cently." Significant effort continues to be directed mto the devel-
opment of efficient methodologies to new isoxazoiidinone-based 
stiTjctures. 
The Vilsmeier-Haack reagent (halomethylen.minium salt) 
formed from the interaction of dialkyi formamide such as DMF 
with POCI3 has attracted the attention of synthetic organic chem-
ists since its discovery in 1927.'"' It is one of the most commonly 
used reagents for the introduction of an aldehydi<: (CHO) group 
into electron rich aromatic systems.'^ However, the scope of the 
Vilsmeier reagent is not confined to the aromatic formylation reac-
tion alone. A wide variety of alkene'" derivatives, cartaonyl''' com-
pounds, activated methyl and methylene'^ groups exhibit 
reactivity towards the Vilsmeier reagent. In addition to the carbon 
nucleophiles, some oxygen'^ and nitrogen'" nucleophiles are also 
reactive towards Vilsmeier reagent. Numerous transformations of 
the iminium salts into products other than aldehydes have been 
achieved'^™ and these transformations enhance the scope and 
versatility of the Vilsmeier-Haack reaction. Following our inter-
est on the synthesis of new steroidal derivatives'* we herein 
report a prompt and novel strategy for the synthesis of Sa-cholest-
ano-[5,6-c]-isoxazolidin-5'-ones (7-9) based on the reaction of 
5a-6-hydroxyiminocholestanes (4-6) with Vilsmeier reagent 
Interestingly, the reaction proceeded smoothly and the desired 
steroidal 5'-isoxazolidinone derivatives (7-9) were obtained in 
good yield (80-87%). With the best of our knowledge there 
are no reports, however describing the synthesis of steroidal 
5'-isoxazolidinones via Vilsmeier-Haack reaction. 
The 5a-6-hydroxyiminocholestanes''^ (4-6) employed for the 
present investigarion, were conveniently obtained from the corre-
organic compounds 
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disorder in main residue; R factor = 0.049; wR factor = 0.129; data-to-parameter 
ratio = 13.7. 
The title compound, C27H47NO, is a steroid derivative 
composed of a saturated carbon fused-ring framework with 
an alkyl side chain. Ring bond lengths have normal values with 
an average of 1.533 (2) A, while the cholestane side chain 
shows an average bond length of 1.533 (2) A. The three 
cyclohexane rings adopt chair conformations or close to chair 
conformations while the cyclopentane ring is twisted. The 
cholesterol side-chain is fully extended with a gauche-tram 
conformation of the terminal methyl groups. There are eight 
chiral centres in the molecule; the absolute configuration of 
these sites was determined from the structure presented. 
There are two molecules in the asymmetric unit; in one, the 
alkyl chain is disordered over two sets of sites [occupancy 
ratios of 0.50:0.50 and 0.67:0.33]. 
Related literature 
For liackground on steroidal hormone applications, see: 
Grover et al. (2007). For background to this study and 
previous syntheses, see: Shoppee et al. (1955). For related 
structures, see: Ketuly et al. (2011); Park (2004). For reference 
bond-length data, see: Allen et al. (1987), For the stability of 
the temperature controller used for the data collection, see: 
Cosier & Glazer (1986). 
Experimental 
Crystal data 
C,,H47NO 
M, = 401.65 
Monoclinic, K , 
a ^= 13.7.5,3.5 (7) A 
b == 9.5266 (4) A 
c = 18.681 (1) A 
P = 102.829 (3)-
Data collection 
Bruker Kappa APEXll Duo 
diffractometer 
Absorption correction; multi-scan 
(Blessing, 1995) 
T„^, = 0%5, r „ „ = 0,989 
Refinement 
RIF- > 2cr(/-")] := 0.(M9 
wR{F') •=--• 0.129 
S = 1.12 
7706 reflections 
564 parameters 
59 restraints 
V - 2386.6 (2) A ' 
Z - 4 
Mo A'a radiation 
/J 0.07 mm"' 
r lOOK 
0.54 X 0.31 X '1.17 mm 
51-587 measureJ teflections 
7706 independc-ni reflections 
6021 reflections with / > 2<T(/) 
«:„, = 0.052 
H atoms treated h\ a mLxlure of 
independent and constr;iined 
refinement 
AAn^ o. = 0-48 e A^' 
AA„in -0.32 e .A"' 
Data collection: APEX2 (Bruker, 2008); cell refinement: \PF.X2\ 
data reduction: APEX2: program(s) used to solve structure: 
SHELXS97 (Sheldrick, 2008); program(s) used to refine structure: 
SHELXL97 (Sheldrick, 2008); molecular graphics: ORTEP-3 
(Farrtigia, 1997); software used to prepare material Cor publication; 
publCIF (Westrip, 2010). 
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